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Cyclic-3’,5’-guanosine monophosphate (cGMP) is a fundamental intracellular 
signalling molecule that regulates vascular homeostasis through the tight 
control of vascular smooth muscle cell (VSMC) reactivity (i.e. 
vasoconstriction/relaxation) and proliferation. Aberrant VSMC growth and 
sustained vasoconstriction are hallmarks of cardiovascular disease, exemplified 
by pulmonary hypertension (PH). Multidrug resistance proteins (MRPs) are 
membrane bound transporters that facilitate cGMP cellular export thereby 
representing a potential mechanism that regulates intracellular cGMP-driven 
signalling. C-type natriuretic peptide (CNP) is an important vasoactive peptide 
released from the endothelium that maintains vascular homeostasis. CNP binds 
to natriuretic peptide receptor-B (NPR-B), generating cGMP, and NPR-C, which 
acts as a clearance receptor removing CNP from the circulation and a signalling 
pathway regulating vascular function via a cGMP-independent mechanism.  
 
Herein, I investigated two separate hypotheses: that MRPs play an important 
role in maintaining vascular homeostasis, and that endothelium-derived CNP 
and its cognate receptor, NPR-C, protects against the development of PH.  
 
The role of MRPs in regulating vascular homeostasis was investigated using 
organ bath pharmacology, human VSMC (hVSMC) proliferation and measuring 
mean arterial blood pressure (MABP) in conscious and anaesthetised mice. To 
investigate the role of endothelium-derived CNP and NPR-C in PH, male and 
female CNP and NPR-C knockout (KO) mice were used in two experimental 
models of PH: hypoxia plus Sugen5416 (SU5416) and bleomycin-induced. The 
severity of PH was measured using right ventricular systolic pressure (RVSP), 
MABP, right ventricular hypertrophy (RVH) and pulmonary vascular 
remodelling.  
 
MRP inhibition resulted in concentration-dependent vasorelaxation of mouse 
aorta per se and increased the potency of cGMP-dependent vessel relaxation 
in response to activation of both particulate and soluble guanylate cyclases 
(pGC and sGC). MRP inhibition alone also caused concentration-dependent 
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attenuation of hVSMC proliferation, and enhanced cGMP-mediated attenuation 
of hVSMC growth via pGC and sGC activation. MRP inhibition per se did not 
decrease MABP in either anaesthetised or telemeterised mice. However, MRP 
inhibition did dose-dependently enhance reductions in MABP due to pGC 
activation in anaesthetised mice.  
 
Deletion of endothelial cell-derived CNP (ecCNP KO) in male and female mice 
did not result in any significant differences in RVSP, RVH or pulmonary 
vascular remodelling between WT and KO in the hypoxia plus SU5416 model of 
PH. However, global deletion of NPR-C in both male and female mice caused a 
significant increase in RVH but not RVSP or vascular remodelling when 
compared to WT. Both male and female NPR-C KO mice developed 
significantly increased RVSP compared to WT in the bleomycin-induced model 
of PH. However, only females exhibited a significant increase in RVH and lung 
weight in addition to RVSP.  
 
In conclusion, MRP inhibition demonstrates potential therapeutic utility to treat 
cardiovascular diseases by potentiating the vasodilatory and VSMC anti-
proliferative actions of natriuretic peptides and nitric oxide. Endothelial cell-
derived CNP is not essential to host protection against PH, whereas its cognate 
receptor NPR-C demonstrates a cardioprotective capacity. NPR-C attenuates 
bleomycin-induced PH in both males and females, with a greater effect 
observed in females. Overall, NPR-C agonism could potentially be used to 
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hPASMC Human pulmonary artery smooth muscle cell 
HR Heart rate 
Hsp Heat shock protein 
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IFN  Interferon  
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SU5416 Sugen5416 
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TGF  Transforming growth factor  
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UK United Kingdom 
USA United States of America 
VEGF  Vascular endothelial growth factor  
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CHAPTER 1: INTRODUCTION 
 
1.1 Cardiovascular disease 
 
Cardiovascular disease (CVD) is defined by dysfunction of the homeostatic 
mechanisms that regulate the circulatory system (heart and vasculature). As 
this encompasses a huge multifaceted system, a plethora of diseases are 
incorporated into the general umbrella term of CVD, including coronary heart 
disease (CHD) which can lead to a myocardial infarction (MI; “heart attack”), 
hypertension, stroke, heart failure and atherosclerosis. CVD is the biggest 
cause of mortality globally; in 2012 31 % of all deaths (~17.5 million people) 
were due to CVD (WHO, 2015). Within the same year, the most common CVD 
was CHD, accounting for 7.4 million deaths, followed by stroke (6.7 million 
deaths); as such, these two disorders give rise to approximately 75 % of the 
total mortality due to CVD (WHO, 2015).  
 
In the United Kingdom (UK), CVD is the second highest cause of mortality 
behind cancer (Townsend et al., 2015). From 2012 to 2014 CVD dropped from 
being the highest cause of mortality in the UK; despite this CVD still accounts 
for over a quarter of all deaths (155,000 people), with similar rates in males (28 
%) and females (26 %). Of these, CHD is the biggest single cause of mortality, 
responsible for 15 % and 10 % of deaths in males and females, respectively 
(~69,000 deaths in total). Mirroring the global situation, the second most 
common cause of CVD mortality is stroke, accounting for around 39,000 deaths 
(6 % and 8 % men and women respectively; Townsend et al., 2015). Despite 
CVD being a substantial cause of mortality in the UK, age-standardised death 
rate from CVD has continuously decreased since 1961 demonstrating an 
increasing ability to combat these disorders (Scarborough et al., 2011). 
 
In addition to the unacceptably high mortality, the morbidity associated with 
CVD is substantial. In 2014, CVD accounted for 1.7 million in-patient episodes 
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in all National Health Service (NHS) hospitals in the UK (Townsend et al., 
2015). The number of people in the UK living with a CVD is approximately 2.29 
million for CHD, 1.18 million for stroke, 9.25 million for hypertension and 
493,000 for heart failure. This equates to more than 370 million prescriptions 
dispensed for CVD in the UK, including anti-platelet, lipid-lowering, anti-
hypertensive and heart failure drugs. This equates to a £4.3 billion cost for the 
treatment and management of CVD (Townsend et al., 2015). However, 
healthcare cost is not the entire financial burden. Cardiovascular disease 
causes huge losses in productivity in those of working age through a 
combination of death and illness which greatly impedes UK economics. The 
Centre for Economics and Business Research (CEBR) published a report in 
2014 which states an estimated £11.3 billion total healthcare cost, with a cost 
from lost work days being £3.9 billion due to mortality and £151.6 million from 
morbidity. In total, the annual cost of CVD to the UK economy is £15.2 billion, 
which is predict to increase to £18.7 billion in 2020 (Townsend et al., 2015). 
 
In summary, CVD is a massive global health and economic problem, and a 
major drain of resources to publically-funded healthcare systems. The most 
disturbing fact is that most CVDs can be prevented by altering lifestyle 
behaviours, for example smoking (tobacco), alcohol abuse, unhealthy diet and a 
lack of physical activity. Whilst public health initiatives have helped to curb 
these precipitating factors, new medicines that target novel pathways 
responsible for preserving cardiovascular health, or prevent those precipitating 
CVDs, are a significant unmet medical need. 
 
1.2 Cyclic guanosine-3’,5’-monophosphate 
(cGMP) signalling 
 
Cardiovascular disease results from an imbalance in many complex and 
dynamic homeostatic mechanisms. The human circulatory system was 
originally described by London based physician William Harvey, in 1628, who 
described the structure of a unidirectional, double circulatory system enforced 
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by valves, with blood being driven by the heart and transported through arteries, 
then veins, and returning to the heart (Harvey, 1628). This intricate organ 
system is regulated by a range of different cells that work together to maintain 
homeostatic physiology, which in turn are regulated by a multitude of inter- and 
intra- cellular mechanisms which react to external stimuli leading to a cascade 
in intracellular signalling, culminating in a specific cellular response. In 1958, 
Earl Sutherland discovered what is now appreciated as a central player in these 
homeostatic mechanisms; the intracellular second messenger, cyclic 
adenosine-3’,5’-monophosphate (cAMP; Rall & Sutherland 1958, Sutherland & 
Rall 1958). As a result of his work on cAMP and the actions of hormones, Earl 
Sutherland was the solo winner of the Nobel Prize in Physiology or Medicine in 
1971 (Nobel Media AB 2014, 2016). Following the identification of cAMP, a 
sibling molecule, cyclic guanosine-3’,5’-monophosphate (cGMP) was 
synthesised and hypothesised to act in a similar manner to cAMP because of its 
ability to be enzymatically hydrolysed (Smith et al., 1961). Subsequently, cGMP 
was also found to occur endogenously by a group that isolated and identified 
the molecule in rabbit urine (Ashman et al., 1963). The enzyme responsible for 
hydrolysing the 3’,5’-phosphodiester bond in both cGMP and cAMP was first 
identified in 1964 (Kuriyama et al. 1964; Figure 1). Since then a family of 
analogous enzymes which hydrolyse these second messengers have been 
identified and characterised; phosphodiesterases (PDEs; see 1.4.1; Bender & 
Beavo 2006). Since their discovery over half a century ago, cGMP and cAMP 
have been at the centre of research that has led to several Nobel Prizes in 
Physiology or Medicine; furthermore we are still discovering new roles of these 
fundamental intracellular second messengers. 
 
We now know that spatio-temporal changes in intracellular cGMP 
concentrations are responsible for controlling a broad range of physiological 
mechanisms that require a fine-controlled balance between cGMP production 




Figure 1. An illustration of the molecular structural changes to cGMP 
during generation and degradation. 
Cyclic guanosine-3',5'-monophosphate (cGMP) is generated from guanosine-5'-
triphosphate (GTP) by the enzyme guanylyl cyclase (GC). Cyclic GMP is 
degraded to guanosine-5'-monophosphate (GMP) by the enzyme 
phosphodiesterase (PDE).  
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1.3 Cyclic GMP production 
 
Cyclic guanosine-3’,5’-monophosphate is generated from guanosine-5’-
triphosphate (GTP) by a family of enzymes termed guanylyl cyclases (GCs; 
Price et al. 1967; Figure 1). GCs are further divided according to structure and 
membrane localisation; cytosolic or soluble GC (sGC) and membrane-bound or 
particulate GC (pGC). Although, there is now evidence to suggest that 
chaperone proteins facilitate the membrane-association of sGC (e.g. heat-shock 
protein90; Hsp90; Agullo et al. 2005,Venema et al. 2003). 
 
1.3.1 Soluble guanylyl cyclase (sGC) 
 
Soluble GC is a heterodimeric protein formed of two subunits, α and β (Giuili et 
al. 1992, Giles et al. 2003). Two isoforms of each subunit exist, α1, α2, β1 and β2, 
with the most commonly studied and physiologically relevant combination being 
an α1β1 dimer, that is ubiquitously expressed in mammals (Budworth et al., 
1999). Each subunit is composed of the same distinct domains; an N-terminal 
H-NOX (haem-nitric oxide and oxygen binding family) domain, a Per/Arnt/Sim 
(PAS) domain, a amphipathic helix region and a C-terminal catalytic domain 
(Derbyshire and Marletta, 2012). Although, both α and β monomers have an N-
terminal H-NOX domain, only the β subunit coordinates a haem iron (Fe2+) 
capable of binding nitric oxide (NO; Zhao and Marletta, 1997). NO is the major 
ligand for sGC and upon binding to the haem domain leads to over a 200-fold 
increase in cGMP production (Stone & Marletta 1994; Figure 2). Soluble GC, 
and specifically the β1 subunit, is essential to life demonstrated by the 
generation of knockout (KO) mice for this protein which die within 3-4 weeks 
after birth due to intestinal dysmotility. However, these animals also have 
catastrophic detrimental cardiovascular characteristics, exemplified by 
dysfunctional platelet aggregation and aortic vasorelaxation, plus systemic 
hypertension. Moreover, in sGC KO mice NO donors demonstrate a complete 
inability to relax pre-contracted isolated vessels and lower blood pressure (BP) 
in vivo compared to wild-type (WT) littermates, illustrating the importance of 
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sGC to orchestrate the cardiovascular effects of NO (see 1.3.2; Friebe et al., 
2007). These unfavourable cardiovascular traits in sGC KO mice are mirrored in 
the human population, in which mutations in the genes that encode the sGC β 
or α subunits are also linked to the development of cardiovascular disease 
(Ehret et al., 2011). Soluble GC expression exhibits anti -proliferative and -
migratory effects on vascular smooth muscle cells (VSMCs). For instance, 
increased expression of sGC in rats using recombinant adenoviruses, increases 
cGMP production in aortic smooth muscle cells, and decreases carotid 
neointima formation, in a balloon-induced vascular injury model compared to 
controls (Sinnaeve et al., 2001).  
 
1.3.2 Nitric oxide (NO) 
 
NO was originally discovered to be an endogenously produced, physiologically 
important signalling molecule during the hunt to identify the elusive 
endothelium-derived relaxing factor (EDRF) in the 1980s (Katsuki et al. 1977, 
Ignarro et al. 1987, Ignarro et al. 1986, Ignarro et al. 1982, Furchgott & 
Zawadzki 1980, Arnold et al. 1977). The discovery of NO led to Louis Ignarro, 
Ferid Murad and Robert Fuchgott being awarded the 1998 Nobel Prize in 
Physiology or Medicine (Nobel Media AB 2014, 2016). The powerful 
cardiovascular effects of NO were initially illustrated as a vasorelaxant (Palmer 
et al., 1987) and inhibitor of platelet aggregation (Radomski et al., 1987a) and 
adhesion (Radomski et al., 1987b), of leukocyte adhesion (Kubes et al., 1991), 
and anti-proliferative mediator in VSMCs (Garg & Hassid 1989). Subsequent to 
these impressive early findings further work has substantiated the 
cardiovascular-protective role of NO/sGC/cGMP signalling. 
 
NO is generated enzymatically by nitric oxide synthase (NOS; Alderton et al., 
2001). NOS is found in mammals expressed as three different isoforms, 
neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or NOS2) and 
endothelial NOS (eNOS or NOS3). These enzymes generate NO through the 
same process but differ in their activation, cellular localisation and expression. 
NOS proteins are homodimers, with each monomer containing two different 
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catalytic regions, an oxygenase and a reductase domain (Crane et al., 1998). 
NO is generated via a two-step, 5 electron oxidation of the amino acid L-
arginine. Reduced nicotinamide adenine dinucleotide phosphate (NADPH) is 
oxidised by the reductase domain enabling electrons to be transferred to the 
cofactors flavin adenine dinucleotide (FAD) then flavin mononucleotide (FMN), 
present within the same region, and subsequently transported to a haem 
present in the oxygenase domain (Noble et al. 1999; Klatt et al. 1996). Binding 
of calmodulin, from elevated intracellular calcium (Ca2+) concentrations, to the 
reductase domain increases the flow of electrons to the haem, and represents a 
key mechanism of activation (Abu-Soud and Stuehr, 1993). The haem binds O2 
and L-arginine, and in addition to the transferred electrons, hydroxylates L-
arginine in the first step to produce an intermediate compound, NG-hydroxy-L-
arginine, which is in turn oxidised to L-citrulline and NO. This occurs in the 
presence of an essential cofactor, tetrahydrobiopterin (BH4), which maintains 
enzyme structural integrity, facilitates L-arginine binding, and acts as an 
electron donor (Nishimura et al. 1995; Crane et al. 1998; List et al. 1997; 




Figure 2. An illustration of the activation of sGC by endothelium-derived 
NO. 
cGMP in vascular smooth muscle cells is generated by sGC, activated by NO, 
produced by eNOS expressed in vascular endothelial cells. 
Cyclic guanosine-3',5'-monophosphate (cGMP), guanosine-5'-triphosphate 
(GTP), endothelial nitric oxide synthase (eNOS), soluble guanylyl cyclase 
(sGC), oxygen (O2), inorganic pyrophosphate (PPi), nicotinamide adenine 
dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin 
mononucleotide (FMN), tetrahydrobiopterin (BH4), calmodulin (CaM), Fe2+ 
(haem).   
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Endothelial NOS is considered the predominant NOS isoform of the 
cardiovascular system because of its abundant expression in endothelial cells 
(ECs) which intuitively enables the enzyme to utilise NO to maintain 
cardiovascular homeostasis (Pollock and Fiirstermanna, 1993; Pollock et al., 
1991). In addition to elevated intracellular calcium concentrations, another 
important cardiovascular dependent-mechanism that can activate eNOS is fluid 
shear stress. This mechanism occurs through phosphorylation of serine 
(Ser1177, Ser633), threonine (Thr495) and/or tyrosine (Tyr81, Tyr657) residues 
present in the eNOS enzyme. Kinases that are known to do this include Akt 
(activated by oestrogen, vascular endothelial growth factor; VEGF and insulin), 
Ca2+/calmodulin-dependent protein kinase II (CaMKII; triggered by bradykinin), 
and most notably protein kinase-A (PKA; stimulated by fluid shear stress; Boo 
et al., 2002; Fulton et al., 1999; McCabe, 2000; Schleicher et al., 2009). To 
illustrate the importance of eNOS in the cardiovascular system, each of the 
different eNOS KO mice generated to date is hypertensive (Huang et al., 1995; 
Shesely et al., 1996; Thoonen et al., 2013). Moreover, NO generated 
specifically from ECs is essential to the maintenance of vascular homeostasis 
by inhibiting VSMC proliferation (Garg and Hassid, 1989; Nakaki et al., 1990; 
Rudic et al., 1998), platelet aggregation (Alheid et al., 1987; Busse et al., 1987) 
and leukocyte recruitment (Arndt et al., 1993; Zeiher et al., 1995). Patients with 
hypertension demonstrate significant endothelial dysfunction; for example, 
impaired vascular relaxation to acetylcholine (ACh), which activates eNOS, 
generating NO (Panza et al. 1990). Furthermore, in humans mutations to genes 
that encode eNOS are associated with cardiovascular disease (Johnson et al., 
2011; Kathiresan et al., 2005; Mitchell et al., 2007; Salvi et al., 2012). These 
data demonstrate clearly the importance of EC-derived NO in maintaining 
vascular function and protection against cardiovascular diseases. 
 
Neuronal NOS is highly expressed throughout the central nervous system 
(CNS), in the periphery (within non-adrenergic, non-cholinergic [NANC] nerves) 
as well as skeletal muscle (Nakane et al., 1993). Nitric oxide generated by 
nNOS acts as an important neurotransmitter regulating cognition (memory, 
learning, neurogenesis/plasticity; Zhou & Zhu 2009) and non-vascular smooth 
muscle tone (i.e. gastrointestinal tract; Lefebvre, 2002; Tøttrup et al., 1991). 
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Some evidence also points to a direct nNOS-derived NO effect on VSMCs, and 
thus a cardiovascular role, independent of endothelium-generated NO (Melikian 
et al. 2009). Although, mice rendered genetically-deficient in nNOS don’t 
develop hypertension, in contrast to eNOS KO animals (Melikian et al., 2009; 
Nelson et al., 1995). Neuronal NOS KO mice subjected to middle cerebral 
artery (MCA) occlusion (a model of ischaemic stroke), develop significantly 
smaller infarct sizes and improved neurological outcome than wild-type (WT) 
animals, illustrating a pathological neurodegenerative role of nNOS derived NO, 
alongside it’s physiological neuronal signalling function (Huang et al., 1994; 
Lipton et al., 1993; Malinski et al., 1993). This is in contrast to eNOS KO mice, 
which develop larger infarct sizes compared to WTs in ischaemic stroke models 
because of significantly reduced blood flow, lending support to the notion that 
eNOS is the predominant homeostatic NOS isoform in the cardiovascular 
system (Huang et al., 1996; Lo et al., 1996). 
 
Inducible NOS was originally identified in macrophages when exposed to 
inflammatory stimuli such as bacterial liposaccharide (LPS) or cytokines 
(Bergmann et al., 1992). Inducible NOS isn’t basally expressed but can be 
induced in a variety of cell-types, under a multitude of inflammatory conditions, 
such as exposure to infectious agents (human immunodeficiency virus; HIV; 
helicobacter pylori; mycobacterium tuberculosis), in human autoimmune and 
chronic inflammatory diseases due to increased production of cytokines (e.g. 
interleukin-1; IL-1; IL-6), and other conditions including Alzheimer’s, 
Parkinson’s, tumours and MI (Kröncke et al., 1998). Although, it should be 
noted that iNOS is constitutively expressed in airway epithelial cells because of 
continuous exposure to toxins (Guo et al., 1995). NO is a free radical, this 
characteristic enables it to form part of the body’s defensive repertoire, where it 
is utilised to combat infection from microbes and parasites, through its ability to 
inhibit cellular enzymes, especially those containing a haem domain (Green et 
al., 1990). In addition, NO can decrease the stability of deoxyribonucleic acid 
(DNA) and proteins, non-specifically, contributing to its anti-microbial affect. 
However, as a result of this chemistry, excessive production of NO can cause 
host necrosis and promote tumorigenesis (Kröncke et al., 1991; Wink et al., 
1991). In contrast to nNOS and eNOS, iNOS is constitutively active once 
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expressed because of its unique ability to bind calmodulin irreversibly at low 
intracellular calcium concentrations (Cho et al., 1992). Constitutively active 
iNOS results in high-output production of NO and contributes to the life-
threatening hypotension found in patients suffering from septic shock 
(MacMicking et al., 1995; Wei et al., 1995; Wong and Billiar, 1995). 
 
1.3.3 Particulate guanylyl cyclases (pGCs) 
 
In addition to sGC, cyclic GMP is generated by membrane-bound guanylyl 
cyclase (pGC). There are seven known pGCs in mammals, GC-A, GC-B, GC-C, 
GC-D, GC-E, GC-F and GC-G; in humans GC-D and GC-G are pseudogenes 
and therefore not thought to be expressed or functionally active (Manning et al., 
2002). GC-C is highly expressed in the intestinal epithelial cells and is activated 
by the endogenous ligands guanylin and uroguanylin, which regulate colonic 
epithelial cell proliferation. GC-C is also activated by bacterial heat stable 
enterotoxins, which causes intestinal epithelial cells causes increased Cl− 
secretion in intestinal epithelial cells leading to enhanced intestinal water 
content and diarrhoea (Potter, 2011). GC-E and GC-F are expressed on rods 
and cones in the retina and facilitate the conversion of photons into electrical 
signals allowing light to be perceived (Potter, 2011). However, the most 
important pGC enzymes in the context of cardiovascular homeostasis and 
disease are GC-A and GC-B, which are cognate receptors for a family of 
natriuretic peptides (NPs; see 1.3.4); as such, these pGCs are also known as 
natriuretic peptide receptor (NPR)-A and NPR-B, respectively. There is a third 
receptor that binds all three NPs, NPR-C (see 1.3.4.4), but this should not be 
confused with GC-C since NPR-C does not contain a GC domain and therefore 
cannot generate cGMP (Fuller et al., 1988).  
 
NPR-A and NPR-B are homodimers composed of an extracellular ligand 
binding domain, followed by a transmembrane domain, then an intracellular 
portion consisting of a kinase-like domain (no known kinase activity), followed 
by a hinge region and finally the GC domain (Garbers & Lowe 1994; Figure 3). 
In some ways the structures of NPR-A and NPR-B are homologous to sGC due 
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to their shared GC domain and thus cGMP generating capability (Potter, 2011). 
Arguably outside the shared GC functionality their structure is quite different 
(Chinkers and Garbers, 1989; Chinkers et al., 1989; Lowe et al., 1989; Thorpe 
and Garbers, 1989). Similar to NPR-A and NPR-B in its extracellular region, 
NPR-C differs in its intracellular domain which lacks catalytic activity. As a 
result, this NPR was traditionally thought of as a clearance receptor with no 
signalling capability; however the receptor is now known to signal as a G-
protein coupled receptor (GPCR; Fuller et al. 1988; Koh et al. 1992; 
Nussenzveig et al. 1990; Figure 3). 
 
1.3.4 Natriuretic Peptides (NPs) 
 
NPR-A and NPR-B are activated by a family of endogenous ligands, the NPs. 
Each of the three principal mammalian NPs have a very similar structure, 
sharing a 17 amino acid ring of which 11 amino acids are conserved; the 
structural differences determine their specific receptor affinities (Potter et al. 
2006; Figure 4; Table 1). The dissociation constants for each of these ligands 
binding to NPR-A, -B, and -C were originally published by Bennett et al., (1991; 
Table 1). The ligand selectivity of NPR-A is ANP≥BNP≫CNP, whereas for 
NPR-B it is CNP≫ANP≥BNP; and finally for NPR-C: ANP≥CNP>BNP (Bennett 
et al. 1991; Koller et al. 1991; Suga et al. 1992; Table 1). In sum, ANP and BNP 
are the predominant ligands for NPR-A; CNP is the principal ligand for NPR-B, 
and NPR-C binds ANP, BNP and CNP almost equally with a slight preference 




Figure 3. An illustration of natriuretic peptide cellular signalling. 
Atrial natriuretic peptide (ANP), Brain natriuretic peptide (BNP), C-type 
natriuretic peptide (CNP), natriuretic peptide receptor-A;-B;-C (NPR-A;-B;-C), 
phospholipase-C (PLC), adenylyl cyclase (AC), cyclic adenosine-3',5'-
monophosphate (cAMP), cyclic guanosine-3',5'-monophosphate (cGMP), 
guanosine-5'-triphosphate (GTP), G protein-coupled inwardly-rectifying 
potassium channel (GIRK), ligand binding domain (LBD), transmembrane 




 ANP BNP CNP Summary 
NPR-A 1.9 pM 7.3 pM >500 nM ANP≥BNP≫CNP 
NPR-B 5.4 nM 30 nM 13 pM CNP≫ANP≥BNP 
NPR-C 2.6 pM 13 pM 10.8 pM ANP≥CNP>BNP 
 
Table 1. A table describing the affinity of each natriuretic peptide for their 
respective receptors. 
Dissociation constants (Kd) of natriuretic peptides for each natriuretic peptide 
receptor (Bennett et al., 1991) and summary of preferential ligand binding 
(Koller et al., 1991; Suga et al., 1992a). 
 
1.3.4.1 Atrial Natriuretic Peptide (ANP) 
 
Atrial natriuretic peptide was first identified from atrial myocardial extracts in 
1981 by de Bold and colleagues (de Bold et al., 1981). Although, a clue as to 
the physiological effects of ANP was alluded to before the actual discovery; 
balloon distension of canine atria correlated with urine production (Henry et al., 
1956). Later, de Bold and colleagues showed that ANP released from atrial 
myocardial extracts reduced BP through natriuresis and diuresis (Flynn et al., 
1983). We now know that ANP is first synthesised as a preprohormone, 
preproANP (151 amino acid peptide) that is cleaved to form proANP (126 amino 
acid peptide) the predominant form of the peptide, synthesised and stored in 
atrial cardiomyocyte granules (Hosoda et al., 1991; Oikawa et al., 1984). The 
transmembrane cardiac serine protease, corin, is highly expressed on the 
extracellular surface of atrial cardiomyocytes, and responsible for the 
conversion of proANP to its physiologically active form ANP (28 amino acid 
peptide; Yan et al. 2000; Figure 4). The physiological relevance of corin was 
established by generation of the corin deficient mouse that has no detectable 
endogenous ANP and therefore develops a phenotype dependent on ANP-
deficiency; hypertension (enhanced with dietary salt) and increased cardiac 
hypertrophy compared to WT littermates (Chan et al., 2005). Of note, proANP in 
the kidney can be processed into a longer, related protein, urodilatin (32 amino 
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acid peptide), and acts as a local paracrine signal increasing natriuresis and 
diuresis (Forssmann, 2001; Saxenhofer et al., 1990). Atrial natriuretic peptide is 
an integral regulator of cardiovascular homeostasis through a number of 
different effects. The most obvious of these is in response to increased 
intravascular volume (hypervolaemia), which stimulates the release of proANP 
from atrial cardiomyocytes due to wall stretch; ANP is secreted into the 
circulation, reducing intravascular volume by acting directly on the kidneys, 
increasing natriuresis and diuresis (de Bold et al., 1981). Natriuretic peptide 
receptor-A is expressed in many tissues including brain, lung, kidney, adrenal, 
adipose, heart, vascular endothelium and smooth muscle (Goy et al., 2001; 
Lowe et al., 1989; Nagase et al., 1997; Sabrane et al., 2005; Wilcox et al., 
1991). ANP is active throughout the body, promoting natriuresis and diuresis 
through a number of different mechanisms. ANP inhibits the release of 
antidiuretic hormone (ADH; vasopressin) from the hypothalamus, increasing the 
glomerular filtration rate (GFR) and renal plasma flow (RPF) in the kidney 
(Samson et al., 1987). ANP also modulates the renin-angiotensin aldosterone 
system (RAAS), specifically by lowering renin and aldosterone secretion from 
the kidneys and adrenal gland, respectively, thereby reducing production of 
angiotensin-II (Ang-II; a potent vasoconstrictor) and attenuating sodium re-
uptake and water reabsorption (Bianchi et al., 1986; Burnett et al., 1984; Cogan 
et al., 1986; Fried et al., 1986; Kurtz et al., 1986; Shi et al., 2001, 2003). 
However, the powerful cardiovascular effects of ANP go beyond this single 
mechanism (intravascular volume); ANP is a potent vasodilator (Currie et al., 
1983), inhibitor of: VSMC proliferation (Sharma et al., 2002), endothelial 
permeability (Sabrane et al., 2005) and cardiac hypertrophy independent of BP 
(Knowles et al., 2001). Finally, in humans, depression of ANP expression as a 
consequence of single nucleotide polymorphisms in the NPPA gene is 
associated with the development of hypertension (P. Arora et al., 2013; Newton-
Cheh et al., 2009). Anaritide (Carperitide), a synthetic version of ANP, is 
prescribed in Japan for the treatment of acute decompensated heart failure 




Figure 4. An illustration of the structure of ANP, BNP and CNP. 
Atrial natriuretic peptide (ANP), Brain natriuretic peptide (BNP), C-type 




1.3.4.2 Brain Natriuretic peptide (BNP) 
 
Brain natriuretic peptide was originally named due to its initial discovery in 
porcine CNS, however it is now known to be an important cardiac hormone, and 
the major source of BNP is ventricular cardiomyocytes (Hosoda et al., 1991; 
Mukoyama et al., 1991, 1990; Sudoh et al., 1988). Mirroring the bioactivation of 
ANP, preproBNP (134 amino acid peptide) is converted to proBNP (108 amino 
acid peptide), which is then cleaved to BNP (32 amino acid peptide; Figure 4) 
by corin (Ichiki et al., 2011). Although secreted by ventricular cardiomyocytes, 
unlike ANP, BNP is not stored in granules, instead BNP gene transcription 
increases rapidly “on demand,” in response to stimuli such as cardiac wall 
stretch (Grépin et al., 1994; Nakagawa et al., 1995; Thuerauf et al., 1994). Both 
ANP and BNP are elevated in patients who suffer from cardiovascular diseases; 
indeed, BNP (and its N-terminal fragment, NT-proBNP) is used as a biomarker, 
and increased plasma concentrations of this peptide correlates with poor 
prognosis (Burnett et al., 1986; Mark Richards et al., 2004). BNP plasma 
concentrations increase substantially more than ANP, due to differences in their 
plasma half-life (Mukoyama et al., 1991). The half-life of BNP (~20 min; 
Richards et al. 1993) is much longer than ANP (~2 min; Yandle et al. 1986; 
Nakao et al. 1986). This is underpinned by differences in degradation and 
clearance between these two NPs; ANP has a higher affinity for NPR-C and is 
cleared quicker than BNP (Matsukawa et al., 1999) and although both are 
broken down by neutral endopeptidase 24.11 (neprilysin; NEP), BNP requires 
prior cleavage by meprin A (a metalloprotease present in the kidney), slowing 
degradation as a whole (Pankow et al., 2007). Both NPs generate cGMP by 
activating NPR-A but interestingly they have very different biological effects. 
Mice that have the NPPA gene disrupted develop hypertension and cardiac 
hypertrophy (Melo et al., 1999; Newton-Cheh et al., 2009; Steinhelper et al., 
1990); however, disruption of the BNP gene (NPPB), does not result in 
hypertension or left ventricular hypertrophy but rather a significant increase in 
cardiac fibrosis (Tamura et al., 2000) that is due in part to the ability of BNP to 
promote the degradation of collagen in cardiac fibroblasts (Kapoun et al., 2004; 
Tsuruda et al., 2002). Although, NPPB over expression in mice reduces blood 
pressure, however this may be due to cross-activation of the NPR-B receptor 
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instead of NPR-A from enhanced (10-100 fold) plasma levels of BNP compared 
to WT littermates (Ogawa et al., 1994), this also leads to significant skeletal 
overgrowth characteristic of CNP/NPR-B signalling (Suda et al., 1998; Yasoda 
et al., 1998). However, the cardiovascular effects of BNP being limited to 
protection against cardiac fibrosis are likely to be underestimated. There is 
strong evidence supporting a more prominent role of BNP in cardiovascular 
homeostasis; in humans, mutations in the NPPB gene are associated with the 
development of cardiovascular disease including hypertension (Newton-Cheh et 
al., 2009). Furthermore, nesiritide, a synthetic version of BNP, that is prescribed 
for the treatment of ADHF, produces significant reductions in blood pressure 
both in the systemic and pulmonary circulation (Colucci et al., 2000; Morita et 
al., 2012). Overall, the evidence demonstrates differential cardiovascular effects 
of NPR-A activation by BNP compared to ANP; this difference may reflect 
temporal variations in the production of the two NP ligands depending on the 
disease. 
 
1.3.4.3 C-type Natriuretic Peptide (CNP)  
 
C-type natriuretic peptide is the third member of the natriuretic peptide family 
but in contrast to its kin, ANP and BNP, CNP is not a cardiac-derived peptide 
but rather a prominent EC-derived vascular autocrine/paracrine signalling 
peptide. First isolated from porcine brain (Sudoh et al. 1990), now known to be 
expressed in the kidney and gastrointestinal tract (Komatsu et al., 1991), 
VSMCs (Casco et al., 2002; Kelsall et al., 2006; Mendonca et al., 2006; Naruko 
et al., 2005, 1996; Suga et al., 1998; Woodard et al., 2002), fibroblasts 
(Chrisman and Garbers, 1999; Horio et al., 2003), cardiomyocytes (Del Ry et 
al., 2011), brain and CNS (Totsune et al., 1994), macrophages (Casco et al., 
2002), chondrocytes (Hagiwara et al., 1994), and ECs (Stingo et al., 1992; Suga 
et al., 1998). In contrast to ANP, but similar to BNP, CNP is synthesised on 
demand. Indeed, under basal conditions CNP levels are low but increase 
substantially when exposed to pro-inflammatory stimuli such as tumour necrosis 
factor (TNF; Suga et al. 1993) and IL-1β (Suga et al. 1993), LPS (Suga et al. 
1993), and transforming growth factor-β (TGF-β; Suga, Nakao, Itoh, et al. 
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1992), basic fibroblast growth factor (bFGF; Woodard et al. 2002), or shear 
stress (Chun et al., 1997). The dogma governing CNP production is similar to 
the other NPs; CNP is first translated into preproCNP (126 amino acid peptide), 
which is cleaved to proCNP (103 amino acid peptide), then converted to CNP-
53 (53 amino acid peptide) by furin (a ubiquitous proprotein convertase; Wu et 
al. 2004; Thomas 2002). This peptide is further processed by an unknown 
mechanism, to yield the predominant biologically active form of CNP: CNP-22 
(22 amino acid peptide; CNP; Stingo et al. 1992; Figure 4).  
 
The cGMP-dependent biological effects of CNP are mediated via activation of 
NPR-B (Chrisman et al., 1993; Drewett et al., 1995). NPR-B consists of the 
same structural domains as NPR-A, possessing an intracellular guanylyl 
cyclase capable of generating cGMP but differs slightly in its extracellular ligand 
binding domain eliciting an altered preferred substrate-binding profile (Figure 3; 
Table 1). Natriuretic peptide receptor-B has a similar tissue expression profile 
as its ligand. This receptor is expressed in many tissues including bone 
(Yasoda et al., 1998), brain (Herman et al., 1996; Langub et al., 1995), 
fibroblasts (Chrisman and Garbers, 1999), kidney (Yoshimoto et al., 1996), 
heart (Del Ry et al., 2011; Dickey et al., 2007), lung (Bryan et al., 2006; Nagase 
et al., 1997), ECs (Del Ry et al., 2011) and VSMCs (Abbey and Potter, 2002; 
Casco et al., 2002).  
 
CNP/NPR-B signalling has a number of roles within the cardiovascular system. 
Firstly, like ANP, CNP is a potent vasodilator of conduit vessels; the ability of 
the peptide to cause vasodilation via NPR-B has been well characterised using 
pre-contracted vessels in the absence and presence of the NPR-A/B antagonist 
HS-142-1, suggesting a prominent role in regulating vascular tone (Drewett et 
al., 1995; Madhani et al., 2003; Wennberg et al., 1999; Wiley and Davenport, 
2001). Further, and similar to NPR-A activation, CNP/NPR-B signalling inhibits 
VSMC proliferation through the production of cGMP (Doi et al., 2001; Furuya et 
al., 1995, 1991; Hutchinson et al., 1997). Moreover, CNP/NPR-B signalling is 
essential for vascular homeostasis by sustaining the integrity of the 
endothelium; CNP promotes EC proliferation even after injury, thereby 
preventing the underlying SMC from being exposed to pro-mitogenic factors, 
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present in the circulation, which may result in pathological VSMC proliferation 
(Ohno et al., 2002; Yamahara et al., 2003). From this data one might expect to 
find clear effects of CNP/NPR-B signalling in reducing BP in vivo, however, this 
data is currently controversial. One of the most definitive methods to investigate 
the physiological effect(s) of CNP/NPR-B signalling is through the generation of 
transgenic animals. Both CNP (Komatsu et al., 2002) and NPR-B KO (Tamura 
et al., 2004) mice have been generated, and uncovered a striking biological role 
for CNP/NPR-B signalling; these animals were significantly shorter than WT 
littermates because of severe bone growth retardation. In both types of 
transgenic mice, this is due to blunting of endochondral ossification resulting in 
a reduction in longitudinal vertebra and limb-bone growth, dependent on cGMP 
generation triggered by CNP/NPR-B activation. The importance of CNP/NPR-B 
signalling in bone growth is mirrored in humans; loss of function mutations of 
NPR-B cause a specific type of dwarfism called acromesomelic dysplasia, type 
Maroteaux (AMDM; Bartels et al. 2004). In addition, members of the general 
population with a single defective allele of NPR-B are on average shorter than 
others (Olney et al., 2006). Surprisingly however, in these studies both CNP 
and NPR-B KO mice do not have significantly higher BP compared to WT 
littermates even when given high-salt diet (Komatsu et al., 2002; Tamura et al., 
2004). Indeed, no difference in the cardiovascular system were reported. 
Although, the characteristic bone growth retardation observed in NPR-B and 
CNP KO mice may have impeded investigations into the cardiovascular system 
(Chusho et al., 2001; Komatsu et al., 2002; Tamura et al., 2004).  
 
To overcome this caveat and better investigate the cardiovascular effects of 
CNP/NPR-B signalling Langenickel et al. (2006) generated a transgenic rat 
expressing a dominant negative NPR-B resulting in “knockdown” of the receptor 
leading to significantly blunted cGMP generating capacity dependent on NPR-B 
activation. These rats only develop modest skeletal abnormalities and so can be 
used to investigate cardiovascular parameters. Again, these NPR-B ‘deficient’ 
animals did not develop significantly altered haemodynamic capacity measured 
using telemetry in conscious animals. The rats also exhibited no changes in 
diuresis or natriuresis, a prominent characteristic of NPR-A activation. However, 
the animals did develop significant cardiac hypertrophy which was exacerbated 
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with chronic volume overload, independent of BP, suggesting an important role 
of NPR-B in cardiac remodelling. This finding has been substantiated by other 
groups. Using a model of congestive heart failure in mice (trans-aortic banding), 
Dickey et al. (2007) found CNP/NPR-B activity was twice as high compared to 
ANP/NPR-A activity in failing hearts, and Wang et al., (2007), using CNP over-
expression in mice, significantly reduced left ventricular hypertrophy developed 
following ischemia/reperfusion (I/R) injury. Such observations provide further 
evidence for an essential role of CNP/NPR-B signalling in protection against 
cardiac hypertrophy. However, despite experimental evidence in vivo 
demonstrating the inability of CNP/NPR-B signalling to reduce blood pressure, 
one study involving dosing healthy human volunteers with synthetic CNP 
caused irrefutable reductions in BP, mirrored by significant increases in plasma 
cGMP concentration, urinary excretion, diuresis and natriuresis, and a reduction 
in aldosterone secretion (Igaki et al., 1998). This effect is also observed in 
healthy rats, dogs and primates, again, with concomitant increases in cGMP 
(Aizawa et al., 2008; Clavell et al., 1993). In the context of cardiovascular 
disease plasma CNP levels are increased in both heart failure patients (Kalra et 
al., 2003; Tarazón et al., 2014; Wright et al., 2004) and patients with pulmonary 
hypertension (Kaiser et al., 2015).  
 
In sum, CNP/NPR-B signalling plays an important role in conduit vessel 
relaxation, inhibiting SMC proliferation, promoting the re-endothelialisation of 
damaged vessels, protection against cardiac hypertrophy and reducing BP in 
vivo. However, although it is clear CNP infusions significantly reduce blood 
pressure, deletion of NPR-B does not cause a significant increase in BP, which 
suggests CNP may be acting through an additional mechanism to regulate 
blood pressure, possibly within the resistance vasculature and not conduit 
vessels. This hypothesis is reinforced by HS-142-1, having almost no effect on 




1.3.4.4 Natriuretic Peptide Receptor-C (NPR-C)  
 
A third member of the natriuretic peptide receptor family, NPR-C, binds all three 
NPs with similar affinities (Table 1). NPR-C also plays a key role in the 
regulation of cardiovascular homeostasis but is not a guanylyl cyclase-coupled 
protein. NPR-C has a similar structure to NPR-A and NPR-B, in that it has a 
extracellular ligand binding domain that binds all NPs, followed by a 
transmembrane domain, but it lacks a C-terminal guanylyl cyclase domain and 
only contains a 37 amino acid long intracellular portion (Fuller et al., 1988; 
Porter et al., 1990). NPR-C is expressed throughout the body including the 
heart, kidney, brain, fibroblasts, adrenal gland, VSMCs, ECs, adipose, lung and 
platelets (Anand-Srivastava, 2005; Anand-Srivastava et al., 1990; Casco et al., 
2002; Fujishige et al., 1998; Fuller et al., 1988; Huntley et al., 2006; Jeffery et 
al., 2005; Nagase et al., 1997; Porter et al., 1990; Sun et al., 2001; Tsuruda et 
al., 2002; Xing et al., 2012). NPR-C was originally thought of as only a 
clearance receptor internalising and degrading all three NPs with relatively 
uniform binding affinities. When a NP binds to NPR-C, the peptide is removed 
from the extracellular space by peptide/receptor internalisation, followed by 
degradation of the peptide by lysozymes, after which the receptor is recycled 
back to the membrane (a phenomenon not found to occur with NPR-A and -B 
receptors; Cohen et al., 1996; Fan, 2005; Nussenzveig et al., 1990)  
 
The importance of NPR-C as a clearance receptor was made apparent by the 
generation of NPR-C KO mice which develop significantly elongated spine and 
limbs, hypotension (in males), and an inability to concentrate urine (Matsukawa 
et al., 1999). The skeletal effects are thought to be due to excessive local CNP 
concentrations in the vicinity of bone resulting from a deficient clearance 
mechanism. This hypothesis is supported by the reverse phenotype (dwarfism) 
observed in both CNP and NPR-B KO mice where endochondral ossification is 
impaired from reduced CNP/NPR-B signalling (Komatsu et al., 2002; 
Matsukawa et al., 1999). Natriuretic peptide receptor-C KO mice generate 
significantly higher urinary cGMP concentrations suggesting enhanced NPR-A 
and/or NPR-B activation, and decreased ANP clearance (BNP and CNP were 
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not reported). However, plasma levels of ANP and BNP (CNP plasma levels 
were not reported) were not significantly elevated refuting the rationale that 
reducing the expression of NPR-C leads to significantly higher levels of NPs, in 
the circulation at least. This led the authors to reasonably infer that NP 
signalling is enhanced at the local level (D’Souza et al., 2004). NPR-C KO mice 
have a significantly elevated haematocrit, compared to their age matched WT 
littermates, suggesting NPR-C KO mice have lower intravascular volume. 
Moreover, NPR-C KO mice have significantly elevated urinary output. 
Therefore, the absence or reduction in NPR-C, in the kidney specifically, leads 
to a blunted clearance of ANP (a potent diuretic), increased availability, 
activation of NPR-A, causing an enhanced GFR, and increased urinary cGMP 
and urinary output. This hypothesis was supported by water loading NPR-C KO 
mice which demonstrated an impaired ability to concentrate urine compared to 
WT littermates, and with the pharmacological use of cANF4-23 (a ring-deleted, 
truncated ANP which acts as an NPR-C partial agonist; Maack et al., 1987)  
 
The notion that NPR-C can additionally behave as a direct signalling pathway 
was first eluded to by Anand-Srivastava & Cantin (1986) who treated cultured 
rat neonatal atrial and ventricular myocytes with ANP and found it to inhibit, 
concentration-dependently, inherent adenylyl cyclase activity (lowering cAMP). 
In addition, adenylyl cyclase activators (e.g. forskolin and isoproterenol) were 
also inhibited by ANP. This same group determined the mechanism behind this 
phenomenon by utilising Pertussis toxin (PT), a known antagonist of inhibitory 
guanine nucleotide regulatory proteins (Gi/o), which abolished the inhibitory 
effects of ANP on cAMP generation in rat aorta (Anand-Srivastava and Cantin, 
1986). The effects of ANP were mimicked using cANF4-23 in rat VSMCs, 
showing specifically that NPR-C agonism leads to decreases in intracellular 
cAMP without changing intracellular cGMP, ruling out inhibitory effects of cGMP 
production (Anand-Srivastava et al., 1990). Building on this work, using an 
antibody raised against the intracellular 37 amino acid cytoplasmic domain of 
NPR-C, the authors were able to block the action of Gi/o (Anand-Srivastava et 
al. 1996).   
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In addition to cANF4-23, CNP itself has been found to activate NPR-C signalling. 
Villar et al. (2007), using the NPR-C antagonist M372049, demonstrated that in 
the resistance vasculature (rat mesentery) vessel relaxations elicited by CNP 
were dependent on NPR-C activation. In addition, relaxations by ANP and the 
NO donor Spermine NONOate (Sp-NO) were not affected confirming two 
independent relaxant mechanisms. This characteristic was specific to the 
resistance vasculature as M372049 had no effect on CNP, ANP and Sp-NO –
induced relaxations in rat aorta. Interestingly, M372049 also blocked the 
vasoactivity of endothelium-derived hyperpolarising factor (EDHF). 
Endothelium-derived hyperpolarising factor, as the name suggests, is a 
mediator(s) released from the endothelium which acts on VSMCs causing 
vessel relaxation via cell hyperpolarisation (Chen et al., 1988). EDHF is the third 
endothelium-derived factor to be identified after NO and prostacyclin (PGI2); 
EDHF has been found to be the predominant mechanism underpinning vessel 
relaxation in the resistance vasculature (Shimokawa et al., 1996). EDHF causes 
hyperpolarisation by one of two mechanisms, or both; by activating G protein-
coupled inwardly rectifying K+ channels (GIRK) or Na+/K+ ATPase (Chauhan et 
al., 2003). Chauhan et al., (2003) & Villar et al. (2007) found CNP/NPR-C-
dependent relaxations of mesenteric resistance arteries were inhibited by 
barium (Ba2+), a GIRK inhibitor, and M372049, illustrating the importance of 
endothelial-derived CNP in resistance vessel relaxation, and that CNP acts as 
an EDHF through NPR-C signalling. Furthermore, Hobbs et al. (2004) 
demonstrated the effectiveness of targeting CNP/NPR-C signalling in the 
protection against cardiovascular disease; specifically, CNP and cANF4-23 acting 
through NPR-C significantly reduced infarct size and coronary perfusion 
pressure following I/R injury.  
 
Substantiation of the cardiovascular importance of this novel vascular 
mechanism (i.e. CNP/NPR-C signalling) came in 2014 with a publication by 
Moyes et al., (2014). The authors generated an endothelial cell specific CNP 
KO mouse (ecCNP KO), and along with global NPR-C KO mice demonstrated a 
key function of this pathway in protecting against the development of endothelial 
dysfunction and hypertension (females only), atherogenesis, and aneurysm 
(males only). CNP/NPR-C signalling inhibits VSMC proliferation and promotes 
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the proliferation of ECs explaining, at least in part, why ecCNP KO mice 
develop atherosclerosis (Khambata et al., 2011). Overall, these data suggest 
that the preferential female cardiovascular protective effect of EDHF described 
by Scotland et al., (2005), is predominantly derived from the release of CNP 
from the endothelium, to protect against cardiovascular pathogenesis.  
 
1.3.4.5 Proteolysis of natriuretic peptides (NPs) 
 
In addition to clearance by NPR-C, NPs undergo proteolytic degradation. There 
are several different proteases that are known to degrade NPs. One of those is 
neutral endopeptidase-24.11 (NEP; neprilysin; EC 3.4.24.11; enkephalinase; 
common acute lymphoblastic leukemia antigen; CD10), a type-II integral 
membrane metallopeptidase (Turner and Tanzawa, 1997). NEP is a membrane-
bound zinc-dependent enzyme, which degrades all three NPs but has a 
preference for ANP over BNP and CNP (Dussaule et al., 1993; Kenny et al., 
1993; Okolicany et al., 1992; Watanabe et al., 1997). NEP inactivates all three 
NPs in a similar way; several different peptide bonds are hydrolysed across the 
ring structure causing the shape to open up, thus inactivating it (Potter, 2015). 
NEP is expressed throughout the body including kidney, lung, ECs, VSMCs, 
cardiomyocytes, fibroblasts, neutrophils, brain, and adipose tissue (Erdös and 
Skidgel, 1989; Graf et al., 1995; Kerr and Kenny, 1974a, 1974b; Malroy et al., 
1978; Shima et al., 1988; Standeven et al., 2011). This protease does not just 
hydrolyse NPs but instead has a broad substrate profile, consisting of both 
vasodilators and vasoconstrictors including angiotensin I, II and III (Ang-I, II, III), 
endothelin-1 (ET-1), bradykinin (BK), substance P, as well as ANP, BNP and 
CNP (Emoto and Yanagisawa, 1995; Stephenson and Kenny, 1987; 
Vijayaraghavan et al., 1990). NEP inhibition has been a focus of attention in 
terms of a novel therapy for cardiovascular disease for many years. NEP 
inhibition increases circulating ANP concentrations to levels that should be of 
clinical benefit (Bevan et al., 1992; Okolicany et al., 1992; Olins et al., 1989); 
however, clinical trials using the NEP inhibitor candoxatril revealed that NEP 
inhibition does not lower BP, presumably due to simultaneous increases in 
vasoconstrictors (Bevan et al., 1992; Richards et al., 1993). To circumvent this 
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caveat combining NEP inhibition with inhibitors of certain vasoconstrictors (e.g. 
with an angiotensin receptor blockers in the molecule LCZ696) provides greater 
efficacy (Mangiafico et al., 2013; Vardeny et al., 2014). Although NEP inhibition 
significantly increases plasma ANP concentrations, mice deficient in NEP do 
not develop skeletal deformities like NPR-C KO mice suggesting NEP 
dependent degradation of CNP is not as crucial compared to NPR-C dependent 
clearance (Lu et al., 1995).  
 
There are other proteolytic enzymes that degrade NPs such as insulin-
degrading enzyme (IDE) and exopeptidase dipeptidyl-peptidase IV (DPP 
IV/CD26; EC 3.4.14.5). IDE is a zinc metalloprotease found in both cytoplasmic 
and membrane fractions, and hydrolyses all three NPs with a preference for 
ANP, suggesting another potential target for increasing circulating NPs for 
therapeutic gain (Müller et al., 1992; Potter, 2015; Volpe, 2014). DPP IV is a 
cell-surface protease, also present in the plasma in soluble form, is found 
expressed throughout the cardiovascular system including ECs (Silva Júnior et 
al., 2015). DPP IV has a broad substrate profile but only degrades BNP out of 
the NPs (Brandt, 2006; Volpe et al., 2014),  
 
1.4 Cyclic GMP degradation 
 
1.4.1 Phosphodiesterases (PDEs) 
 
Phosphodiesterases (PDEs) are a superfamily of metallophosphohydrolases 
that selectively hydrolyse the 3’,5’-cyclic phosphate moiety of both cAMP and 
cGMP generating the inactive forms of these cyclic nucleotides, 5’-AMP and 5’-
GMP (Butcher and Sutherland, 1962; Figure 1). PDEs are either membrane-
bound or cytosolic enzymes composed of 16 α-helices containing 3 subdomains 
that define where substrates bind (Conti and Beavo, 2007; Jin et al., 1992). In 
total there are 11 families of PDEs; however, splice variants exist within each 
family bringing the number of known PDEs to >100 (Bender and Beavo, 2006). 
The first report of PDE activity was noted in 1961, almost at the same time as 
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the discovery of cyclic nucleotides themselves, and established by the 
identification of PDE inhibitors caffeine and theophylline, forms of 
methylxanthine (Butcher and Sutherland, 1962; Smith et al., 1961, 1958). The 
11 PDE families can be organised by their substrate specificity; cGMP specific 
PDEs (PDE5, 6 and 9), cAMP specific PDEs (PDE4, 7 and 8) and dual 
substrate specificity PDEs (PDE1, 2, 3, 10 and 11; Bender & Beavo 2006; Table 
2). This specificity is based on their affinity for each substrate (cGMP and 
cAMP), and cellular localisation; these characteristics are very important in 
tightly regulating the local concentration of cAMP and cGMP within the cell. 
Moreover, compartmentalisation of cyclic nucleotide signalling is crucial in 
determining the spatial and temporal generation of cGMP (and cAMP) in vivo 
and thus specific physiological effects (K. Arora et al., 2013). This phenomenon 
was first identified 40 years ago in isolated perfused hearts where different 
contractile responses were observed using two different agonists; prostaglandin 
E1 (PGE1; a prostanoid receptor agonist) and isoproterenol (a β-adrenergic 
receptor agonist). Both increased intracellular cAMP and activated the same 
down-stream signalling molecule (i.e. PKA), but isoproterenol activated 
membrane-bound fractions, compared to PGE1 that activated cytosolic 
fractions, explaining the functional differences (Brunton et al., 1979; Corbin et 
al., 1977). Ten years later, other studies using PDE inhibitors in guinea pig 
perfused hearts showed that using isoproterenol to generate intracellular cAMP, 
and therefore improve contraction, could then be significantly enhanced when 
combined with 3-isobutyl-1-methylxanthine (IBMX; a non-specific PDE inhibitor) 
or milrinone (a PDE3 inhibitor) without affecting the activity of known 
downstream signalling molecules (PKA) despite significant increases in global 
intracellular cAMP (Rapundalo et al., 1989; Weishaar et al., 1987). In the 
context of cGMP generation in ECs, concentrations of cGMP generated by sGC 
(cytosolic) are smaller and more brief than concentrations of cGMP generated 
by pGC (membrane-bound), but it is sGC stimulation that is more efficient in 
relaxing ECs, measured as changes of planar cell surface area, compared to 
pGC stimulation leading to the conclusion that sGC excitation-relaxation 
coupling is more efficient (Rivero-Vilches et al., 2003). This same cGMP 
signalling dichotomy (pGC v sGC) has also been observed in cardiac myocytes 
(Castro et al., 2006). Cell signalling compartmentalisation can be observed 
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using fluorescence resonance energy transfer (FRET) allowing the generation 
and degradation of intracellular cAMP and cGMP to be visualised in real-time 
(Honda et al., 2001; Ponsioen et al., 2004; Stangherlin and Zaccolo, 2012; 
Zaccolo et al., 2000). It is also been possible to observe cGMP signalling 
coupled with in vivo physiological responses using intravital microscopy and 
transgenic mice expressing FRET based markers for cGMP (Thunemann et al., 
2014, 2013). Using these techniques scientists are now able to observe that 
upon generation, cGMP forms “pools” or “clouds” in specific areas of the cell, 
which is prevented from spreading by the action of PDEs.  
 
There are three cGMP specific PDEs: PDE5, PDE9. PDE6 is known as a 
photoreceptor PDE because it is widely expressed throughout the mammalian 
retina and plays an important role in mediating the conversion of a light into a 
photoresponse (Bender and Beavo, 2006). Until recently little was known about 
the function of PDE9, despite having a broad tissue expression profile (Bender 
and Beavo, 2006). Recently the role of PDE9 has been clearly described in 
hypertrophic heart disease (Lee et al., 2015). The authors of this paper showed 
that PDE9 inhibition protects against pressure-overload stress in heart 
myocytes and muscle, and reverses pre-established heart disease by 
increasing cGMP levels, preferentially favouring pGC generated cGMP (since 
specific sGC generated cGMP had no affect; Lee et al., 2015). Arguably the 
most well-known cGMP-specific PDE is PDE5, which is expressed widely in the 
body (e.g. VSMC, heart, lung, brain, kidney and platelets; Giordano et al., 2001; 
Kotera et al., 2000; Loughney et al., 1998; Stacey et al., 1998; Yanaka et al., 
1998). Inhibitors of this enzyme were originally designed to treat hypertension 
but, during clinical trials, were soon found to produce penile erection in males; 
these inhibitors, exemplified by sildenafil (Viagra), are now widely prescribed to 
treat erectile dysfunction. More recently, using vascular reactivity studies, 
sildenafil has been shown to significantly potentiate the cGMP-dependent 
vasodilatory effect of ANP in the pulmonary, but not systemic circulation (Baliga 
et al., 2008). In addition, PDE5 expression is significantly increased in the lungs 
of PH patients and in preclinical models; in accord, clinical evaluation has 
proven efficacy of sildenafil (and other PDE5 inhibitors) in patients with PH and 
is now licensed for this indication (Sastry et al., 2004; Wharton et al., 2005). 
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cGMP specific cAMP specific Dual specificity 
PDE5 PDE4 PDE1 
PDE6 PDE7 PDE2 
PDE9 PDE8 PDE3 
  PDE10 
  PDE11 
 
Table 2. A table describing cyclic nucleotide degradation specificity of all 
11 phosphodiesterases (PDEs). 
 
1.4.1.1 Dual specificity PDEs (PDE2 and PDE3)  
 
PDE2 is expressed widely in mammals including the brain, heart, platelets, 
ECs, adrenal glomerulosa cells (Bender and Beavo, 2006). Known as a dual 
substrate enzyme and present in both the membrane and cytosol, PDE2 not 
only degrades the cAMP and cGMP signal but also acts as an effector protein 
because the binding of cGMP to an allosteric site stimulates the activity of the 
enzyme. Through this phenomenon this enzyme mediates both “cross-talk” 
between the two signalling pathways (cGMP and cAMP), and provides a 
negative feedback mechanism. Activation of the allosteric site increases the 
rate at which PDE2 hydrolysis either cAMP or cGMP and therefore its effect is 
dependent on the local concentration of either cyclic nucleotide at the time. 
Moreover, in areas of high cGMP concentration, PDE2 will be stimulated and 
act has a negative feedback mechanism; however, in areas of high 
concentrations of cAMP, PDE2 can be activated by low concentrations of cGMP 
(the allosteric site has a ~10-fold higher affinity for cGMP compared to cAMP) to 
hydrolyse cAMP. An example of this “cross-talk” is from the addition of ANP to 
adrenal glomerulosa cells which increases the breakdown of cAMP by PDE2 to 
inhibit aldosterone production (MacFarland et al., 1991). PDE2 is also important 
in the heart as a negative feedback mechanism; PDE5 is a cGMP specific PDE 
and controls cGMP levels generated in the cytosol of cardiomyocytes, whereas 
membrane produced cGMP is degraded by PDE2, this is another example of 
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cGMP signalling compartmentalisation (Fischmeister et al., 2006). These 
phenomena have been demonstrated functionally in a rat disease model of PH, 
where PDE2 inhibition (BAY 60-7550) potentiates the therapeutic benefit of 
NPs, NO and the PGI2 analogue treprostinil, suggesting a new therapeutic 
target for the treatment of this disease (Bubb et al., 2014). 
 
PDE3 is also a membrane-bound and cytosolic, dual substrate, enzyme 
hydrolysing both cAMP and cGMP (Bender and Beavo, 2006). Unlike PDE2, 
which is activated by cGMP, PDE3 is inhibited by cGMP and thus another 
cGMP effector protein (Bender and Beavo, 2006). Although, PDE3 binds to 
cAMP and cGMP with similar affinities, the concentration at which PDE3 is 
saturated (Vmax) when hydrolysing cAMP is 10-fold higher than it is for cGMP, 
therefore at higher concentrations of cGMP, cAMP degradation is lower (Bender 
and Beavo, 2006). PDE3 is expressed in platelets, VSMCs, cardiac myocytes 
and adipose tissue (Shakur et al., 2001). The PDE3 inhibitors milrinone, 
cilostamide, cilostazol, and trequinsin, attenuate platelet aggregation, VSMC 
proliferation and vasodilation (Maurice and Haslam, 1990; Shakur et al., 2001). 
 
1.4.2 Multidrug resistance proteins (MRPs) 
 
In addition to the well-established degradative pathways conveyed by PDEs, 
efflux of cGMP (and cAMP) has been hypothesised to play a role in dynamically 
regulating the signalling attributed by both cyclic nucleotide second 
messengers. Originally, efflux as a mechanism of regulating intracellular cyclic 
nucleotide concentrations was not deemed important because of its small 
magnitude compared to degradation by PDEs (Mercapide et al., 1999). 
However, recently there has been an abundance of evidence demonstrating 
cyclic nucleotide efflux as an important regulator of physiological function.  
 
Cellular efflux of cyclic nucleotides was first observed around the same time as 
their discovery; hormones stimulating the generation of cAMP led to 
concomitant increases in extracellular cAMP (Davoren and Sutherland, 1963; 
Sutherland and Rall, 1958). Indeed, for many years plasma and urinary cAMP 
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and cGMP concentrations have been used as a routine measure for this 
phenomenon without knowledge of the mechanisms responsible (Hamet et al., 
1989). It was not until 1999 that the first multidrug resistance protein (MRP4) 
capable of transporting nucleotide analogues was identified (Schuetz et al., 
1999). This was soon followed by identification of MRP5 which has the ability to 
export cGMP and cAMP (Jedlitschky et al., 2000). MRP5 is part of a family of 
MRPs which are members of the large ABC (ATP-binding cassette) superfamily 
of energy-dependent, transmembrane transporters, and is also known by the 
name ABCC5. The subfamily C of the ABC superfamily, in other words the 
“ABCC” proteins, is composed of 13 separate transporters (Deeley et al., 2006; 
Table 3); these comprise of 10 MRPs, two sulfonylurea receptors (SUR) and the 
cystic fibrosis transmembrane-conductance regulator (CFTR; Dean et al. 2001; 
Table 3). The general structure of ABC transporters consists of two membrane 
spanning domains (MSDs) and two intracellular nucleotide binding domains 
(NBDs; Deeley et al. 2006; Figure 5). MRP4, 5, 8 and 9 have the usual ABC 
transporter structure but MRP1, 2, 3, 6 and 7 have an extra transmembrane 
domain (three in total; Deeley et al. 2006). ABCC family transporters, as a 
whole, have a hugely diverse substrate profile; this includes chemotherapeutics 
which, in 1992, was how the first MRP (MRP1) was identified, because of its 
contribution to multidrug resistance (MDRs) in a human lung cancer cell line 
(Cole et al., 1992; Mirski et al., 1987). MRPs have specific properties; they are 
unidirectional (transport from intracellular to extracellular) that can operate 
against substantial concentration gradients, ATP-dependent, inhibited by 
compounds such as probenecid (an organic anion transporter protein inhibitor; 
OAT) and prostaglandins, and have saturable kinetics (Campbell and Taylor, 
1981; Doore et al., 1975; Finnegan et al., 2011; Rindler et al., 1978). Multidrug 
resistance proteins vary in their ability to export individual substrates but as a 
family they transport, either on their own or as glucuronide (GSH) or glutathione 
disulphide (GSSG) conjugates, a huge array of substrates which makes them 
crucial in the protection against accumulation of cytotoxic xenobiotics (Cole and 
Deeley, 1998; Deeley et al., 2006; Slot et al., 2011). MRPs are known to export 
arachidonic acid derivatives (e.g. PGE2, PGE1, leukotriene C4; LTC4), steroids 
and conjugates (e.g. bilirubin glucuronide, glycocholic acid, oestradiol 
glucuronide), purine nucleotide/nucleoside analogues, pyrimidine nucleoside 
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analogues, nucleobase analogues, cyclic nucleotides (e.g. cAMP, cGMP), folic 
acid analogues (e.g. methotrexate), antibiotics, endobiotics, xenobiotics (e.g. 
paracetamol, morphine, adefovir), tyrosine kinase inhibitors (TKI; e.g. imatinib, 
nilotinib, erlotinib) and many more substrates (Borst et al., 2007; Deeley et al., 
2006; Slot et al., 2011; Sodani et al., 2012).  
 
Figure 5. An illustration of multidrug resistance protein substrate efflux. 
Multidrug resistance protein (MRP), adenosine-5'-triphosphate (ATP), 
adenosine-5'-diphosphate (ADP), inorganic phosphate (Pi), transmembrane 
domain (TMD), nucleotide binding domain (NBD).  
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ABCC1 MRP1 No No 
ABCC2 MRP2 No No 






Km = 9.69 ± 2.3 µM 
Vmax = 2.01 ± 0.34 
pmol/mg/min 
Yes$  
Km = 44.5 ± 5.8 µM 







Km = 2.1 ± 0.2 µM 
Vmax/Km = 2100 µl x 
mg-1 protein x min-1 
Yes# 
Km = 379 ± 24 µM;  
Vmax/Km = 90 µl x 
mg-1 protein x min-1 
ABCC6 MRP6 No No 
ABCC7 CFTR No No 
ABCC8 SUR1 No No 
ABCC9 SUR2A/2B No No 
ABCC10 MRP7 No No 
ABCC11 MRP8 Yes Yes 
ABCC12 MRP9 No No 
ABCC13 MRP10 No No 
ABCG* BCRP* Yes No 
Table 3. A table describing the members of the ABC superfamily that 
transport cyclic nucleotides.  
A table describing the members of the ABC superfamily that transport cGMP 
and cAMP (ABCC4/MRP4, ABCC5/MRP5 and ACC11/MRP8), plus 
ABCG/BCRP. Sulfonylurea receptors SUR, cystic fibrosis conductance 
regulator (CFTR), multidrug resistance protein (MRP), breast cancer resistance 
protein (BCRP; Dean and Allikmets, 2001; Dean et al., 2001). *BCRP/ABCG is 
a member of the ABC superfamily but not subfamily C, rather subfamily G. 
$MRP4 Km value expressed as mean ± SEM (Chen et al., 2001). #MRP5 Km 
value expressed as mean ± standard deviation (SD; Jedlitschky et al. 2000). 
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There are three MRPs that transport both cAMP and cGMP with varying 
affinities: MRP 4, 5 and 8 (Slot et al., 2011; Table 3). The human breast cancer 
resistance protein (BCRP; ABCG) is also a member of the ABC superfamily but 
subfamily G (rather than subfamily C); its role in chemotherapy resistance is 
well characterised but it has only recently been identified to transport cGMP. 
Little is known about its cGMP-dependent function although it has recently been 
found expressed in the heart suggesting a possible cardiovascular role (de Wolf 
et al., 2007; Evans et al., 2008; Meissner, 2006).  
 
MRP4 is ubiquitously expressed in the mammalian body, found in the adrenal 
glands, brain, heart, lung, kidney, erythrocytes, platelets, VSMCs and ECs 
(Mitani et al., 2003; Ritter et al., 2005; Sager and Ravna, 2009; Slot et al., 2011; 
Tagami et al., 2010). MRP4 exports both cGMP and cAMP leading to the 
rationale that this protein may play a role in cardiovascular homeostasis (Chen 
et al. 2001; Cheepala et al. 2011; Wielinga et al. 2003; Table 3). In 2008, Sassi 
et al. established for the first time a definitive link between cyclic nucleotide-
dependent decreases in VSMC proliferation due to MRP inhibition. The authors 
of this study, using cultured human coronary smooth muscle cells (hCASMC), 
found a MRP4 specific silencing ribonucleic acid (siRNA) significantly inhibited 
proliferation with a concomitant increase in both cAMP and cGMP 
intracellular/extracellular ratios. This effect was further enhanced upon addition 
of the non-specific PDE inhibitor IBMX, suggesting MRPs are used as a 
compensatory cyclic nucleotide “degradative” mechanism in the absence of 
functional PDE. Interestingly, the authors found that MRP4 expression at the 
mRNA and protein level was significantly enhanced in proliferating hCASMCs 
suggesting a possible therapeutic target in pathological VSMC proliferation. 
Furthermore, using an in vivo model, rat carotid artery balloon injury, treatment 
with an adenoviral vector expressing short-hairpin RNA (shRNA) against rat 
MRP4 resulted in a significantly reduced intima thickening (i.e. VSMC 
proliferation). However, despite significant increases in intracellular/extracellular 
ratios of both cGMP and cAMP, it appeared that this was predominantly a 
cAMP-dependent mechanism because only inhibition of PKA, and not PKG, re-
established VSMC proliferation. The authors of this study concluded that MRP4, 
in this context, acted as a predominantly cAMP extrusion mechanism (Sassi et 
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al., 2008). These findings led to further studies from this same group in a 
preclinical model of PH (Hara et al., 2011). The authors found that MRP4 
expression was significantly increased, in both VSMCs and ECs, at the mRNA 
and protein level in lungs from patients with PH compared to controls. This 
finding was mirrored in mice exposed to chronic hypoxia (5 weeks, 10 % O2) in 
which MRP4 expression was significantly increased in the pulmonary arteries 
compared to normoxic control mice. Furthermore, these authors used the MRP 
inhibitor MK571 and MRP4 KO mice to implicate this MRP isoform in the 
pathogenesis of PH, and as a potential therapeutic target. Mice administered 
MK571 or deficient in MRP4 had significantly reduced right ventricular systolic 
pressures (RVSP), right ventricular hypertrophy (RVH) and muscularised 
pulmonary vessels, all hallmarks of PH. Interestingly, in lung lysates the activity 
PKA and PKG were significantly increased in mice treated with MK571, 
suggesting MRP inhibition was eliciting its therapeutic action by significantly 
increasing cAMP and cGMP levels. This observation was mirrored in cultured 
human pulmonary artery smooth muscle cells (hPASMCs), treated with an 
MRP4 specific siRNA, in which the activity of PKA and PKG were also 
significantly increased (as shown by significantly elevated 
intracellular/extracellular ratios of both cAMP and cGMP). Notably, the effect of 
MRP inhibition was accentuated in the presence of sildenafil, suggesting that in 
the absence of PDE degradation, MRP activity is significantly elevated, which 
enhances cGMP concentrations, subsequently increasing cAMP levels, possibly 
via PDE3 inhibition. Indeed, genetic deletion of MRP4 leads to significantly 
increased heart weight, cardiomyocyte size, left ventricular wall thickness and 
interventricular septum with a concomitant increase in cardiac ANP gene 
expression (Sassi et al., 2012). These mice also have extended bleeding times 
demonstrating that MRP4 promotes platelet aggregation by decreasing 
intracellular cAMP and cGMP (Borgognone and Pulcinelli, 2012; Decouture et 
al., 2015). Such observations substantiate a cardiovascular homeostatic role for 
this protein, and cAMP/cGMP efflux. 
 
To further investigate a possible the link between MRP4 and cGMP efflux in the 
vasculature, Krawutschke et al. (2015) used a FRET based system to visualise 
in real-time the generation of cGMP in primary VSMCs. In this setting, the 
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authors used MK571 as an “MRP4-specific” inhibitor, which enhanced the 
magnitude and duration of cGMP generated from increasing concentrations of 
CNP, ANP and the NO donor S-nitroso-L-glutathione (GS-NO). Although, the 
authors concluded this was a MRP4 specific phenomenon, MK571 has also 
been shown to inhibit MRP5 (Reid et al., 2003). 
 
In sharp contrast to MRP4, little or nothing is known about the function of MRP5 
in the context of cyclic nucleotide transport. MRP5 is not ubiquitously expressed 
and appears to have a more specific expression profile in brain, heart, 
fibroblasts, erythrocytes, VSMCs and ECs (Borst et al., 2007; Dazert et al., 
2003; Meissner et al., 2007; Mitani et al., 2003; Sager, 2004; Slot et al., 2011). 
MRP5 exports both cAMP and cGMP making it a prime candidate, alongside 
MRP4, for regulating cardiovascular homeostasis; however, the actual role of 
MRP5 is not fully understood (Cheepala et al., 2011; Jedlitschky et al., 2000; 
Reid et al., 2003; Slot et al., 2011). Sassi et al., (2008) consider MRP5 as an 
endothelial specific protein because minimal expression of this MRP can be 
found in VSMCs. However, this is in contrast to other evidence showing 
significant MRP5 expression in VSMCs (Dazert et al., 2003; Meissner et al., 
2007; Mitani et al., 2003; Xu et al., 2004). MRP5 is highly expressed in 
throughout the human heart, in cardiac ECs and VSMCs, atrial and ventricular 
cardiomyocytes, and the endocardium (Dazert et al., 2003). Interestingly, MRP5 
expression is also increased in the hearts of patients suffering from ischemic 
(ICM) and dilated (DCM) cardiomyopathy, suggesting MRP5 may be 
contributing to the pathology and that inhibition of MRP5 might be an attractive 
target to increase beneficial intracellular cyclic nucleotide concentrations 
(Dazert et al., 2003). Notably, MRP5 KO mice do not have an overt phenotype, 
and this is the same for the MRP4/MRP5 double KO (Borst et al., 2007). This is 
at odds with the adverse cardiovascular phenotype in MRP4 KO mice, and 
more in-depth and rigorous cardiovascular investigations need to be performed 
to discern differences (Sassi et al., 2012).  
 
Even less is known about the physiological role of MRP8; it is known to export 
both cAMP and cGMP, and is found in a variety of tissues including the brain, 
lung, liver and kidney (Bera et al., 2001; Slot et al., 2011; Tammur et al., 2001; 
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The Human Protein Atlas, 2008; Yabuuchi et al., 2001). However, there is no 
evidence describing its role in the cardiovascular system. Interestingly, a single 
nucleotide polymorphism exists in the human gene that codes for MRP8; this 
mutation is commonly found in East Asian populations and causes dry earwax 
because of its role in determining the type of earwax (cerumen) produced by the 
ceruminous apocrine glands through secretion of the aliphatic or aromatic 
hydrocarbon constituents, although it is not known whether cyclic nucleotides 
are involved in this phenomenon (Martin et al., 2010; Yoshiura et al., 2006). 
 




One cardiovascular pathology in which modulation of cGMP signalling has 
proven particularly fruitful in terms of therapeutics, and in understanding the 
cardio- and vaso- protective mechanisms proffered by cyclic nucleotides, is 
pulmonary hypertension (PH).  
 
PH is a syndrome per se, manifested by a large collection of diseases that 
mainly affect the cardiorespiratory system. PH is defined by a single diagnostic 
haemodynamic feature: mean pulmonary artery pressure >25 mm Hg, at rest 
(PAPm >25 mm Hg, at rest; Hoeper et al., 2013). Patients diagnosed with PH 
are categorised into a subgroup based on identifiable causes and risk factors, 
and similar pathological findings, hemodynamic characteristics and treatment 
management. Group 1: pulmonary arterial hypertension (PAH); Group 2: 
pulmonary hypertension due to left heart disease; Group 3: pulmonary 
hypertension due to lung diseases and/or hypoxia; Group 4: chronic 
thromboembolic pulmonary hypertension (CTEPH); Group 5: pulmonary 
hypertension with unclear multifactorial mechanisms (Simonneau et al. 2013; 
Figure 6). Group 1 PH or pulmonary arterial hypertension (PAH) is clinically 
defined by a pulmonary artery wedge pressure (PAWP) ≤15 mm Hg and 
elevated pulmonary vascular resistance (PVR) >3 wood units (WU), in addition 
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to PAPm ≥25 mm Hg, at rest and in the absence of other known causes of PH 
(Hoeper et al. 2013; Figure 6). The Registry to Evaluate Early and Long-term 
Pulmonary Arterial Hypertension Disease Management (REVEAL Registry) 
conducted in the United States of America (USA) includes, to date, the largest 
cohort of PH patients (3,515) of any such study, and found the median survival 
for patients diagnosed with PAH to be seven years (Benza et al., 2012; McGoon 
et al., 2013). Although this is a major improvement on the median survival of 
patients diagnosed with PAH in 1991 (2.8 year), and reflects the substantial 
improvement in treatment strategies. In addition, PAH demonstrates a 
significant sex-difference; within the REVEAL study cohort, around 80 % of 
patients were female (McGoon et al., 2013). Even with modern therapies 
patients suffer from a 15 % mortality rate within the first year of receiving 
treatment, demonstrating that PAH is still a severe unmet medical need and 
would benefit from novel effective therapies (Alonzo et al., 1991; Benza et al., 




Figure 6. Current classification of pulmonary hypertension.  
Bone morphogenic protein receptor type II (BMPR); caveolin-1 (CAV1); 
endoglin (ENG); human immunodeficiency virus (HIV); pulmonary arterial 
hypertension (PAH); mothers against decapentaplegic 9 (Smad9); activin-like 
receptor kinase-1 (ALK1); bone morphogenic protein receptor type 2 (BMPR2); 





PAH is a complex and severe pan-vasculopathy with increased PAP resulting 
from a combination of sustained vasoconstriction, progressive vascular 
remodelling and thrombosis in situ, primarily affecting the pre-capillary arterioles 
(<100 µm diameter; Archer et al., 2010; Intengan and Schiffrin, 2000; Tuder et 
al., 2013). A loss of vascular luminal cross-sectional area restricts flow, 
increasing pulmonary vascular resistance (PVR), generating a compensatory 
increase in RVSP; the right ventricle (RV) remodels to sustain high pressures 
through adaptive RVH, which eventually leads to maladaptive right ventricular 
hypertrophy (RVH), failure, and ultimately death (Voelkel et al., 2012, 2006; 
Vonk-Noordegraaf et al., 2013).  
 
It is thought that endothelial dysfunction or injury initiates PAH pathogenesis; 
however, the cause(s) of the deficit is yet to be determined (Rabinovitch, 2012). 
Examples of endothelial dysfunction are chronically impaired production of the 
vasodilators PGI2 and NO, and/or a shift to production of vasoconstrictors 
thromboxane A2 (TXA2), ET-1 and 5-hydroxytryptamine (5-HT; Christman 1992; 
Zakrzewicz et al. 2007; Giaid & Saleh 1995; Bauer et al. 2002; Behr & Ryu 
2008; Yu et al. 2004; Hervé et al. 1995; Stewart et al. 1991; Tuder et al. 1999; 
Rubens et al. 2001). In addition, expression and activity of cGMP degrading 
PDEs (e.g. PDE1 and PDE5) is increased in PAH, further impairing the 
beneficial effects of cGMP signalling (Baliga et al., 2008; Klinger et al., 2006; 
Rabe et al., 1994). In addition to effects of vascular tone, endothelial 
dysfunction/injury promotes proliferation in pulmonary VSMCs leading to the 
characteristic histopathological features medial hyperplasia and hypertrophy 
(Pietra et al., 2004; Stacher et al., 2012). Pulmonary VSMC proliferation is 
promoted in a number of different ways; the vasoconstrictors ET-1 and 5-HT 
promote growth (Davie et al., 2002; Eddahibi et al., 2006), altered expression 
and function of K+ and Ca2+ channels can lead to membrane depolarisation and 
an increase in intracellular Ca2+ triggering cell-cycle progression and 
proliferation (Burg et al., 2008; Yu et al., 2004; Yuan et al., 1998). Increased 
expression of tyrosine kinase receptors (e.g. vascular endothelial growth factor 
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receptor 2; VEGFR-2) as well as secretion of growth factors (e.g. VEGF, bFGF, 
TGF-α, PDGF; epidermal growth factor; EGF) act as potent mitogens of 
fibroblasts, ECs and VSMCs (Archer et al., 2010; Benisty et al., 2004; Geiger et 
al., 2000; Izikki et al., 2009; Kranenburg et al., 2005; Tuder et al., 2001). During 
the later stages of the disease, there is an appearance of complex plexiform 
arteriopathy, commonly known as “plexiform lesions” (Abe et al., 2010; Archer 
et al., 2010; Pietra et al., 2004). These lesions are a hallmark of PAH and lead 
to vessel occlusion and obliteration (Tuder et al. 2007; Heath & Edwards 1958; 
Abe et al. 2010; Stacher et al. 2012; Figure 7). This is illustrated experimentally 
where inhibition of VEGFR combined with hypoxic conditions causes apoptosis 
of ECs and gives rise to a pro-survival and anti-apoptotic EC phenotype, 
leading to the development of the characteristic lesions (Abe et al., 2010; 




Figure 7. Examples of pulmonary vascular remodelling in PH. 
Plexiform lesion (B) with high magnification of proliferated endothelial cells (A; 
arrowhead marks a luminal projection, and arrows mark cellular core). Atypical 
endothelial cell (B; arrowheads) with a myxoid component organised as 
concentric layers of smooth muscle cells (arrow). Abnormal endothelial cells 
(arrowhead) and the myxoid sub-endothelial layer (arrow; D). Intimal projection 
(arrowhead; E). Intimal projection (arrowhead), endothelial cells (arrowheads) in 
the intima, myxoid subintimal layer (arrow; F). Plexiform lesion, endothelial cells 






Until the 1990’s PAH was historically considered a vasoconstrictive disease with 
treatment being predominantly calcium (Ca2+) channel blockers based on 
retrospective experience and uncontrolled studies (Fuster et al., 1984; Rich and 
Brundage, 1987; Rich, 1988; Rich et al., 1992; Rubin, 1985; Sitbon et al., 2005; 
Weir et al., 1989). This treatment focused on the symptom of the disease, 
vasoconstriction, rather than the cause, vascular remodelling (Packer, 1985). 
Progression arrived when evidence based research developed a synthetic 
version of PGI2, epoprostenol (Christman, 1992; Tuder et al., 1999). 
Epoprostenol along with PGI2 analogues were not only found to improve 
vascular tone but also reverse vessel remodelling, raising hopes for a treatment 
that targets the cause of the disease (Akagi et al., 2014; Barst et al., 1996; 
Clapp et al., 2002; Kuhn et al., 2003; Sitbon et al., 2002). However, the 
effectiveness of epoprostenol and PGI2 analogues in attenuating pulmonary 
vascular remodelling is controversial. One example is of a single patient treated 
long-term (18 year) with epoprostenol, which prolonged life (the patient 
ultimately died of colon cancer) but did not halt the progression of vascular 
remodelling (Rich et al., 2010). Histopathological and morphometric studies 
have been conducted on explanted lungs of PH patients who received PGI2 
treatment and such individuals showed no difference in percentage thickness of 
intima, media, or adventitia or in the density of plexiform lesions compared to 
untreated patients (Achcar et al., 2006). This illustrates the need for more 
effective treatments that target the pulmonary vascular remodelling component 
of this disease. 
 
In general, there are three main treatment paradigms for PH, these target three 
fundamental biological pathways that maintain vascular homeostasis; 
prostacyclin, endothelin, and GC. Examples of these treatments are the 
prostanoids (e.g. epoprostenol, treprostinil, beraprost, iloprost), which activate 
prostanoid receptors and promote vasodilation and prevent proliferation, the 
endothelin receptor (ETA and ETB) antagonists (e.g. ambrisentan, bosentan) 
that inhibit the potent vasoconstrictor and mitogenic effect of ET-1, and those 
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treatments that potentiate the cGMP pathway (Gali et al., 2013). 
 
Cyclic GMP elevating treatments approved for the treatment of PH include the 
PDE5 inhibitors (sildenafil and tadalafil), inhaled NO (iNO) and the sGC 
stimulator (Riociguat; Gali et al. 2013). Inhaled NO is an extremely effective 
treatment for persistent pulmonary hypertension of neonates (PPHN) also 
known as ”blue baby syndrome”, a condition that previously had no non- 
invasive therapy (Creagh-Brown et al., 2009; Macrae et al., 2004; Roberts et al., 
1997, 1992). However, this treatment is very expensive and impractical 
because NO gas itself is very unstable and stored in large, heavy cylinders 
(Ichinose et al., 2004). Although, the invention of a device that produces NO 
from the atmosphere, on demand, has been developed and studies show that it 
can effectively reduce PAP in an acute model of PH in lambs, and thus could 
provide a low cost, portable alternative iNO treatment for PPHN (Yu et al., 
2015). 
 
The PDE5 inhibitors sildenafil (Galiè et al., 2005), tadalafil (Galiè et al., 2009) 
and vardenafil (Jing et al., 2011) are all effective treatments for PH; they 
improve PAP, exercise capacity, FC and survival. This illustrates the 
effectiveness of augmenting pulmonary specific NO/sGC/cGMP and 
NP/NPR/cGMP signalling by PDE5 inhibition, although one caveat is the 
development of side effects such as flushing, dyspepsia, and diarrhoea. Despite 
strong evidence in preclinical research, there is currently no evidence 
demonstrating the effectiveness of PDE5 inhibition in preventing vascular 
remodelling in PH patients (Galiè et al., 2005). Of note, PDE5 inhibitors have 
been found to also inhibit MRPs, leading to the hypothesis that their therapeutic 
effectiveness may be, in part, due to synergism through simultaneous 
prevention of cGMP degradation and export (Jedlitschky et al., 2000; Reid et 
al., 2003).  
 
Recently, sGC agonists have been developed for the treatment of PH by 
increasing cGMP production through augmentation of the NO/sGC pathway. 
sGC ‘stimulators’ (e.g. riociguat) stimulate the native haem (Fe2+) domain of 
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sGC and synergise with NO. In contrast to PDE5 inhibition, sGC 
activation/stimulation lacks pulmonary selectivity which can result in dose-
limiting systemic hypotension (Belik, 2009).  
 
1.5.4 Potential role for CNP in pulmonary hypertension 
(PH)? 
 
Despite the broad cardioprotective role of CNP, maintaining endothelial barrier, 
function and inhibiting VSMC proliferation and fibrosis (described previously), a 
function for this peptide in the pulmonary vascular specifically, certainly in the 
context of PH, remains unclear. Patients with PH have increased plasma 
concentrations of CNP (Kaiser et al., 2015). In addition, rats exposed to chronic 
hypoxia develop significantly increased plasma levels of CNP, although 
expression in the lung is decreased (Klinger et al., 1998). Itoh et al., (2004) 
investigated the role of CNP in the monocrotaline model of PH and found that 
CNP infusion increased survival and improved haemodynamics in both 
prophylactically treated animals and animals with established PH. Most 
importantly, CNP treatment enhanced expression of markers of proliferation in 
pulmonary ECs, this was mirrored by a decrease in medial thickness and 
inflammatory cell infiltrates, and an increase in pulmonary eNOS protein 
expression. Together these data demonstrate that CNP infusion promotes the 
maintenance of the EC barrier, a well characterised pathological target of 
monocrotaline, thus preventing exposure of the underlying VSMCs to mitogens 
and preventing hyperplasia. In addition, CNP promoted a protective EC 
phenotype evident by enhancing expression of the NO producing enzyme, 
eNOS (Itoh et al., 2004). This study was followed by a contrasting publication by 
Casserly et al., (2011). This group found using the chronic hypoxia and hypoxia 
plus SU5416 model (see 1.5.5.3) in rats, that treatment with a continuous 
infusion of CNP did not attenuate the development of PH. The authors were 
unable to conclude definitively why CNP infusion was not effective despite its 
well characterised cardiovascular protective effects; they hypothesised that due 
to a significant reduction in NPR-B expression measured in the lungs of the 
hypoxic rats, along with previous evidence showing that pulmonary NPR-C 
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expression is significantly decreased by hypoxia, that any beneficial effect of 
increased circulating CNP may have been mitigated (Klinger et al., 1994; Sun et 
al., 2000). 
 
CNP potently inhibits leukocyte adhesion and can therefore reduce 
inflammation associated with pathologic pulmonary vascular remodelling 
(Moyes et al., 2014; Ohno et al., 2002; Qian et al., 2002). Furthermore, 
inflammation can precede the deposition of extracellular matrix and fibrosis. 
This concept has been well characterised in other cardiovascular diseases; 
CNP infusion reduces cardiac fibrosis (Izumiya et al., 2012; Soeki et al., 2005), 
and decreased CNP production is linked with increased left ventricular fibrosis 
in aged rat hearts (Sangaralingham et al., 2011), and CNP infusion attenuates 
cardiac fibrosis following MI (Soeki et al., 2005). In the lung, CNP infusion also 
increases survival and attenuates pulmonary fibrosis in a mouse model of 
pulmonary fibrosis (bleomycin-induced; Murakami et al., 2004). In this study 
CNP was able to significantly reduce the number of infiltrating inflammatory 
cells (macrophages, neutrophils, and lymphocytes) and subsequent secretion of 
pro-inflammatory cytokines (IL-1β), which prevented the development of 
pulmonary fibrosis. This work was built on further by Kimura et al., (2016) who 
have shown that CNP over expression in fibroblasts specifically, attenuates the 
development of pulmonary fibrosis in the bleomycin model through the same 
process (reduction in inflammation and subsequent fibrosis). In sum, the 
effectiveness of CNP infusion in treating PH has proven controversial, although 
CNP is shown to be a potent anti-fibrotic agent and is effective at treating 
diseases with a substantial fibrotic component. In the context of PH, driven 
predominantly by vascular remodelling and not fibrosis, it still remains to be 
understood whether CNP can be used as an effective therapy. However, no 
matter what the context, the exact mechanism (CNP/NPR-B or CNP/NPR-C) by 
which CNP is acting to elicit any beneficial action has yet to be delineated.  
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1.5.5 Animal models of pulmonary hypertension (PH) 
 
Animal models are used to simulate the clinical and pathological features of a 
disease, with the aim of increasing understanding and ultimately developing 
novel therapeutic strategies. PH is a multifactorial disease; it has been 
challenging to simulate the disease accurately and therefore a number of 
animal models of PH exist, none of which recapitulate all the human 
manifestations of the disease. 
 
1.5.5.1 Chronic Hypoxia 
 
The link between exposure to either normo- or hypobaric hypoxic conditions 
and the development of PH was made by studying mountain climbers at high 
altitude, shedding light into a possible pathophysiological mechanism of PH 
(Arias-Stella and Saldana, 1963; Houston et al., 1987). Pulmonary hypoxia 
caused by either environmental conditions (e.g. high altitude) or disease (e.g. 
sleep apnoea) triggers an adaptive pulmonary specific physiological 
mechanism; the lung attempts to optimise the ventilation/perfusion (V/Q) ratio 
and gas exchange by diverting blood flow away from poorly ventilated areas 
(Ward and McMurtry, 2009). O2 concentrations are detected by mitochondria 
present in PASMCs, this initiates a signalling cascade, ultimately leading to 
increased intracellular calcium (Ca2+) concentration and thus vasoconstriction 
(Aaronson et al., 2006; Ward et al., 2004; Waypa and Schumacker, 2008). 
However, in situations where hypoxic conditions are sustained (i.e. chronic 
hypoxia), for example at high altitude, the enhanced shear stress leads to the 
release of vasoconstrictors (TXA2, ET-1, 5-HT), which maintain the high 
pulmonary vascular tone but also leads to adaptive vascular remodelling 
(Eddahibi et al., 2000; Fike et al., 2002; Frid et al., 2006; Li et al., 1994). In 
general, this is characterised by PASMC and adventitial fibroblast proliferation 
causing muscularisation of precapillary resistance vessels with no significant 
EC proliferation, thus leaving the vessel un-occluded and retaining flow 
(Rabinovitch et al., 1979; Stenmark et al., 1987). This response to hypoxia is 
not universal across species, strains within species and even individuals within 
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strains; gender and age are factors that influence an individual’s response to 
hypoxic conditions (Dempsey et al., 1996; Haworth and Hislop, 2003; Miettinen 
et al., 1981). The most obvious example of species differences is studying 
animals that do not develop PH at high altitude; for example, the yak, pika, 
snow pig and llama (Durmowicz et al., 1993; Stenmark et al., 2006b). Animals 
that develop PH in hypoxic conditions include humans, mice, rats and neonatal 
calves; however despite developing PH, they differ in severity and specific 
pathological features. Moreover, humans and neonatal calves develop severe 
PH characterised by large increases in PAPm (can be as high as systemic 
pressures), significant muscularisation of normally non-muscularised vessels 
and adventitia thickening, although it’s key to note that these features are 
reversible upon returning to normoxic conditions, contrary to what is observed in 
patients with PH (Anand et al., 1988; Arias-Stella and Saldana, 1963; Stenmark 
et al., 1987). In contrast, rats and mice develop less severe PH characterised 
by smaller increases in PAPm and less severe pulmonary vascular remodelling 
(Estrada and Chesler, 2009; Frank et al., 2008; Meyrick and Reid, 1980; 
Miettinen et al., 1981; Tuchscherer et al., 2007). In addition, RVH in response to 
hypoxia is not severe enough to develop to the point of failure, again, in contrast 
to PH patients where the development of RVH inevitably leads to death (Drexler 
et al., 2008). In addition to differences between animals, chronic hypoxia 
induces variable pathology between strains within the same species. Different 
strains of rat, Fischer 344 (F344), Sprague-Dawley (SD), Fawn hooded (FH) 
and Wistar Kyoto (WKY), respond differently to chronic hypoxia, with some 
strains demonstrating far greater resistance to others (e.g. FH; Wilkins et al., 
2015). Although, until recently, the cause of this phenomenon has mostly 
remained a mystery; except in the case of FH rats who develop PH 
spontaneously (4 weeks of age) because of an inherent inability to uptake 
serotonin into platelets, a similar feature observed in PH patients (Cras et al., 
2000; Hervé et al., 1995; Kentera et al., 1988). Zhao et al., (2015), identified a 
series of single nucleotide polymorphisms resulting in frameshift mutations in 
several genes within different strains of rat, which account for their different 
susceptibility to development of PH. These studies identified a novel 
pathological mechanism for PH implicating the zinc ion transporter ZIP12, such 
reduced ZIP12 expression attenuates the development of PH in rats exposed to 
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chronic hypoxia. Similar stain differences are also seen in mice, driven by a 
differing gene expression profile within the pulmonary vascular cell (Bull et al., 
2007; Hoshikawa et al., 2003; Tada et al., 2013). Despite this, the use of 
rodents in the chronic hypoxia model for PH research remains the most 
commonly utilised technique, probably because of its phenotypic reproducibility, 
practicality and low cost, compared to using larger mammals (Lawrie, 2014).  
 
1.5.5.2 Monocrotaline model 
 
Seeds from the plant Crotalaria Spectabilis contain a toxic compound called  
monocrotaline (MCT) and when ingested causes PH (Kay et al., 1967). MCT is 
a 11-membered macrocyclic pyrrolizidine alkaloid that is subsequently activated 
to the pyrrole metabolite by oxidases present in the liver, converting it into a 
reactive bi-functional, cross-linking compound, dehydromonocrotaline (Reid et 
al., 1998; Wilson et al., 1992). Production of the reactive pyrrole metabolite is 
the pathological determining factor. Differences in cytochrome-P450 3A isoform 
as a result of sex, age and species vary the pathology produced by MCT. The 
importance of the cytochrome-P450 3A isoform has been demonstrated by 
specifically inhibiting this enzyme, reducing the severity of MCT-dependent PH. 
Conversely, induction of this enzyme can increase the severity of pathology 
(Kasahara et al., 1997; Reid et al., 1998). The exact mechanism by which MCT 
causes PH is not completely understood. However, MCT exposure is found to 
damage the pulmonary arterial endothelial cells (PAECs) causing a disruption of 
NO signalling and an increase in proliferative and anti-apoptotic factors (Huang 
et al., 2010; Lee et al., 2009; Rosenberg and Rabinovitch, 1988). The prominent 
histopathological feature of this model is medial hypertrophy and not 
obstructive, EC derived, complex lesion formation (Stenmark et al., 2009). The 
exact mechanism underlying medial hypertrophy is also not known and whether 
it is directly caused by interactions with ECs or by systemic inflammation 
triggered by MCT. Therefore, there are several caveats with this model 
including the limited understanding of the mechanisms underlying vascular 
remodelling. Firstly, vascular remodelling is not strictly confined to the distal 
pulmonary arteries as seen in PH patients but is also found in the veins 
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(Meyrick, 1982; Wilson et al., 1989). In addition, other pathological features, not 
found in PH patients, are associated with MCT exposure, including liver toxicity, 
occlusion of pulmonary veins, alveolar oedema and alveolar septal cell 
hyperplasia (Copple, 2003; Dumitrascu et al., 2008; Lalich et al., 1977). 
Furthermore and probably most importantly, although MCT treated rats develop 
significant increases in PAPm and RVH which eventually leads to heart failure, 
similar to that of PH patients, MCT acts directly on the heart inducing 
lymphocytic myocarditis, making RV failure due to PH hard to determine and 
likely MCT-induced (J. G. Gomez-Arroyo et al., 2012). 
 
1.5.5.3 Hypoxia plus SU5416 model 
 
In 2001, Taraseviciene-Stewart et al., investigated the role of EC hyper-
proliferation that form the characteristic plexiform lesions in an animal model of 
PAH. VEGF signalling is important for maintaining and differentiating vascular 
ECs and expression is increased in complex lesions found in PAH patients 
(Tuder et al., 2001, 1994). Increased angiogenesis appears to be a 
compensatory mechanism in response to hypoxia with enhanced expression of 
pro-angiogenic substances (e.g. VEGF) attenuating experimental PH, in 
addition the number of peripheral vessels is commonly reduced in patients with 
PH, a phenomenon called vascular pruning (McLaughlin and McGoon, 2006; 
Partovian et al., 2000; Pascaud et al., 2003). Using the VEGFR-2 inhibitor 
Sugen5416 (SU5416; Semaxinib), this group found that VEGFR inhibition in 
normal conditions caused slight pulmonary vascular remodelling, but when 
combined with hypoxic conditions, resulted in severe, progressive, irreversible 
PAH, characterised by extensive EC proliferation in the pulmonary arterioles 
(Taraseviciene-Stewart et al., 2001). The authors concluded VEGFR inhibition 
caused EC apoptosis leading to the rise of an apoptotic-resistant, hyper-
proliferating EC phenotype, commonly found in complex lesions of PH patients 
(Sakao et al., 2005; Voelkel et al., 2002). This hypothesis was investigated 
using a caspase inhibitor, preventing EC apoptosis, and attenuating the PH 
developed in this model (Taraseviciene-Stewart et al., 2001). Loss of 
endothelial barrier integrity through EC apoptosis results in exposing the 
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underlying PASMCs to circulating growth factors, prompting PASMC 
proliferation. A significant and defining feature of this model is that in the rats, 
when returned to normoxic conditions, pulmonary vascular remodelling 
progresses (unlike in the chronic hypoxia model). Furthermore, this remodelling 
progresses until complex lesions develop similar to that seen in PH patients, 
accompanied by severe RVH that eventually leads to failure and death, offering 
a more representative model of the human disease (Abe et al., 2010). 
Unsurprisingly, upon development of this model this same combination was 
attempted in mice, largely to allow exploitation of transgenics. Taraseviciene-
Stewart et al., (2001) found using the same protocol used in rats (a single 
injection of SU5416) did not produce a PH like pathology (J. Gomez-Arroyo et 
al., 2012). However, subsequently it was found that if the SU5416 was dosed 3 
times (once per week) whilst the mice were still exposed to hypoxia, this elicited 
significant increases in PAPm, RVH and vascular remodelling with the 
appearance complex occlusive lesions characteristic of PH, compared to that 
seen in mice exposed to hypoxia alone (Ciuclan et al., 2011). However, slight 
reversal of RVSP and RVH was observed after returning the animals to 
normoxia for 2 weeks and the extent of complex lesion were not quantified, 
begging the question how permanent this pathology is (Ciuclan et al., 2011). 
Nevertheless, the authors of this study did observe significant early EC 
apoptosis followed by late EC proliferation in the lungs of these mice, evident by 
significantly enhanced early caspase-3 staining that plateaus over time and is 
followed by increased EC proliferating cell nuclear antigen (PCNA) staining, 
demonstrating a shift from EC apoptosis to proliferating phenotype, which is 
now understood to be the defining feature of PH but this feature has yet to be 
recapitulated in other mouse models of PH. 
 
1.5.5.4 Bleomycin-induced model of PH 
 
Bleomycin is a chemotherapeutic antibiotic, produced by the bacterium 
Streptomyces verticillus (Adamson, 1976; Umezawa et al., 1967). The drug is 
used in the treatment of lymphoma, squamous cell carcinomas and germ cell 
tumours, but has the undesirable side effect of producing interstitial lung 
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disease (ILD), specifically pulmonary fibrosis; this observation led to the 
rationale that this drug can be used in the research of PH secondary to ILD 
(Muggia et al., 1983). Bleomycin is among a large groups of agents which 
cause ILD, including: anti-microbial (e.g. amphotericin B), anti-inflammatory 
(e.g. methotrexate), biological (e.g. rituximab), cardiovascular (e.g. 
procainamide), chemotherapeutic (e.g. doxorubicin), and miscellaneous (e.g. 
talc; Schwaiblmair et al., 2012). The acute lung injury caused by these agents 
leads to the development of pneumonia, and the ensuing chronic pulmonary 
inflammation eventually leads to a fibrotic change that ultimately interferes with 
gas exchange. Areas of poor gas exchange results in hypoxia and 
vasoconstriction, thus PH (Seeger et al., 2013). 
 
Bleomycin is believed to produce superoxide and hydroxyl free radicals, which 
disrupt DNA within tumour cells, thereby interrupting the cell-cycle (Claussen 
and Long, 1999). In the lung, this leads to an inflammatory response, activating 
fibroblasts, leading to fibrosis (Chaudhary et al., 2006; Grande et al., 1998). The 
lungs are particularly susceptible to bleomycin because of relatively low 
expression of bleomycin hydrolase, an enzyme that inactivates the drug (Sebti 
et al., 1989). Lung instillation (oropharyngeal; o.p.) of bleomycin causes acute 
lung injury, specifically formed of increased epithelial apoptosis, followed by a 
characteristic increase in the secretion of pro-inflammatory cytokines (e.g. IL-
1β, TNF-α, IL-6, interferon-γ; INF-γ) from macrophages and neutrophils, the 
crucial first-step in this models fibrotic pathogenesis (Chaudhary et al., 2006; 
Janick-Buckner et al., 1989; Mungunsukh et al., 2010). Next, significant 
production of pro-fibrotic markers (TGF-β, fibronectin, procollagen-1) occurs, 
which peaks at around day 14 (Chaudhary et al., 2006; Kolb et al., 2001). Of 
note, TGF-β and myofibroblasts are considered central to the aberrant fibrotic 
response as they specifically contribute to the exaggerated extracellular matrix 
deposition and are also found in human IPF (Coward et al., 2010; Dhainaut et 
al., 2003; Harari and Caminati, 2010; Hardie et al., 2009; Sheppard, 2001; Zhao 
et al., 2002). This extracellular matrix consists mainly of collagen, which forms 
distinctive histopathological formations; intra-alveolar buds, mural incorporation 
and obliterative changes (Ebihara et al., 2000; Lucey et al., 1996; Usuki and 
Fukuda, 1995). This model of pulmonary fibrosis is highly reproducible and 
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produces a fibrotic histologic picture similar to human disease, characterised by 
patchy parenchymal inflammation, epithelial cell injury with reactive hyperplasia, 
basement membrane damage and interstitial as well as intra-alveolar fibrosis 
(Epperly et al., 2006). However, fibrosis initiated using this model eventually 
resolves, unlike the human disease, although this process can take many 







1.6 Hypotheses and specific aims 
 
For well over half a century, cGMP has been thoroughly characterised as an 
integral regulator of cardiovascular homeostasis. My thesis research focused on 
further optimisation of cGMP for therapeutic gain in cardiovascular disease and 
comprised two main strands: (1) the role of MRPs in vascular physiology and 
(2) the cytoprotective function of CNP in pulmonary vascular disease: 
 
(1) There is emerging evidence demonstrating MRPs play a role in regulating 
vascular homeostasis by modulating cGMP and cAMP levels, and as potential 
targets for the treatment of cardiovascular disease. However, previous work has 
focussed on cAMP-dependent effects of MRPs. Therefore, in this thesis I have 
investigated the hypothesis that ‘MRPs play a pivotal role in regulating local 
cGMP concentrations and cardiovascular homeostasis’. To address this 
question I explored the function of MRPs to potentiate well characterised roles 
of cGMP in the vasculature; vascular reactivity, VSMC proliferation and BP. 
 
(2) CNP plays an integral role in cardiovascular homeostasis regulating 
leukocyte adherence, VSMC proliferation, endothelial integrity, BP and fibrosis 
via both cGMP -dependent and -independent processes. PH is a severe 
pulmonary vascular disease underlined by vascular dysfunction, which is 
treated by drugs promoting cGMP signalling, but currently a role for CNP in 
maintaining pulmonary vascular homeostasis, or the pathogenesis of PH, 
remains unclear. In addition, the mechanism by which CNP might elicit a 
beneficial activity has not been elucidated (i.e. CNP/NPR-B or CNP/NPR-C). 
Thus, in this thesis I have also tested the hypothesis that ‘endogenous 
endothelial-derived CNP is an innate defence mechanism that protects 
against PH’. To achieve this goal, I used an experimental models of PH and 




















CHAPTER 2: METHOD & MATERIALS 
 
2.1 Materials & reagents 
 
ANP (Cambridge Bioscience, Cambridge, UK), CNP (Calbiochem, Nottingham, 
UK), spermine-NONOate (Sp-NO; Sigma Aldrich, Poole, UK), MK571 (MK; 
Sigma Aldrich, Poole, UK), Iso (Sigma Aldrich, Poole, UK), phenylephrine (PE; 
Sigma Aldrich, Poole, UK), acetylcholine (ACh; Sigma Aldrich, Poole, UK), were 
dissolved in deionised, distilled water (ddH2O). For acute blood pressure 
studies, sodium nitroprusside (SNP; Sigma Aldrich, Poole, UK), 
diethylenetriamine/nitric oxide adduct (D-NO; Sigma Aldrich, Poole, UK) and 
MK571 were dissolved in saline (0.9 %; Baxter, Newbury, UK). For telemetry 
studies MK571 was dissolved in normal animal drinking water. Probenecid (PB; 
Sigma Aldrich, Poole, UK) was dissolved in dimethyl sulfoxide (DMSO; Sigma 
Aldrich, Poole, UK) and identical percentage DMSO concentrations added to 
tissues (0.3 % DMSO). SU5416 (Tocris Bioscience, Bristol, UK) was suspended 
in carboxymethylcellulose sodium, (CMC; 0.5 %; w/v), NaCl (0.9 %; w/v), 
polysorbate 80 (Tween 80; 0.4 %; v/v), benzyl alcohol (0.9 %; v/v; all sourced 
from Sigma Aldrich, Poole, UK). 
 
2.2 Organ bath pharmacology 
 
All animal procedures were conducted in accordance with the UK Home Office 
Animals (Scientific Procedures) Act of 1986 and adhered to ARRIVE (Animal 
Research: Reporting of In Vivo Experiments) guidelines. Animals were housed 
in a temperature-controlled environment (~24 °C) with a 12-hour light–dark 
cycle. Food and water were accessible ad libitum.   
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Male and female mice (C57/BL6; 20-30 g) were euthanised by cervical 
dislocation. The thoracic aortae were carefully removed, cleaned of connective 
tissue and cut into three to four ring segments of approximately 4 mm in length. 
Aortic rings were mounted in 10 ml organ baths containing Krebs-bicarbonate 
buffer (composition (mM): Na+ 143; K+ 5.9; Ca2+ 2.5; Mg2+ 1.2; Cl- 128; HCO3- 
25; HPO42- 1.2; SO42- 1.2; D-Glucose 11) and gassed with carbogen (95 % O2/ 
5 % CO2; British Oxygen Company; BOC; Guildford, UK). Tension was initially 
set at 0.3 g and reset at intervals following an equilibration period of 
approximately 1 h during which time fresh Krebs-bicarbonate buffer was 
replaced every 15 min. After equilibration, the rings were primed with three 
separate additions of KCl (48 mM; Sigma Aldrich, Poole, UK), at each addition 
maximum tension was observed (3 min) before being washed out by the 
addition of fresh Krebs-bicarbonate buffer at 10 min intervals for a total of 30 
min. Cumulative concentrations of PE (1 nM to 3 µM) were then added until a 
maximum contraction was observed. Another washout period was performed. 
The vessels were then contracted to 80 % of the tension elicited by the 
maximum PE concentration (EC80). Once this response had stabilised, a single 
addition of ACh (1 µM) was added to the bath to assess the integrity of the 
endothelium. If the contractions to PE were not maintained, or relaxations less 
than 50 % of the PE-induced tension to ACh were not observed, the tissues 
were discarded. After another wash period, the vessels were again contracted 
to 80 % of the maximum tension elicited by PE and then cumulative 
concentrations of each pharmacological treatment were administered. 
Pharmacological treatments investigated were ANP (1 pM to 300 nM), ACh (1 
nM to 3 µM), MK571 (100 nM to 50 µM), CNP (1 nM to 3 µM), the NO-donor 
spermine-NONOate (Sp-NO; 1 nM to 30 µM), the β-adrenoceptor agonist Iso 
(300 pM to 300 nM), and PB (1 µM to 1 mM). In separate experiments, tissues 
were pre-incubated with sub-threshold concentrations of MK571 (3 µM) or PB 
(300 µM; determined following construction of concentration-response curves 
for each compound; Figure 13 & Figure 14) for 10 min prior to cumulative 
concentrations of either; ACh, ANP, CNP, Sp-NO and Iso being added to pre-
contracted vessels.  
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2.3 Freezing cells 
 
Cells were stored in liquid nitrogen (N2; BOC) when not being cultured. Cells 
were aliquoted into cryogenic vials in 90 % bovine serum (BS; Life 
Technologies Ltd, Paisley, UK) and 10 % DMSO at 0.5 x 106 cells/ml. Vials 
were then slowly frozen in a -80 ⁰C freezer using a Mr. Frosty™ freezing 
container (Thermo Fisher Scientific, Leicestershire, UK) for 24 h before being 
moved and transferred to liquid N2 for long term storage.  
 
2.4 Thawing cells 
 
Vials of cells were removed from liquid N2 and immediately placed into a water 
bath kept at 37 ⁰C. The lid was unscrewed slightly, to allow pressure 
equilibration, then re-tightened. Once most of the vial was thawed, pre-warmed 
cell culture media was added, then the cell suspension pipetted directly into a 
cell culture flask containing pre-warmed media. The flask was placed in a cell 
culture incubator over night before the medium was changed the next day to 
remove all the DMSO.  
 
2.5 Cell proliferation assays 
 
Human coronary artery smooth muscle cells (hCASMC; passage 6-7; Lonza, 
Basel, Switzerland) were seeded onto 6-well plates at a density of 3 x 105 
cells/well. Cells were initially grown for 24 h in routine cell culture medium 
(Smooth Muscle Growth Medium-2; Lonza, Basel, Switzerland) with SmGM™-2 
BulletKit containing foetal bovine serum (FBS; 5 %), human epidermal growth 
factor (hEGF), insulin, human fibroblastic growth factor (hFGF), and 
gentamicin/amphotericin B (proprietary concentrations). Subsequently, the cells 
were serum-starved (FBS: 0.5 %; 1:10 dilution of routine cell culture medium) 
for 48 h to synchronise cell-cycles. Cells were then incubated in medium 
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containing 5 % serum in the presence of vehicle (sterile ddH2O) or 
pharmacological treatment, and cells (stained with trypan blue diluted 1:1 to 
identify dead cells) counted at 0, 24, 48, 72, 96 h intervals using a 
haemocytometer. Individual plates were set up with the same treatments, in 
duplicate wells, one for each time-point. The pharmacological agents 
investigated were ANP (1 µM), D-NO (10 µM), MK571 (30 nM, 300 nM, 3 µM, 
30 µM) and ANP or D-NO combined with MK571 (30 nM). 
 
2.6 Cyclic GMP assay 
 
Intracellular and extracellular cGMP concentrations were measured by enzyme-
linked immunosorbent assay (ELISA; GE Healthcare, Hatfield, UK) following 24 
h of treatment in the same cells used for the proliferation assays described 
above. Each well was pre-incubated with the non-selective PDE inhibitor 3-
isobutyl-1-methylxanthine (IBMX; 100 µM; Sigma Aldrich, Poole, UK) for 30 min 
prior to cell and supernatant harvest to prevent breakdown of cGMP during cell 
processing. Cell pellet (for intracellular cGMP) and supernatant (for extracellular 
cGMP) were frozen and stored at -80 oC until use. The ELISA was conducted 
as per manufacturer’s instructions. 
 
2.7 Acute blood pressure measurement in 
anaesthetised mice 
 
Male C57/BL6 mice (~25 g) were anaesthetised with 1.5 % isoflurane (Abbott 
Laboratories Ltd, Queenborough, UK) in O2 and placed supine on a 
thermostatically controlled heating blanket (37.0 °C ± 0.5 °C). To measure blood 
pressure, the left common carotid artery was isolated and a fluid-filled (heparin; 
100 U/ml diluted in 0.9 % saline), 0.28 mm internal diameter cannula (Critchley 
Electrical Products Pty Ltd, Castle Hill, Australia) introduced into the artery. 
Blood pressure was measured using an in-line P23 XL transducer (Viggo-
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Spectramed, USA, California) and PowerLab system (ADInstruments, Castle 
Hill, Australia), calibrated beforehand, and recorded using LabChart 
(ADInstruments, Castle Hill, Australia). The jugular vein was cannulated for drug 
administration. The arterial cannula was flushed once with heparinised saline 
(heparin; 100 U/ml diluted in 0.9 % saline). After a minimum 10 min equilibration 
or until continuous stable pressure was observed, mice were given a weight 
adjusted (1 µl to 1 g of body weight) intravenous bolus injection of accumulative 
doses of MK571 (0.001, 0.01, 0.1, 1, 3 mg/kg). Since MK571 had little or no 
effect on blood pressure per se (Figure 32), the 3 mg/kg dose was chosen as 
‘sub-threshold.’ Subsequently, blood pressure was measured following 
intravenous (i.v.) bolus administration of the NO-donor sodium nitroprusside 
(SNP; 1, 3, 10 µg/kg) or ANP (1, 10, 100 µg/kg) in the absence and presence of 
MK571 (3 mg/kg; pre-incubated for 30 min). 
 
2.8 Chronic blood pressure measurement in 
conscious, telemeterised mice 
 
Male C57/BL6 mice (~25 g) were implanted with either a DSI PhysioTel® PA-
C10 or HD-X11 telemetry probe (Data Sciences International, Minneapolis, 
USA). Each probe was cleaned and sterilised according to the manufacturer’s 
guidelines. The probe was soaked in Terg-A-Zyme® (1 % w/v; Sigma Aldrich, 
Poole, UK) for a maximum of 72 h, rinsed with water, dried and stored until the 
day of implantation. Prior to insertion the probe was sterilised by soaking in 4 % 
glutaraldehyde (Sigma Aldrich, Poole, UK) for a maximum of 40 min, then 
washed with sterile saline and finally re-gelled to ensure the absence of air 
bubbles in the catheter tip. Mice were sedated with 5 % isoflurane in O2 and 
anaesthesia was maintained using 1.5-2 % isoflurane in O2. The left common 
carotid artery was exposed, isolated and cleaned of any surrounding tissue. A 
small incision was made in the carotid and the catheter inserted whilst 
submerged in saline to ensure no bubble form inside the catheter tip. The tip of 
the catheter was placed into the aortic arch, securely fastened and the 
transmitter body placed subcutaneously (s.c.) on the right flank. The incision 
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was stitched and each animal received post-operative analgesia consisting of 
0.3 μg vetergesic (Abbott Laboratories Ltd, Queenborough, UK) in 0.5 ml saline 
(s.c.). Animals were left to recover for a minimum of 7 days, after which 
haemodynamic recordings were taken for 64 h over the weekend to minimise 
noise disturbance. Mean arterial blood pressure (MABP), heart rate (HR) and 
activity were recorded for 2 min at 15 min intervals using Dataquest Art 
Acquisition System (Data Sciences International, Minneapolis, USA). Baseline 
haemodynamic measurements were taken one week before dosing. The body 
weight of animals was measured at the beginning of the experiment. The mean, 
normal daily drinking water consumption was calculated by measuring the 
volume of water consumed per day for three days. At the start of drug 
administration, drinking water bottles were replaced with bottles containing 
MK571 at a concentration which entailed each mouse received 25 mg/kg/day 
(based on a pre-determined mean consumption of 4 ml/mouse/day). A 24 h 
time period was used for analysis: starting from 1 pm Saturday and ending 1 pm 
Sunday (12 h light/dark) with dosing commencing 24 h before the start of this 
time period. 
 
2.9 Experimental models of pulmonary 
hypertension (PH) 
 
Based on arguments regarding experimental model suitability made in the 
Introduction, I employed two well-established protocols to evaluate a potential 
role for CNP in the pathogenesis of PH. 
 
2.9.1 Genotyping of animals 
 
NPR-C KO mice were generously donated to our laboratory by Prof. Oliver 
Smithies (University of North Carolina, USA; Matsukawa et al., 1999). 
Endothelial-specific CNP KO mice were generated and characterised in our 
laboratory (Moyes et al., 2014). Mouse ear clip samples were digested using 
DirectPCR lysis reagent (Viagen Biotech, Los Angeles, USA) and 0.3 mg/ml 
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proteinase K (Scientific Laboratory Supplies Ltd, Benfleet, UK) overnight at 55 
ºC. Samples were incubated at 85 ºC for 45 min to denature proteinase K 
followed by cooling to room temperature. A master mix of the polymerase chain 
reaction (PCR) mixture composed of: MyTaq™ Red Mix (Bioline, London, UK), 
primers (Table 4) DNA template (digested mouse ear clip solution) and sterile 
ddH2O in a total volume of 25 µl. The PCR conditions for each reaction are 
described in (Table 5). PCR products were loaded into wells formed from a pre-
made 2 % agarose gel (Sigma Aldrich, Poole, UK) containing GelGreen™ 
(Biotium, Hayward, USA) nucleic acid stain and resolved by gel electrophoresis, 
then viewed using an AlphaImager (Alpha-Innotech, Kasendorf, Germany). 
NPR-C KO mice were identified by a product of 413 base pairs (detecting the 
neomycin cassette used to delete the gene) compared to a 250 base pair 
product for WT; ecCNP KO mice were identified by the presence of two bands: 
CNP-floxed (956 base pairs) and Tie2-Cre (512 base pairs). The WT was 
identified by a 842 base pair product. 
 
Primer Primer nucleic acid sequence 
Floxed CNP forward 5’-CCCTGTGCTCAGACAGAAATGAG-3’ 
Floxed CNP reverse 5’-CGCATAACCAGTGAAACAGCATTGC-3’ 
Tie2 forward 5’-CCTTTATGCCAAGAGAACTTCCAGGAGG-3’ 
Tie2 reverse 5’-TCCTTCCTGACTTCCTTCTGCTCTCTATCC-3’ 
NPR-C forward 5’-CTTGGATGTAGCGCACTATGTC-3’ 
NPR-C reverse 5’-CACAAGGACACGGAATACTC-3’ 
NPR-C NEO 5’-ACGCGTCACCTTAATATGCG-3’ 
 
Table 4. A table describing the nucleic acid sequence of the primers used 
to genotype ecCNP and NPR-C KO and WT mice. 
A table describing the nucleic acid sequence of the primers used to genotype 
endothelial cell-specific C-type natriuretic peptide (ecCNP) and natriuretic 
peptide receptor-C (NPR-C) knockout (KO), heterozygous and wild-type (WT) 
mice. Adenine (A), cytosine (C), guanine (G), thymine (T), neomycin (NEO).  
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PCR Step Floxed CNP Tie2 NPR-C 






94°C 30 s 
60°C 1 min 
68°C 2 min 
x40 cycles 
95°C 30 s 
58°C 1 min 
72°C 1 min 
x35 cycles 
93°C 1 min 
60°C 1 min 
72°C 1 min 
Extension 68°C 10 min 72°C 10 min 72°C 10 min 
 
Table 5. A table describing the PCR thermal cycler conditions used for 
each reaction. 
A table describing the polymerase chain reaction (PCR) thermal cycler 
conditions used to detect each of the three DNA sequences to genotype 
endothelial cell-specific C-type natriuretic peptide (ecCNP) and natriuretic 
peptide receptor-C (NPR-C) knockout (KO), heterozygous and wild-type (WT) 
mice. 
 
2.9.2 Hypoxia plus SU5416 model 
 
The VEGFR-2 inhibitor SU5416 was suspended in CMC (0.5 %; w/v), NaCl (0.9 
%; w/v), polysorbate 80 (Tween 80; 0.4 %; v/v), benzyl alcohol (0.9 %; v/v) in 
ddH2O, then vigorously vortexed, and sonicated for 6 min to produce a uniform 
suspension. In optimisation studies, animals (male C57/BL6 mice; ~25 g) were 
exposed to chronic normobaric hypoxia (10 % O2) for either 21 or 35 days, or 
21 days followed by 14 days of normoxia (21 %; the latter protocol termed 
‘Reversal’; Figure 8). Mice were administered SU5416 (20 mg/kg; s.c.) via 3 
injections (at weekly intervals). Control mice received vehicle (s.c.) with the 
same dosing regimen (3 injections, at weekly intervals; days 0, 7 and 14; Figure 
8). Control mice were kept at normoxia (21 % O2) for 21 days and treated with 
vehicle as described previously. For studies involving transgenic animals (e.g. 
ecCNP and NPR-C KO), 16 week old, male and female mice received weekly 
injections of SU5416 (20 mg/kg; s.c.; days 0, 7 and 14) in combination with a 21 
day hypoxia (10 % O2) period (Figure 8). Control mice received vehicle (s.c.; 
64 
 
days 0, 7 and 14) in combination with a 21 day normoxia period (21 % O2). 
 
Figure 8. Schematic describing method used for hypoxia plus SU5416 
experiments. 
For optimisation studies mice were dosed with SU5416 (20 mg/kg; s.c. at days 
0, 7 & 14) and exposed to either normoxia (21 % O2; control) or hypoxia (10 % 
O2) for 21 or 35 days, or 21 days hypoxia followed by 14 days normoxia 
(Reversal). For studies involving male and female endothelium-specific CNP 
knockout (ecCNP KO) and natriuretic peptide receptor-C knockout (NPR-C KO) 
mice with corresponding wild-type (WT) littermates involved dosing with 
SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle and exposure to hypoxia 
or normoxia for 21 days.  
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2.9.3 Bleomycin-induced model of pulmonary 
hypertension (PH)  
 
Male and female WT and NPR-C KO mice received a single oropharyngeal 
(o.p.) instillation, under light isoflurane anaesthesia, of Bleo-Kyowa® (Bleomycin 
Sulphate; Bleo; Nippon Kayaku Co. Ltd, Tokyo, Japan) weight adjusted (1 µl to 
1 g of body weight), resulting in individual mice receiving 4 mg/kg (4,000 IU or 4 
USP) dissolved in saline. Control mice received saline (o.p.) only. The mice 




Figure 9. Schematic describing method used for bleomycin-induced 
pulmonary hypertension model. 
Studies involving male and female natriuretic peptide receptor-C knockout 
(NPR-C KO) mice and wild-type (WT) littermates were administered bleomycin 
(4 mg/kg; o.p.; day 0) followed by 14 days at normal laboratory conditions. 
 
2.9.4 Lung & heart morphology 
 
The whole lung was fixed with 5 % paraformaldehyde (PFA; Sigma Aldrich, 
Poole, UK) by inflating under constant pressure using a gravity fed apparatus 
(20 cm of H2O, 14.7 mm Hg; equivalent to physiological pulmonary pressure). 
The lungs were then left to fix for 4 h, transferred to a 15 % sucrose (Sigma 
Aldrich, Poole, UK) solution for 6 h, and permanently stored in 70 % ethanol 
(Fisher Scientific Ltd, Leicestershire, UK). The left lung was then removed, cut 
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transversely and the lower section paraffin embedded, sectioned and stained. 
Embedding, sectioning, mounting and staining were performed by the Barts 
Cancer Institute (BSI; London, UK) histology department. Mouse lungs from the 
hypoxia plus SU5416 model of PH were stained for α-smooth muscle actin (α-
SMA; Sigma Aldrich, Poole, UK) and used to assess pulmonary vascular 
remodelling. Pulmonary vascular remodelling was assessed by counting the 
number of non-muscularised (<25 % total α-SMA staining), partially-
muscularised (25 – 75 % α-SMA staining) and fully-muscularised (>75 % α-
SMA staining) vessels (Table 21 & Table 22). Every vessel <100 µm in 
diameter was counted using a microscope (x20 magnification) from a single 
slice of α-SMA stained lung, for each mouse. Percentage non-muscularised, 
partially-muscularised and fully-muscularised were then expressed graphically. 
Mouse lung sections from the bleomycin-induced model of PH were stained 
with Picrosirius red (PSR; BSI, London, UK) to stain for collagen and 
representative images of pulmonary fibrosis were taken (Table 23). The heart 
was removed, the right ventricle dissected under x8 magnification, and weighed 
to determine RVH (as calculated by right ventricle to left ventricle plus septum 
ratio; RV/[LV+S]; Fulton’s Index). 
 
2.9.5 Right ventricular systolic pressure (RVSP) & 
mean arterial blood pressure (MABP) 
measurement 
 
Both RVSP and MABP measurements were taken. The mice were 
anaesthetised with ~1.5 % isofluorane in O2 and placed supine on a 
thermostatically controlled heating blanket (37.0 °C +/- 0.5 °C). RVSP was 
measured first; the right jugular vein was isolated and a Millar catheter (Millar 
Instruments; SPR-671, size 1.4F; Houston, USA) introduced into the superior 
vena cava and then advanced into the right ventricle. The breathing rate was 
maintained between 100-120 breaths per minute and a 2 min section of stable 
pressure was recorded. For MABP, the left common carotid artery was isolated 
and a fluid-filled catheter (described previously) introduced into the artery and a 
2 min period of stable pressure recorded. Both MABP and RVSP were 
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measured using an in-line P23 XL transducer (Viggo-Spectramed, Oxnard, 
USA) and recorded onto a pre-calibrated PowerLab system (ADInstruments, 
Castle Hill, Australia). RVSP and MABP were calculated as mean pressure over 




Statistical analyses were carried out using GraphPad Prism version 5 
(GraphPad software, California, USA). When comparing two groups of data a 
two-tailed, unpaired, Student’s t-test was used. Three or more groups of data 
were compared using one-way ANOVA followed by a Bonferroni multiple 
comparisons test. Two-way analysis of variance (ANOVA) was used to compare 
data affected by two factors; organ bath pharmacology (relaxation/contraction & 
concentration), acute changes in BP (BP & dose), animal models of PH (body 
weight & time), vascular remodelling (vessel type & number of vessels) and cell 
proliferation studies (cell growth & time). For organ bath experiments curves 
were fitted to the data using nonlinear regression and the concentration of each 
drug, giving a half-maximal response (EC50), was used to compare potency. 
Exponential growth curves were fitted to cell proliferation data. Statistical 
significance was achieved when P<0.05. Results are expressed as mean ± 


















CHAPTER 3: RESULTS 1 
 
3 Investigation of the role of MRPs in 
vascular homeostasis 
 
3.1 Effect of MRP inhibition on vascular reactivity 
 
Functional pharmacological studies were performed on mouse thoracic aorta. 
Concentration-dependent responses to the contractile agent PE were 
performed to determine vessel viability and an appropriate EC80 concentration 
to pre-contract vessels for the study of vasorelaxant drugs (Figure 10 & Figure 
11). All vessels relaxed >50 % to ACh (1 µM) pre-contracted with an EC80 
concentration of PE, indicating the presence of an intact endothelium (Figure 
12). The MRP inhibitors MK571 (100 nM to 50 µM) and PB (1 µM to 1 mM) 
produced concentration-dependent relaxations of PE-induced tone, with the 
highest concentrations of each resulting in 100 % relaxation (Figure 13 and 
Figure 14). Sub-threshold (relaxation <20 %) concentrations of MK571 (3 µM) 
and PB (300 µM) were chosen to assess the effects of these MRP inhibitors on 
vasorelaxant responses. 
 
The endothelium-dependent vasorelaxant ACh exerted concentration-
dependent relaxations of PE pre-contracted mouse aorta that were not 
significantly different in the presence of either MK571 (3 µM; Figure 15) or PB 
(300 µM; Figure 16). The NO-donor, Sp-NO, CNP, ANP and the β-adrenoceptor 
agonist Iso all induced concentration-dependent relaxations of PE-tone that 
were sensitive to MRP inhibition. The greatest effect of MRP inhibition was 
observed on vasorelaxant responses to ANP; MK571 significantly increased 
ANP potency by almost a half Log (Log EC50: -8.53 ± 0.085 to -9.011 ± 0.12; 
P<0.001; Figure 17). PB also significantly enhanced the vasodilator effect of 
ANP (Log EC50: -8.51 ±0.091 to -8.64 ± 0.12; P<0.001; Figure 18). Responses 
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to CNP were significantly, albeit modestly, increased by MK571 (Log EC50: -
6.84 ± 0.041 to -6.98 ± 0.034; P<0.001; Figure 19) and PB (Log EC50: -6.87 ± 
0.14 to -9.011 -6.91 ± 0.098; P<0.05; Figure 20). In addition, PB, but not 
MK571, significantly enhanced the maximal response to CNP (Emax 88.50 ± 
8.94 to 95.97 ± 5.32 % Figure 20). The potency of Sp-NO was marginally, but 
significantly, enhanced when combined with MK571 (Log EC50: -6.84 ± 0.068 to 
-6.58 ± 0.028; P<0.01; Figure 21). Conversely, PB reduced the potency of Sp-
NO producing a significant rightward shift in the relaxation response curve (Log 
EC50: -6.36 ± 0.07 to -6.58 ± 0.03; P<0.05; Figure 22). Finally, PB (Log EC50  
-6.64 ±0.13 to -6.90 ±0.16; P<0.01; Figure 24) and MK571 (Log EC50 -6.63 ± 





EFFECT OF PE IN MOUSE AORTIC RINGS 
 


















Figure 10. Concentration-response curve to PE in mouse aortic rings.  





Log EC50 (M) Emax (g) 
-7.03 ± 0.11 0.38 ± 0.03 
 
Table 6. Log EC50 and Emax values for PE-induced contraction of mouse 
aortic rings.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 




EFFECT OF PE IN MOUSE AORTIC RINGS 
 























Figure 11. Concentration-response curve to PE in mouse aortic rings.  
Contraction is expressed as mean ± SEM percentage of the maximal 




Log EC50 (M) Emax (%) 
-7.12 ± 0.10 67.49 ± 4.24 
 
Table 7. Log EC50 and Emax values for PE-induced contraction of mouse 
aortic rings.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 




EFFECT OF ACh IN MOUSE AORTIC RINGS 
 




















Figure 12. Concentration-response curve to ACh in mouse aortic rings.  





Log EC50 (M) Emax (%) 
-7.33 ± 0.06 72.02 ± 2.15 
 
Table 8. Log EC50 and Emax values for ACh-induced relaxation of mouse 
aortic rings.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 




EFFECT OF MK571 IN MOUSE AORTIC RINGS 
 




















Figure 13. Concentration-response curve to MK571 in mouse aortic rings.  





Log EC50 (M) Emax (%) 
-4.96 ± 0.05 109.70 ± 10.79 
 
Table 9. Log EC50 and Emax values for MK571-induced relaxation of mouse 
aortic rings.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 




EFFECT OF PB IN MOUSE AORTIC RINGS 
 




















Figure 14. Concentration-response curve to PB in mouse aortic rings.  





Log EC50 (M) Emax (%) 
-2.87 ± 0.26 133.30 ± 34.63 
 
Table 10. Log EC50 and Emax values for PB-induced relaxation of mouse 
aortic rings. 
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 




EFFECT OF ACh IN MOUSE AORTIC RINGS IN THE ABSENCE AND 
PRESENCE OF MK571 
 





















Figure 15. Concentration-response curves to ACh in mouse aortic rings in 
the absence and presence of MK571. 
Relaxation is expressed as mean ± SEM percentage reversal of PE-induced 
tone in the absence and presence of MK571. n=6-8. 
 
 Log EC50 (M) Emax (%) 
Control -7.33 ± 0.055 72.02 ± 2.15 
+ MK571 (3 µM) -7.27 ± 0.072 69.71 ± 2.83 
 
Table 11. Log EC50 and Emax values for ACh-induced relaxation of mouse 
aortic rings in the absence and presence of MK571. 
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 
percentage reversal of PE-induced tone in the absence and presence of 
MK571. n=6-8.  
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EFFECT OF ACh IN MOUSE AORTIC RINGS IN THE ABSENCE AND 
PRESENCE OF PB 
 






















Figure 16. Concentration-response curves to ACh in mouse aortic rings in 
the absence and presence of PB.  
Relaxation is expressed as mean ± SEM percentage reversal of PE-induced 
tone in the absence and presence of PB. n=8-12. 
 
 Log EC50 (M) Emax (%) 
Control -7.05 ± 0.18 66.66 ± 7.86 
+ PB (300 µM) -6.90 ± 0.23 69.36 ± 10.90 
 
Table 12. Log EC50 and Emax values for ACh-induced relaxations of mouse 
aortic rings in the absence and presence of PB.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 




EFFECT OF ANP IN MOUSE AORTIC RINGS IN THE ABSENCE AND 
PRESENCE OF MK571 
 






















Figure 17. Concentration-response curves to ANP in mouse aortic rings in 
the absence and presence of MK571.  
Relaxation is expressed as mean ± SEM percentage reversal of PE-induced 
tone in the absence and presence of MK571. ***P<0.001 v control. n=10-17. 
 
 Log EC50 (M) Emax (%) 
Control -8.53 ± 0.09 101.00 ± 5.42 
+ MK571 (3 µM) -9.01 ± 0.12 102.00 ± 6.038 
 
Table 13. Log EC50 and Emax values for ANP-induced relaxation of mouse 
aortic rings in the absence and presence of MK571.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 
percentage reversal of PE-induced tone in the absence and presence of 
MK571. n=10-17.  
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EFFECT OF ANP IN MOUSE AORTIC RINGS IN THE ABSENCE AND 
PRESENCE OF PB 
 























Figure 18. Concentration-response curves to ANP in mouse aortic rings in 
the absence and presence of PB.  
Relaxation is expressed as mean ± SEM percentage reversal of PE-induced 
tone in the absence and presence of PB. **P<0.01 v control. n=7-9. 
 
 Log EC50 (M) Emax (%) 
Control -8.51 ± 0.091 93.71 ± 4.40 
+ PB (300 µM) -8.64 ± 0.12 100.80 ± 5.71 
 
Table 14. Log EC50 and Emax values for ANP-induced relaxation of mouse 
aortic rings in the absence and presence of PB.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 





EFFECT OF CNP IN MOUSE AORTIC RINGS IN THE ABSENCE AND 
PRESENCE OF MK571 
 






















Figure 19. Concentration-response curves to CNP in mouse aortic rings in 
the absence and presence of MK571.  
Relaxation is expressed as mean ± SEM percentage reversal of PE-induced 
tone in the absence and presence of MK571. ***P<0.001 v control. n=6-7. 
 
 Log EC50 (M) Emax (%) 
Control -6.84 ± 0.0.041 96.96 ± 2.96 
+ MK571 (3 µM) -6.98 ± 0.034 98.67 ± 2.28 
 
Table 15. Log EC50 and Emax values for CNP-induced relaxation of mouse 
aortic rings in the absence and presence of MK571.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 
percentage reversal of PE-induced tone in the absence and presence of 
MK571. n=6-7.  
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EFFECT OF CNP IN MOUSE AORTIC RINGS IN THE ABSENCE AND 
PRESENCE OF PB 
 























Figure 20. Concentration-response curves to CNP in mouse aortic rings in 
the absence and presence of PB.  
Relaxation is expressed as mean ± SEM percentage reversal of PE-induced 
tone in the absence and presence of PB. *P<0.05 v control. n=8-11. 
 
 Log EC50 (M) Emax (%) 
Control -6.87 ± 0.14 88.50 ± 8.94 
+ PB (300 µM) -6.97 ± 0.08 95.97 ± 5.32 
 
Table 16. Log EC50 and Emax values for CNP-induced relaxation of mouse 
aortic rings in the absence and presence of PB.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 





EFFECT OF Sp-NO IN MOUSE AORTIC RINGS IN THE ABSENCE AND 
PRESENCE OF MK571 
 






















Figure 21. Concentration-response curves to Sp-NO in mouse aortic rings 
in the absence and presence of MK571.  
Relaxation is expressed as mean ± SEM percentage reversal of PE-induced 
tone in the absence and presence of MK571 **P<0.01 v control. n=5. 
 
 Log EC50 (M) Emax (%) 
Control -6.36 ± 0.07 102.40 ± 3.85 
+ MK571 (3 µM) -6.58 ± 0.03 100.50 ± 1.41 
 
Table 17. Log EC50 and Emax values for Sp-NO-induced relaxation of mouse 
aortic rings in the absence and presence of MK571.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 
percentage reversal of PE-induced tone in the absence and presence of 
MK571. n=5.  
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EFFECT OF Sp-NO IN MOUSE AORTIC RINGS IN THE ABSENCE AND 
PRESENCE OF PB  
 























Figure 22. Concentration-response curves to Sp-NO in mouse aortic rings 
in the absence and presence of PB.  
Relaxation is expressed as mean ± SEM percentage reversal of PE-induced 
tone in the absence and presence of PB. *P<0.05 v control. n=7-8. 
 
 Log EC50 (M) Emax (%) 
Control -6.69 ± 0.12 93.43 ± 5.65 
+ PB (300 µM) -6.33 ± 0.12 93.08 ± 5.98 
 
Table 18. Log EC50 and Emax values for Sp-NO-induced relaxation of mouse 
aortic rings in the absence and presence of PB.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 





EFFECT OF Iso IN MOUSE AORTIC RINGS IN THE ABSENCE AND 
PRESENCE OF MK571  
 























Figure 23. Concentration-response curves to Iso in mouse aortic rings in 
the absence and presence of MK571.  
Relaxation is expressed as mean ± SEM percentage reversal of PE-induced 
tone in the absence and presence of MK571. ***P<0.001 v control. n=7-9. 
 
 Log EC50 (M) Emax (%) 
Control -6.63 ± 0.14 94.03 ± 9.21 
+ MK571 (3 µM) -6.97 ± 0.13 96.65 ± 8.23 
 
Table 19. Log EC50 and Emax values for Iso-induced relaxation of mouse 
aortic rings in the absence and presence of MK571.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 
percentage reversal of PE-induced tone by Iso in the absence and presence of 





EFFECT OF Iso IN MOUSE AORTIC RINGS IN THE ABSENCE AND 
PRESENCE OF PB  
 























Figure 24. Concentration-response curves to Iso in mouse aortic rings in 
the absence and presence of PB.  
Relaxation is expressed as mean ± SEM percentage reversal of PE-induced 
tone in the absence and presence of PB. **P<0.01 v control. n=7-8. 
 
 Log EC50 (M) Emax (%) 
Control -6.64 ± 0.13 70.93 ± 5.62 
+ PB (300 µM) -6.90 ± 0.16 75.12 ± 6.86 
 
Table 20. Log EC50 and Emax values for Iso-induced relaxation of mouse 
aortic rings in the absence and presence of PB.  
Log EC50 is expressed as mean ± SEM [M]. Emax is expressed as mean ± SEM 





3.2 Effect of MRP inhibition on vascular smooth 
muscle cell (VSMC) proliferation 
 
Having demonstrated that MRP inhibition augmented cGMP- (and cAMP-) 
dependent relaxations of isolated aorta, the objective of these experiments was 
to determine whether MRP inhibition also reduces VSMC proliferation by 
enhancing cGMP signalling. Human CASMCs were used due to their relevance 
to human cardiovascular disease (e.g. CAD). Routine culture of hCASMCs 
produced a uniform monolayer when confluent which contained “hill and valley” 
formations characteristic of SMCs (Figure 25). Cells seeded at an initial density 
of 30,000 cells/well grew at an exponential rate under control conditions without 
becoming confluent (Figure 26). MK571 (30 nM-30 µM) concentration-
dependently inhibited hCASMC proliferation compared to control (Figure 26); 30 
µM MK571 completely arrested cell growth and changed cell morphology 
(Figure 26 & Figure 25). Based on these data, a sub-threshold concentration of 
MK571 (30 nM) was selected to study effects of MRP inhibition on the anti-
proliferative effects of the NO-donor D-NO and ANP. D-NO was chosen due to 
its relatively long half-life (20 h) at 37 ⁰C compared to other NO donors such as 
Sp-NO (39 min) and SNP (2 min) since treatments were changed once every 24 
h (Keefer, 2005). D-NO (10 µM) and ANP (1 µM) were chosen due to their 
ability to elicit sub-maximal inhibition of human VSMC proliferation (Bubb et al., 
2014). D-NO and ANP alone did not significantly alter hCASMC proliferation, 
although a tendency for both to reduce mean fold-change in cell number was 
observed (Figure 27 & Figure 28). An essentially identical result was gleaned 
using the sub-threshold concentration of MK571 (30 nM; Figure 27 & Figure 
28). However, when the sub-threshold concentration of MK571 was combined 
with either ANP (1 µM) or D-NO (10 µM) a significantly enhanced inhibitory 
effect on hCASMC proliferation was observed compared to control (Figure 27 & 
Figure 28). Moreover, MK571 combined with D-NO significantly inhibited 
hCASMC growth compared to D-NO alone (Figure 27), although a similar 
potentiation was not seen with MK571 plus ANP compared to ANP alone 
(Figure 28).    
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REPRESENTATIVE IMAGES OF HUMAN CORONARY ARTERY SMOOTH 
MUSCLE CELLS IN THE ABSENCE AND PRESENCE OF MK571 
 
 
Figure 25. Representative images of hCASMC under routine culture and 
after seeding in the absence and presence MK571. 
Representative images of confluent hCASMCs under routine culture (A); 
hCASMC 24 h after seeding (30,000 cell/well) treated with sterile ddH2O 
(control; B), MK571 (3 µM; C) or MK571 (30 µM; D). x4 objective used for 




EFFECT OF MK571 ON THE PROLIFERATION OF HUMAN CORONARY 
ARTERY SMOOTH MUSCLE CELLS 
 



































Figure 26. Effect of increasing concentrations of MK571 on hCASMC 
proliferation. 
Proliferation of hCASMC in the absence (control) or in the presence of 
increasing concentrations of MK571 (30 nM, 300 nM, 3 µM, 30 µM). Data are 
expressed as mean ± SEM fold change in cell number compared to 0 h. 





EFFECT OF D-NO ON THE PROLIFERATION OF HUMAN CORONARY 
ARTERY SMOOTH MUSCLE CELLS IN THE ABSENCE AND PRESENCE 
OF MK571 
 



































Figure 27. Effect of D-NO in the absence and presence or MK571 on 
hCASMC proliferation. 
Proliferation of hCASMC in the absence (control) or in the presence of MK571 
(30 nM), D-NO (10 µM) or MK571 plus D-NO. Data are expressed as mean ± 
SEM fold change in cell number compared to 0 h. ***P<0.001 v control. #P<0.05 




EFFECT OF ANP ON THE PROLIFERATION OF HUMAN CORONARY 
ARTERY SMOOTH MUSCLE CELLS IN THE ABSENCE AND PRESENCE 
OF MK571 
 


































Figure 28. Effect of ANP in the absence and presence or MK571 on 
hCASMC proliferation. 
Proliferation of hCASMC in the absence (control) or in the presence of MK571 
(30 nM), ANP (10 µM) or MK571 plus ANP. Data are expressed as mean ± 
SEM fold change in cell number compared to 0 h. **P<0.01 v control. n=10 
observations from 5 separate experiments.  
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3.3 Effect of MRP inhibition on intra and extra -
cellular cGMP concentrations 
 
In the previous set of experiments I showed that MRP blockade is able to 
augment the anti-proliferative effects of NO and NPs. To investigate whether 
MRP inhibition augments VSMC growth through effects on cGMP 
dynamics/transport, intracellular and extracellular cGMP concentrations were 
measured in hCASMC at the 24 h time point, under identical conditions 
employed for the proliferation assays described above. Human CASMC grown 
under control conditions show an essentially equal intra and extra -cellular 
production of cGMP (Figure 29). In hCASMCs treated with MK571 (30 nM, 300 
nM and 3 µM), the intra- and extra- cellular cGMP concentrations did not differ 
significantly from control (Figure 26). Following 24 h treatment with D-NO (10 
µM) in the absence or presence of MK571 (30 nM) intra-, or extra- cellular 
cGMP concentrations did not significantly change compared to control (Figure 
30). However, 24 h treatment with ANP (1 µM) produced a marked, statistically-
significant (14.91 ± 3.82 fmol/well; P<0.05) increase in extracellular cGMP 
compared to control (3.79 ± 0.56 fmol/well), which showed a trend towards 
being blunted when combined with MK571 (30 nM; 11.76 ± 3.17 fmol/well; 
P>0.05 v control; Figure 31). Importantly, the intra:extra-cellular ratio of cGMP 
revealed a significant decrease with ANP treatment (0.37 ± 0.05 intra:extra –
cellular ratio; P<0.01) compared to control (1.33 ± 0.20 intra:extra –cellular 
ratio) which was significantly (P<0.05) attenuated by the presence of MK571 
(30nM; 0.69 ± 0.13 intra:extra –cellular ratio; P<0.05 v ANP; Figure 31).  
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EFFECT OF MK571 ON INTRA- AND EXTRA- CELLULAR cGMP 








































































































































































Figure 29. Effect of MK571 on hCASMC cGMP concentrations. 
Intracellular (A) & extracellular (B) cGMP concentrations and intra:extra  
–cellular cGMP ratio (C) in hCASMC in the absence or presence of increasing 
concentrations of MK571 for 24 h. Data are expressed as mean ± SEM [cGMP] 
in fmol/well (A & B), or cGMP intra/extra -cellular ratio (C). n=8-12.  
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EFFECT OF D-NO ON INTRA- AND EXTRA- CELLULAR cGMP 
CONCENTRATIONS IN HUMAN CORONARY ARTERY SMOOTH MUSCLE 





















































































































































Figure 30. Effect of D-NO on hCASMC cGMP concentrations in the 
absence and presence of MK571. 
Intracellular (A) and extracellular (B) cGMP concentrations and intra:extra  
–cellular cGMP ratio (C) in hCASMC under control conditions or treated with or 
D-NO (10 µM) in the absence or presence of MK571 (30 nM). Data are 
expressed as mean ± SEM [cGMP] in fmol/well (A & B), or cGMP intra/extra -
cellular ratio (C). n=8-12.  
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EFFECT OF ANP ON INTRA- AND EXTRA- CELLULAR cGMP 
CONCENTRATIONS IN HUMAN CORONARY ARTERY SMOOTH MUSCLE 


























































































































































Figure 31. Effect of ANP on hCASMC cGMP concentrations in the absence 
and presence of MK571. 
Intracellular (A) and extracellular (B) cGMP concentrations and intra:extra  
–cellular cGMP ratio (C) in hCASMC under control conditions or treated with 
ANP (1 µM) in the absence or presence of MK571 (30 nM). Data are expressed 
as mean ± SEM [cGMP] in fmol/well (A & B), or cGMP intra/extra –cellular ratio 
(C). *P<0.05, **P<0.01 v control. #P<0.05 v ANP. n=8-12.  
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3.4 Effect of MRP inhibition on acute changes in 
blood pressure 
 
My in vitro observations in isolated blood vessels and cells suggest that 
inhibition of MRPs augments the vasorelaxant and anti-proliferative activity of 
NO and ANP, and that this is underpinned, at least in the case of ANP, by a 
change in the intra:extra cellular -cGMP ratio (i.e. cGMP efflux via MRPs). 
These data identify MRPs as playing a key role in regulating cGMP biology in 
the cardiovascular system, particularly in the case of natriuretic peptides. To 
determine if such an influence was also functionally apparent in vivo, the effect 
of MRP inhibition on NO- and ANP- induced acute changes in blood pressure 
was explored in anaesthetised mice.  
 
Administration of 0.0001, 0.001, 0.01, 0.1, 1 and 3 mg/kg MK571 caused a 
small decrease in MABP that was indistinguishable compared to saline (Figure 
32). Accordingly, the highest dose (3 mg/kg) MK571 was used in subsequent 
experiments to assess the effect of MRP inhibition on haemodynamic 
responses to NO and ANP. The NO-donor SNP (1, 3, 10 µg/kg; i.v. bolus) and 
ANP (1, 10, 100 µg/kg; i.v. bolus) were chosen due to their ability to elicit dose-
dependent reductions in MABP (Madhani et al., 2006). SNP produced a dose-
dependent decrease in MABP (1 µg/kg: MABP = -4.42 ± 1.34 mm Hg; 3 
µg/kg: MABP = -11.83 ± 1.63 mm Hg; 10 µg/kg: MABP = -23.85 ± 1.59 mm 
Hg; Figure 33) which was not significantly altered when combined with MK571 
(3 mg/kg; Figure 33). ANP also produced dose-dependent decreases in MABP 
(1 µg/kg: MABP = -2.79 ± 1.46 mm Hg; 10 µg/kg: MABP = -7.92 ± 1.98 mm 
Hg; 100 µg/kg: MABP= -11.07 ± 1.64 mm Hg; Figure 34); however, in this 
case the hypotensive response to ANP was significantly (P<0.01) enhanced 
when combined with MK571 3 mg/kg; (1 µg/kg: MABP = -10.37 ± 2.00 mm 
Hg; 10 µg/kg: MABP = -11.72 ± 2.66 mm Hg; 100 µg/kg: MABP = -17.20 ± 
1.91 mm Hg; Figure 34). 
 
Administration of MK571 at the doses above caused a small decrease in HR but 
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this was indistinguishable compared to saline (Figure 32). SNP alone produced 
a significant, dose-dependent increase in HR which was not significantly altered 
when combined with MK571 (Figure 33). ANP alone did not produce dose-
dependent changes in HR and this was not significantly altered when combined 
with MK571 (Figure 34).  
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Figure 32. Effect of MK571 on blood pressure and heart rate in 
anaesthetised mice. 
Mean arterial blood pressure (MABP; A) and heart rate (HR; B), in 
anaesthetised mice treated with vehicle (saline) or increasing doses of MK571 
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Figure 33. Effect of SNP on blood pressure and heart rate in the absence 
and presence of MK571 in anaesthetised mice. 
Mean arterial blood pressure (MABP; A) and heart rate (HR; B), in 
anaesthetised mice treated with SNP (1, 3, 10 µg/kg; i.v. bolus) in the absence 
and presence of MK571 (3 mg/kg; i.v. bolus). Data are expressed as mean ± 
SEM. n=6.  
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EFFECT OF ANP IN THE ABSENCE AND PRESENCE OF MK571 ON 
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Figure 34. Effect of ANP on blood pressure and heart rate in the absence 
and presence of MK571 in anaesthetised mice. 
Mean arterial blood pressure (MABP; A) and heart rate (HR; B), in 
anaesthetised mice treated with ANP (1, 10, 100 µg/kg; i.v. bolus) in the 
absence and presence of MK571 (3 mg/kg; i.v. bolus). Data are expressed as 
mean ± SEM. **P<0.05 v ANP alone. n=5.   
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3.5 Effect of MRP inhibition on blood pressure in 
conscious, telemeterised mice 
 
Since my initial in vivo studies in anaesthetised mice suggested that MRP 
inhibition with MK571 can acutely enhance the hypotensive activity of ANP, I 
proceeded to conduct investigations to determine if a more chronic 
administration of MK571 was able to modulate blood pressure in vivo. Male WT 
C57/BL6 mice were implanted with a telemetry probes, allowing continuous 
measurement of MABP, HR and activity. Data shown in this section are over a 
24 h period. Baseline recording were made over one weekend and then mice 
administered MK571 (25 mg/kg/day) in the drinking water 12 h before 
haemodynamic parameters were recorded a second time the following 
weekend.  
 
3.5.1 Mean arterial blood pressure (MABP) 
 
Mice had a normal circadian rhythm with respect to MABP during the 24 h time 
period (Figure 35). There were no significant differences in MABP over the 
whole 24 h or during either the 12 h light or dark phase in the absence or 
presence of MK571 (Figure 36). 
 
3.5.2 Heart rate (HR) 
 
Mice exhibited a normal HR circadian rhythm over the 24 h time period (Figure 
35). HR was significantly (P<0.05) reduced in mice treated with MK571 (24 h 
period: 564.60 ± 5.16 bpm; light phase: 512.6 ± 5.72 bpm) compared to 
baseline (24 h period: 581.1 ± 5.15 bpm; light phase: 532.7 ± 5.21 bpm), during 
the light (inactive) phase and over the whole 24 h period, but not during the dark 






Mice exhibited a normal circadian rhythm of activity over the 24 h time period 
with marked increases in the dark phase, as expected (Figure 35). Activity 
tended to be reduced when treated with MK571 over the whole 24 h period and 
during the light and dark phases (Figure 36). However, it was only significantly 
(P<0.05) reduced during the dark phase (10.32 ± 0.57 a.u., 8.83 ± 0.47 a.u., 
baseline and MK571 treated, respectively; Figure 36).  
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EFFECT OF MK571 ON THE CIRCADIAN RHYTHM OF BLOOD PRESSURE, 
HEART RATE AND ACTIVITY IN CONSCIOUS TELEMETERISED MICE 

































































Figure 35. Effect of MK571 on the circadian rhythm of blood pressure, 
heart rate and activity in conscious telemeterised mice. 
MABP (A), HR (B), and activity (C) in mice under control conditions (normal 
drinking water; baseline) or treated with MK571 (25 mg/kg/day; p.o). n=4.  
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EFFECT OF MK571 ON BLOOD PRESSURE, HEART RATE AND ACTIVITY 


























































































































































































Figure 36. Effect of MK571 on blood pressure, heart rate and activity in 
conscious telemeterised mice. 
MABP (A), HR (B), and activity (C) in mice under control conditions (normal 
drinking water; baseline) or treated with MK571 (25 mg/kg/day; p.o.; for 24 h). 




















CHAPTER 4: RESULTS 2 
 
4 Investigation of the role of CNP and its 
cognate receptor NPR-C in experimental PH 
 
4.1 Optimising the mouse hypoxia plus SU5416 
model of PH 
 
As outlined in the introduction, there are several animal models of PH that are 
utilised to replicate the human condition. The one I chose to use is an 
adaptation of a classic model of PH, that associated with chronic hypoxia (10 % 
O2), except that additionally I administered the VEGFR-2 inhibitor, SU5416. 
This model was originally described in rats Taraseviciene-Stewart et al., (2001) 
and produces pathohistological pulmonary vascular lesions which are 
progressive and non-reversible (upon return to normoxia), and therefore more 
akin to the human disease than chronic hypoxia alone or indeed other animal 
models of PH; as such, the hypoxia plus SU5416 model is largely considered 
the gold standard for this disease (Abe et al., 2010). A mouse hypoxia plus 
SU5416 model was first described by Ciuclan et al., (2011), involving the 
combination of chronic hypoxia (3 weeks) with repeat doses of SU5416 which 
generated a more severe phenotype; higher RVH (Fulton’s Index), RVSP and 
the presence of pulmonary vascular “complex” lesions. Furthermore, this report 
confirmed that the pulmonary vascular remodelling contained markers of EC 
apoptosis/SMC proliferation and when the mice were returned to normal 
laboratory conditions they retained PH pathology; this again more closely 
mimics the disease found in humans and in sharp contrast to chronic hypoxia 
only (reversible pathology and predominantly SMC proliferation not EC 
apoptosis).  
 
Since this model had not been utilised in our laboratory previously, initial studies 
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were designed with the goal of optimising the protocol. SU5416 is available 
commercially (Tocris Bioscience, Bristol, UK), but due to its considerable cost, 
in-house synthesis was conducted by Prof. D. Selwood (UCL, London, UK) 
according to a published method (Sun et al., 1998). In a first set of studies, I 
compared the efficacy of equal doses of SU5416 sourced from either Tocris 
(‘Tocris SU5416’) or synthesised by Prof Selwood (‘DS SU5416’) in the hypoxia 
plus SU5416 experimental mouse model of PH described above (Ciuclan et al., 
2011). This approach allowed me to assess the relative potency of both 
SU5416 preparations and concomitantly optimise the hypoxic exposure. 
 
Male C57/BL6 mice were injected once a week, for 3 weeks with SU5416 (20 
mg/kg; s.c.) and exposed to varying periods of hypoxia (10% O2, normobaric, 
21 or 25 days).  
 
4.1.1 Body weight (BW) 
 
Under control conditions mice steadily gained weight over the complete 35 day 
period (Figure 37). However, animals exposed to hypoxia plus SU5416 rapidly 
(within 3 days) lost body weight (BW; Figure 37). This drop in BW was 
maintained at a constant level for the whole 35 day period and did not differ 
significantly between the two SU5416 sources (Figure 37). After 21 days 
hypoxia, once mice were returned to normoxia, they gained weight at a steady 
rate, comparable to that observed under normoxic/control conditions (Figure 
37). Thus, after a further 14 days in normoxia, mouse BW had returned to the 
value at the start of the experiment (Figure 37). This effect of hypoxia plus 
SU5416 on mouse body weight mirrored that observed originally by Ciuclan et 
al., (2011).  
 
4.1.2 Right ventricular systolic pressure (RVSP) 
 
Mice administered SU5416 from either source and exposed to 21 days hypoxia 
developed significantly (P<0.001) increased RVSP (46.9 ± 2.28 mm Hg & 46.7 
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± 3.08 mm Hg, Tocris & DS SU5416, respectively) compared to normoxia 
controls (33.8 ± 0.61 mm Hg; Figure 38). A further 14 days hypoxia (35 days 
hypoxia in total) resulted in similar RVSP values to that observed at 21 days 
that remained significantly greater than controls (Figure 38). Returning the mice 
to normoxia following 21 days hypoxia (‘Reversal’) resulted in a decrease in 
RVSP (Figure 38). In this setting, mice treated with Tocris SU5416 (41.2 ± 0.98 
mm Hg) maintained an RVSP significantly (P<0.05) greater than control (Figure 
38), whereas in animals receiving DS SU5416 the RVSP (38.1 ± 0.97 mm Hg) 
was no longer statistically higher than normoxic mice (Figure 38). However, 
overall there were no significant differences in RVSP under any conditions 
when comparing animals treated with either Tocris SU5416 or DS SU5416 
(Figure 38). These change in RVSP are similar to those originally reported by 
Ciuclan et al., (2011). 
 
4.1.3 Mean arterial blood pressure (MABP) 
 
MABP was not significantly altered by hypoxia, nor the SU5416 from either 
source, under any experimental conditions (Figure 38). 
 
4.1.4 Right ventricular hypertrophy (RVH) 
 
RVH followed a similar pattern to that seen with RVSP (Figure 39). After 21 
days hypoxia, RVH was significantly increased (as measured by the RV:[LV+S] 
ratio; Figure 39). A further increase in RVH was not observed when 35 days 
hypoxia was compared to 21 days, but at 35 days RVH remained significantly 
increased compared to control (Figure 39). Mirroring effects on RVSP, RVH 
was also decreased in the reversal group and no longer significantly greater 
than control (Figure 39). The effect I observed of hypoxia plus SU5416 on RVH 
relates closely to what was reported by Ciuclan et al., (2011). Importantly, no 
significant difference in RVH was observed between Tocris and DS SU5416. 
Thus, since these data established that SU5416 synthesised by Prof. Selwood 
was functionally equivalent to that commercially available, the former source 
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was used for all subsequent experiments. Moreover, since 21 days hypoxia 
produced an essentially identical phenotype to 35 days hypoxia, the former time 
period was employed for further study. 
 
4.1.5 Pulmonary vascular remodelling 
 
The lungs of mice exposed to 5 weeks hypoxia plus SU5416, which is the most 
severe form of this model, were inspected for the presence of complex lesions 
and occluded vessels, a hallmark of PAH found in humans and in the rat 
hypoxia plus SU5416 model. No complex lesions or occluded vessels were 




EFFECT OF HYPOXIA PLUS SU5416 ON BODY WEIGHT  



























































Figure 37. Effect of hypoxia plus SU5416 on body weight. 
Body weight at days 0, 3, 7, 14, 21, 28 and 35 of mice administered vehicle 
(Control), SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) synthesised in-house (DS 
SU5416) or purchased from Tocris (Tocris SU5416) and exposed to either 
normoxia (21 % O2; control) or hypoxia (10 % O2) for 35 days (A), or 21 days 
hypoxia followed by 14 days normoxia (B). Data represented as mean ± SEM. 
***P<0.001 v control. n=8-21.  
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Figure 38. Effect of hypoxia plus SU5416 on haemodynamics. 
Right ventricular systolic pressure (RVSP; A) and mean arterial blood pressure 
(MABP; B) in mice administered vehicle (control), SU5416 (20 mg/kg; s.c. at 
days 0, 7 & 14) synthesised in-house (DS SU5416) or purchased from Tocris 
(Tocris SU5416) and exposed to either normoxia (21 % O2; control) for 35 days, 
hypoxia (10 % O2) for 21 or 35 days, or 21 days hypoxia followed by 14 days 
normoxia (reversal). Data represented as mean ± SEM. ***P<0.001, **P<0.01, 
*P<0.05 v control. n=3-7.  
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Figure 39. Effect of hypoxia plus SU5416 on right ventricular hypertrophy.  
Right ventricle to left ventricle plus septum ratio (RV/[LV+S]) in mice 
administered vehicle (control), SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) 
synthesised in-house (DS SU5416) or purchased from Tocris (Tocris SU5416) 
and exposed to either normoxia (21 % O2; control) for 35 days, hypoxia (10 % 
O2) for 21 or 35 days, or 21 days hypoxia followed by 14 days normoxia 




4.2 Effect of endothelial-specific deletion of CNP 
on the development of experimental pulmonary 
hypertension  
 
Previous work from our laboratory demonstrated that endothelium-derived CNP 
plays a pivotal role in regulating local vascular tone, systemic blood pressure, 
and the reactivity of platelets and leukocytes (Moyes et al., 2014). In the 
pulmonary circulation, infusion of CNP has been reported to be ineffective in 
reversing the increased pressure associated with pulmonary hypertension 
(Casserly et al., 2011). However, as CNP is metabolised rapidly by peptides in 
the pulmonary circulation, particularly NEP (Kenny et al., 1993), I designed 
experiments to discover if endogenous CNP played a pathophysiological role in 
the development of PH. To achieve this goal, I exploited the endothelial-specific 
CNP knockout (ecCNP KO) mouse developed by our lab (Moyes et al., 2014). 
For this set of investigations, ecCNP KO and WT littermate mice (male and 
female; 16 week old; C57/BL6 background) were injected once a week, for 3 
weeks, with SU5416 (20 mg/kg; s.c.) and exposed to 21 days hypoxia (10 % 
O2, normobaric).  
 




In the first 3 days both WT and ecCNP KO mice lost BW, similar to that 
observed during the optimisation experiments and previously reported by 
Ciuclan et al., (2011; Figure 40). Subsequently, the BW of both groups 
remained steady for the entire 21 day hypoxic period (Figure 40). Although WT 
(30.93 ± 0.68 g) mice were on average marginally heavier than KO animals 
(29.43 ± 0.55 g) the percentage loss in BW between day 0 and 21 was 






Female WT (normoxic 24.68 ± 0.85 g) were also heavier than ecCNP KO 
(normoxic 23.03 ± 0.85 g; P>0.05; Figure 41). Both WT and KO mice lost BW 
steadily over the first 7 days of hypoxia which then remained constant for the 
remainder of the experiment (Figure 41). As for the male animals, the 
percentage decrease in BW between day 0 and 21 was not significantly 
different between WT and KO (-14.5 ± 2.16 %, -12.3 ± 4.45 % WT and KO 
respectively; P>0.05; Figure 41).  
 




Hypoxia significantly increased RVSP in male WT (37.7 ± 1.26 mm Hg; P<0.01) 
and ecCNP KO (40.8 ± 1.56 mm Hg; P<0.001) mice compared to their 
corresponding normoxic controls (29.8 ± 0.93 and 28.7 ± 1.56 mm Hg, WT and 
KO, respectively). Although, there was no significant difference in RVSP 
between WT and KO mice exposed to hypoxia plus SU5416, even when 
comparing change in RVSP for both WT (∆7.9 ± 1.26 mm Hg) and KO (∆12.1 ± 




The RVSP in female WT (38.2 ± 1.76 mm Hg, P<0.001) and ecCNP KO (38.2 ± 
1.52 mm Hg, P<0.001) mice increased significantly, compared to normoxic 
controls (28.3 ± 0.87 and 28.4 ± 2.11 mm Hg, WT and KO, respectively), in 
response to hypoxia plus SU5416 regardless of genotype (Figure 43). Again, 
there was no significant difference in the magnitude of this RVSP increase 








MABP was essentially identical, regardless of genotype, between normoxia and 




An identical profile was observed in female WT and ecCNP KO mice. There 
was no significant difference in MABP between female WT and ecCNP KO mice 
in either control (normoxic) or hypoxic plus SU5416 conditions (Figure 43). This 
is at odds with previous data produced by our lab (Moyes et al., 2014) that 
shows female ecCNP KO mice are hypertensive compared to WT littermates, 
although a more sensitive BP measuring method was utilised (telemetry in 
conscious mice) in those studies compared to that used here (invasive catheter 
in anaesthetised mice).  
 




Hypertrophic responses in the RV in both male and female WT and ecCNP KO 
mice mirrored that observed with RVSP. Exposure to hypoxia plus SU5416 
resulted in significant (P<0.05, P<0.01, WT and KO, respectively) increases in 
RVH in male animals (RV/[LV+S]: 0.25 ± 0.009, 0.26 ± 0.016, WT and KO, 
respectively) compared to control (RV/[LV+S]: 0.19 ± 0.008, 0.20 ± 0.006, WT 
and KO, respectively; Figure 44). Genotype did not significantly affect RV size 
under normoxic or hypoxic conditions (Figure 44). These findings are 
substantiated when change in RV/[LV+S] between normoxic and hypoxic 
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conditions for both WT (∆0.059 ± 0.009) and KO (∆0.061 ± 0.016) mice is 




Both WT (RV/[LV+S]: 0.20 ± 0.004) and ecCNP KO (RV/[LV+S]: 0.22 ± 0.01) 
female mice developed significantly (P<0.05 for both WT and KO) increased 
RVH under hypoxic conditions (RV/[LV+S]: 0.26 ± 0.01, 0.26 ± 0.02, WT and 
KO respectively; Figure 45). Paralleling results in the males, genotype did not 
alter RV under a normoxic or hypoxic environment even when change in 
RV/[LV+S] is calculated for both WT (∆0.053 ± 0.013) and KO (∆0.048 ± 0.016; 
Figure 45 & Figure 47). 
 




Pulmonary vascular remodelling in both male and female ecCNP WT and KO 
mice showed a predominance of partially- and fully- muscularised vessels and 
with no complex lesions or occluded vessels (Table 21). Male ecCNP KO mice 
had a slightly higher percentage of fully-muscularised vessels (54.14 ± 2.27 %) 
than WT (47.19 ± 2.70 %). Although, genotype did not significantly alter the 




Akin to the observations in the male mice, female ecCNP KO did not exhibit 
significant differences in pulmonary vessel muscularisation, despite KO (56.10 ± 
3.90 %) mice having a slightly higher proportion of fully-muscularised vessels 
than WT (49.53 ± 3.63; Figure 49). Lungs were inspected for the presence of 
complex lesions and occluded vessels but none were found (Table 21).  
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EFFECT OF ENDOTHELIUM-SPECIFIC CNP DELETION ON BODY WEIGHT 
IN MALE MICE WITH PULMONARY HYPERTENSION 















































Figure 40. Effect of endothelium-specific CNP deletion on body weight in 
male mice with pulmonary hypertension. 
Body weight (g) at day 0, 3, 7, 14 and 21 (A) and change in body weight 
between day 0 and 21 (%; B) in male endothelium-specific CNP knockout 
(ecCNP KO) mice and wild-type (WT) littermates under control conditions 
(normoxia; 21 % O2) or exposed to hypoxia (10 % O2; 21 days) plus SU5416 





EFFECT OF ENDOTHELIUM-SPECIFIC CNP DELETION ON BODY WEIGHT 
IN FEMALE MICE WITH PULMONARY HYPERTENSION 
















































Figure 41. Effect of endothelium-specific CNP deletion on body weight in 
female mice with pulmonary hypertension. 
Body weight (g) at day 0, 3, 7, 14 and 21 (A) and change in body weight 
between day 0 and 21 (%; B) in female endothelium-specific CNP knockout 
(ecCNP KO) mice and wild-type (WT) littermates under control conditions 
(normoxia; 21 % O2) or exposed to hypoxia (10 % O2; 21 days) plus SU5416 
(20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. Data are represented as mean ± 
SEM. **P<0.01 v WT. n=9-12.  
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Figure 42. Effect of endothelium-specific CNP deletion on haemodynamics 
in male mice with pulmonary hypertension. 
Right ventricular systolic pressure (RVSP; A) and mean arterial blood pressure 
(MABP; B) in male endothelium-specific CNP knockout (ecCNP KO) mice and 
wild-type (WT) littermates under control conditions (normoxia; 21 % O2) or 
exposed to hypoxia (10 % O2; 21 days) plus SU5416 (20 mg/kg; s.c. at days 0, 
7 & 14) or vehicle. Data are represented as mean ± SEM. ***P<0.001 v KO, 
**P<0.01 v WT. n=6-13.  
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Figure 43. Effect of endothelium-specific CNP deletion on haemodynamics 
in female mice with pulmonary hypertension. 
Right ventricular systolic pressure (RVSP; A) and mean arterial blood pressure 
(MABP; B) in female endothelium-specific CNP knockout (ecCNP KO) mice and 
wild-type (WT) littermates under control conditions (normoxia; 21 % O2) or 
exposed to hypoxia (10 % O2; 21 days) plus SU5416 (20 mg/kg; s.c. at days 0, 
7 & 14 or vehicle). Data are represented as mean ± SEM. ***P<0.001 v WT, 
KO. n=7-13.  
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Figure 44. Effect of endothelium-specific CNP deletion on right ventricular 
hypertrophy in male mice with pulmonary hypertension. 
Right ventricle to left ventricle plus septum ratio (RV/[LV+S]) in male 
endothelium-specific CNP knockout (ecCNP KO) mice and wild-type (WT) 
littermates under control conditions (normoxia; 21 % O2) or exposed to hypoxia 
(10 % O2; 21 days) plus SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. 
Data are represented as mean ± SEM. *P<0.05 v WT, **P<0.01 v KO. n=7-13.  
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EFFECT OF ENDOTHELIUM-SPECIFIC CNP DELETION ON RIGHT 






























Figure 45 Effect of endothelium-specific CNP deletion on right ventricular 
hypertrophy in female mice with pulmonary hypertension. 
Right ventricle to left ventricle plus septum ratio (RV/[LV+S]) in female 
endothelium-specific CNP knockout (ecCNP KO) mice and wild-type (WT) 
littermates under control conditions (normoxia; 21 % O2) or exposed to hypoxia 
(10 % O2; 21 days) plus SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. 
Data are represented as mean ± SEM. *P<0.05 v WT, KO. n=8-14.  
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EFFECT OF ENDOTHELIUM-SPECIFIC CNP DELETION ON CHANGE IN 
RIGHT VENTRICULAR SYSTOLIC PRESSURE AND HYPERTROPHY IN 



















































Figure 46. Effect of endothelium-specific CNP deletion on change in right 
ventricular systolic pressure and hypertrophy in male mice with 
pulmonary hypertension. 
Change in right ventricular systolic pressure (RVSP; A) and right ventricle to left 
ventricle plus septum ratio (RV/[LV+S]; B) in male endothelium-specific CNP 
knockout (ecCNP KO) mice and wild-type (WT) littermates under control 
conditions (normoxia; 21 % O2) or exposed to hypoxia (10 % O2; 21 days) plus 
SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. Data are represented as 
mean ± SEM. n=7-13.  
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EFFECT OF ENDOTHELIUM-SPECIFIC CNP DELETION ON CHANGE IN 
RIGHT VENTRICULAR SYSTOLIC PRESSURE AND HYPERTROPHY IN 


















































Figure 47. Effect of endothelium-specific CNP deletion on change in right 
ventricular systolic pressure and hypertrophy in female mice with 
pulmonary hypertension. 
Change in right ventricular systolic pressure (RVSP; A) and right ventricle to left 
ventricle plus septum ratio (RV/[LV+S]; B) in female endothelium-specific CNP 
knockout (ecCNP KO) mice and wild-type (WT) littermates under control 
conditions (normoxia; 21 % O2) or exposed to hypoxia (10 % O2; 21 days) plus 
SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. Data are represented as 
mean ± SEM. n=10-13.  
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EFFECT OF ENDOTHELIUM-SPECIFIC CNP DELETION ON VASCULAR 
REMODELLING IN MALE MICE WITH PULMONARY HYPERTENSION 
 
Figure 48. Effect of endothelium-specific CNP deletion on vascular 
remodelling in male mice with pulmonary hypertension. 
Number of vessels (%; <100 µM in diameter) within the pulmonary vasculature 
that are non-muscularised (<25 % α-SMA stain), partially-muscularised (25-75 
% α-SMA stain) and fully-muscularised (>75 % α-SMA stain) in male 
endothelium-specific CNP knockout (ecCNP KO) mice and wild-type (WT) 
littermates under control conditions (normoxia; 21 % O2) or exposed to hypoxia 
(10 % O2; 21 days) plus SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. 


























































EFFECT OF ENDOTHELIUM-SPECIFIC CNP DELETION ON VASCULAR 
REMODELLING IN FEMALE MICE WITH PULMONARY HYPERTENSION 
 
Figure 49. Effect of endothelium-specific CNP deletion on vascular 
remodelling in female mice with pulmonary hypertension. 
Number of vessels (%; <100 µM in diameter) within the pulmonary vasculature 
that are non-muscularised (<25 % α-SMA stain), partially-muscularised (25-75 
% α-SMA stain) and fully-muscularised (>75 % α-SMA stain) in female 
endothelium-specific CNP knockout (ecCNP KO) mice and wild-type (WT) 
littermates under control conditions (normoxia; 21 % O2) or exposed to hypoxia 
(10 % O2; 21 days) plus SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. 


























































REPRESENTATIVE IMAGES OF THE EFFECT OF ENDOTHELIUM-
SPECIFIC CNP DELETION ON VASCULAR REMODELLING IN MALE AND 








Male ecCNP WT 
   
Male ecCNP KO 
   
Female ecCNP WT 
   
Female ecCNP KO 
   
 
Table 21. Representative images of endothelium-specific CNP deletion on 
vascular remodelling in male and female mice with pulmonary 
hypertension. 
Representative images of vessels within the pulmonary vasculature that are 
non-muscularised (<25 % α-SMA stain), partially-muscularised (25-75 % α-SMA 
stain) and fully-muscularised (>75 % α-SMA stain) in male and female 
endothelium-specific CNP knockout (ecCNP KO) mice and wild-type (WT) 
littermates exposed to hypoxia (10 % O2; 21 days) plus SU5416 (20 mg/kg; s.c. 
at days 0, 7 & 14). H & E stain (blue) and α-SMA stain (brown). Images taken at 
x20 magnification. Scale bar = 50 µm.  
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4.3 Effect of global deletion of NPR-C on the 
development of experimental pulmonary 
hypertension  
 
Recent work by our laboratory has assigned a critical signalling role to NPR-C 
in the systemic circulation (Moyes et al., 2014) in addition to its well-established 
function to clear natriuretic peptides (Maack et al., 1987). In particular, the 
endothelial dysfunction and hypertension observed in ecCNP KO animals 
appears to be recapitulated, at least in part, in global NPR-C deleted mutants. 
Data from the previous set of experiments indicated that endothelium-derived 
CNP does not play a prominent role in regulating pulmonary vascular reactivity 
in the context of PH. However, since other cellular sources of CNP may be 
important in this pro-proliferative disorder (e.g. cardiomyocyte, macrophage, 
fibroblast, VSMC), and the possibility that alternate NPs (i.e. ANP and/or BNP; 
released in patients with PH) might also activate NPR-C, I proceeded to 
examine the phenotype of global NPR-C KO mice in the hypoxia plus SU5416 
model of PH. Of note, although I originally hypothesised that cGMP-dependent 
processes might underlie any beneficial activity of CNP, the demonstrated 
importance of NPR-C in the systemic circulation and the shortage of usable 
NPR-B KO offspring (due to significantly reduced survival) targeted this line of 
investigation towards mice with NPR-C gene deletion. 
 
The same methodology was used in these experiments; male and female, 16 
week old, NPR-C KO and WT littermates were injected once a week, for 3 
weeks, with SU5416 (20 mg/kg ; s.c.) or vehicle, and exposed to 21 days 
hypoxia (10% O2, normobaric) normoxia (21% O2).   
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Male NPR-C KO (34.4 ± 0.95 g) mice were slightly heavier than their WT (31.91 
± 0.69 g) counterparts at the start of the experiment. Both WT and KO animals 
lost BW in the first 3 days which then remained relatively stable for the 
remainder of the experiment, which was also observed by Ciuclan et al., (2011) 
and in optimisation experiments (Figure 50). Comparison of the BW between 
male NPR-C KO and WT revealed a significant (P<0.01) difference over the 
entire time course of the experiment, with WT always having a lower BW 
(Figure 50). This is despite KO mice having an elongated, narrowed bone 
structure, and lean physique observed in this strain (Bordicchia et al., 2012; 
Matsukawa et al., 1999). However, the percentage change in BW from the start 
to the end of the experiment was not significantly different between genotypes  




Female WT (26.21 ± 0.66 g) mice were heavier than KOs (23.03 ± 0.85 g) at 
day 0 (Figure 51). KO animals steadily lost weight over the first 3 days of 
hypoxia but subsequently BW stabilised for the remainder of the experiment 
(Figure 51). A similar pattern was observed in WT mice; BW fell within the first 3 
days, which then remained constant for the balance of the experiment (Figure 
51). Over the whole time course, WT mice were significantly and consistently 
heavier than KO littermates (P<0.001; Figure 51). However, when comparing 
percentage loss in BW from the start to the end of the experiment there is no 
significant difference between genotypes (-12.6 ± 2.3, -10.8 ± 2.8 %; WT and 
KO, respectively; Figure 51).  
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Male WT and NPR-C KO mice demonstrated a similar response to hypoxia plus 
SU5416 with respect to RVSP. NPR-C KO mice had a slightly lower RVSP 
(26.9 ± 1.88 mm Hg) under control (normoxic) conditions when compared to WT 
(28.6 ± 1.22 mm Hg). Hypoxia plus SU5416 resulted in a significant increase in 
RVSP in both WT (36.6 ± 1.60 mm Hg; P<0.01) and KO (38.0 ± 1.73 mm Hg; 
P<0.001) mice (Figure 52). The magnitude of the change was not significantly 
altered by genotype (∆8.0 ± 1.60, ∆11.0 ± 1.73 mm Hg, WT and KO, 




Female NPR-C KO mice developed a significant (P<0.001) increase in RVSP 
when exposed to hypoxia plus SU5416 compared to control (26.5 ± 1.22 mm 
Hg to 39.1 ± 2.67 mm Hg), although this response was not significantly different 
to WT (27.8 ± 1.61 mm Hg to 36.6 ± 1.60 mm Hg; Figure 53). There is also no 
significant difference comparing the increase in RVSP between normoxic and 
hypoxic plus SU5416 conditions for both WT (∆8.8 ± 1.60 mm Hg) and KO 
(∆12.6 ± 2.67 mm Hg) mice (Figure 67). 
 




Male NPR-C KO mice had significantly (P<0.05) lower MABP (77.0 ± 1.53 mm 
Hg) under control conditions than WT littermates (90.3 ± 3.03 mm Hg; Figure 
52), consistent with previous reports (Matsukawa et al., 1999; Moyes et al., 
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2014). This relative profile was mirrored when both WT (88.7 ± 2.28 mm Hg) 





Female WT (90.5 ± 1.58 mmHg) and NPR-C KO (85.2 ± 0.95 mmHg) mice had 
similar MABP under control (normoxic) conditions or when exposed to hypoxia 
plus SU5416 (98.9 ± 2.43 mm Hg, 90.8 ± 4.63 mm Hg; WT and KO, 
respectively; Figure 53).  
 




Hypoxia plus SU5416 produced a significant (P<0.001) increase in RV mass, 
when normalised to LV+S, in NPR-C male KO mice (RV/[LV+S]: 0.18 ± 0.060  
to 0.26 ± 0.018 in normoxia and hypoxia, respectively; Figure 54). However, 
under the same conditions, WT littermates did not exhibit a significant increase 
in RVH (RV/[LV+S]: 0.20 ± 0.011 to 0.23 ± 0.008 in normoxia and hypoxia, 
respectively; Figure 54). When comparing change in RVH between normoxia 
and hypoxia plus SU5416, KO (∆0.081 ± 0.018) RV/[LV+S] ratio was 




Right ventricular hypertrophy in female NPR-C KO mice and WT counterparts 
followed the same pattern observed with RVSP (Figure 55). Female NPR-C KO 
mice under control (normoxic) conditions have similar RV/[LV+S] ratio (0.19 ± 
0.005) compared to  WT (0.20 ± 0.008). When exposed to hypoxia plus 
SU5416, female NPR-C KO develop a significant RVH (0.27 ± 0.043; P<0.001) 
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that is mirrored by WT (0.24 ± 0.027; P<0.01; Figure 55). Similar to that 
observed in males, female NPR-C KO mice (∆0.087 ± 0.018) developed a 
significantly (P<0.05) greater increase in RVH compared to WT mice (∆0.045 ± 
0.009; Figure 57).  
 




Male NPR-C WT and KO mice showed similar pulmonary vascular remodelling 
after hypoxic plus SU5416 (Table 22), with no observed presence of complex 
lesions or occluded lesions. Both genotypes developed mainly partially- and 
fully- muscularised vessels with minimal non-muscularised vessels (Figure 58). 
Male NPR-C KO mice had slightly more fully-muscularised vessels (54.1 ± 2.70 





A similar pattern was observed in female WT and NPR-C KO mice, with no 
complex lesions or occluded lesions (Table 22). These animals developed 
similar levels of non-, partially- and fully- muscularised vessels after exposure to 
hypoxia plus SU5416 (Figure 59). However, there were no significant 
differences between WT and KO mice (Figure 59).   
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EFFECT OF GLOBAL NPR-C DELETION ON BODY WEIGHT IN MALE MICE 
WITH PULMONARY HYPERTENSION 

















































Figure 50. Effect of global NPR-C deletion on body weight in male mice 
with pulmonary hypertension. 
Body weight at day 0, 3, 7, 14 and 21 (g; A) and change in body weight 
between day 0 and 21 (%; B) in male natriuretic peptide receptor-C knockout 
(NPR-C KO) mice and wild-type (WT) littermates under control conditions 
(normoxia; 21 % O2) or exposed to hypoxia (10 % O2; 21 days) plus SU5416 
(20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. Data are represented as mean ± 
SEM. **P<0.01 v WT. n=7-11.  
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EFFECT OF GLOBAL NPR-C DELETION ON BODY WEIGHT IN FEMALE 
MICE WITH PULMONARY HYPERTENSION 

















































Figure 51. Effect of global NPR-C deletion on body weight in female mice 
with pulmonary hypertension. 
Body weight at day 0, 3, 7, 14 and 21 (g; A) and change in body weight 
between day 0 and 21 (%; B) in female natriuretic peptide receptor-C knockout 
(NPR-C KO) mice and wild-type (WT) littermates under control conditions 
(normoxia; 21 % O2) or exposed to hypoxia (10 % O2; 21 days) plus SU5416 
(20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. Data are represented as mean ± 
SEM. ***P<0.001 v WT. n=6-11.  
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Figure 52. Effect of global NPR-C deletion on haemodynamics in male 
mice with pulmonary hypertension. 
Right ventricular systolic pressure (RVSP; A) and mean arterial blood pressure; 
B) in male natriuretic peptide receptor-C knockout (NPR-C KO) mice and wild-
type (WT) littermates under control conditions (normoxia; 21 % O2) or exposed 
to hypoxia (10 % O2; 21 days) plus SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or 
vehicle. Data are represented as mean ± SEM. *P<0.05 v WT, **P<0.01 v WT, 
***P<0.001 v KO. n=5-11.  
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Figure 53. Effect of global NPR-C deletion on haemodynamics in female 
mice with pulmonary hypertension. 
Right ventricular systolic pressure (RVSP; A) and mean arterial blood pressure; 
B) in female natriuretic peptide receptor-C knockout (NPR-C KO) mice and wild-
type (WT) littermates under control conditions (normoxia; 21 % O2) or exposed 
to hypoxia (10 % O2; 21 days) plus SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or 
vehicle. Data are represented as mean ± SEM. **P<0.01 v WT, ***P<0.001 v 
KO. n=5-11.  
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Figure 54. Effect of global NPR-C deletion on right ventricular hypertrophy 
in male mice with pulmonary hypertension. 
Right ventricle to left ventricle plus septum ratio (RV/[LV+S]) in male natriuretic 
peptide receptor-C knockout (NPR-C KO) mice and wild-type (WT) littermates 
under control conditions (normoxia; 21 % O2) or exposed to hypoxia (10 % O2; 
21 days) plus SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. Data are 
represented as mean ± SEM. ***P<0.001 v KO. n=6-15.  
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Figure 55. Effect of global NPR-C deletion on right ventricular hypertrophy 
in female mice with pulmonary hypertension. 
Right ventricle to left ventricle plus septum ratio (RV/[LV+S]) in female 
natriuretic peptide receptor-C knockout (NPR-C KO) mice and wild-type (WT) 
littermates under control conditions (normoxia; 21 % O2) or exposed to hypoxia 
(10 % O2; 21 days) plus SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. 




EFFECT OF GLOBAL NPR-C DELETION ON CHANGE IN RIGHT 
VENTRICULAR SYSTOLIC PRESSURE AND HYPERTROPHY IN MALE 






















































Figure 56. Effect of global NPR-C deletion on change in right ventricular 
systolic pressure and hypertrophy in male mice with pulmonary 
hypertension. 
Change in right ventricular systolic pressure (RVSP; A) and right ventricle to left 
ventricle plus septum ratio (RV/[LV+S]; B) in male natriuretic peptide receptor-C 
knockout (NPR-C KO) mice and wild-type (WT) littermates under control 
conditions (normoxia; 21 % O2) or exposed to hypoxia (10 % O2; 21 days) plus 
SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. Data are represented as 
mean ± SEM. *P<0.05 v WT. n=8-9.  
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Figure 57. Effect of global NPR-C deletion on change in right ventricular 
systolic pressure and hypertrophy in female mice with pulmonary 
hypertension. 
Change in right ventricular systolic pressure (RVSP; A) and right ventricle to left 
ventricle plus septum ratio (RV/[LV+S]; B) in female natriuretic peptide receptor-
C knockout (NPR-C KO) mice and wild-type (WT) littermates under control 
conditions (normoxia; 21 % O2) or exposed to hypoxia (10 % O2; 21 days) plus 
SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. Data are represented as 
mean ± SEM. *P<0.05 v WT. n=5-9.  
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EFFECT OF GLOBAL NPR-C DELETION ON VASCULAR REMODELLING IN 
MALE MICE WITH PULMONARY HYPERTENSION 
 
Figure 58. Effect of global NPR-C deletion on vascular remodelling in male 
mice with pulmonary hypertension. 
Number of vessels (%; <100 µM in diameter) within the pulmonary vasculature 
that are non-muscularised (<25 % α-SMA stain), partially-muscularised (25-75 
% α-SMA stain) and fully-muscularised (>75 % α-SMA stain) in male natriuretic 
peptide receptor-C knockout (NPR-C KO) mice and wild-type (WT) littermates 
under control conditions (normoxia; 21 % O2) or exposed to hypoxia (10 % O2; 
21 days) plus SU5416 (20 mg/kg; s.c. at days 0, 7 & 14) or vehicle. Data are 























































EFFECT OF GLOBAL NPR-C DELETION ON VASCULAR REMODELLING IN 
FEMALE MICE WITH PULMONARY HYPERTENSION 
 
Figure 59. Effect of global NPR-C deletion on vascular remodelling in 
female mice with pulmonary hypertension. 
Number of vessels (%; <100 µM in diameter) within the pulmonary vasculature 
that are non-muscularised (<25 % α-SMA stain per vessel), partially-
muscularised (25-75 % α-SMA stain per vessel) and fully-muscularised (>75 % 
α-SMA stain per vessel) in female natriuretic peptide receptor-C knockout 
(NPR-C KO) mice and wild-type (WT) littermates under control conditions 
(normoxia; 21 % O2) or exposed to hypoxia (10 % O2; 21 days) plus SU5416 




























































REPRESENTATIVE IMAGES OF GLOBAL NPR-C DELETION ON 










Male NPR-C WT 
   
 
Male NPR-C KO 
   
 
Female NPR-C WT 
   
 
Female NPR-C KO 
   
Table 22. Representative images of global NPR-C deletion on vascular 
remodelling in male and female mice with pulmonary hypertension. 
Representative images of vessels within the pulmonary vasculature that are 
non-muscularised (<25 % α-SMA stain), partially-muscularised (25-75 % α-SMA 
stain) and fully-muscularised (>75 % α-SMA stain) in male and female 
natriuretic peptide receptor-C knockout (NPR-C KO) mice and wild-type (WT) 
littermates exposed to hypoxia (10 % O2; 21 days) plus SU5416 (20 mg/kg; s.c. 
at days 0, 7 & 14). H & E stain (blue) and α-SMA stain (brown). Images taken at 
x20 magnification. Scale bar = 50 µm.  
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4.4 Effect of global deletion of NPR-C on the 
development of bleomycin-induced lung fibrosis 
and secondary pulmonary hypertension  
 
Data gleaned from the hypoxia plus SU5416 experimental model of PH 
indicated that NPR-C might play a significant role in the development of RVH. In 
addition, CNP signalling has been shown to exert beneficial (i.e. anti-fibrotic) 
effect in several models of fibrosis (e.g. Kimura et al., 2016; Murakami et al., 
2004; Soeki et al., 2005). Therefore, I designed experiments to assess whether 
genetic deletion of NPR-C affected disease severity in a second model of PH, 
which is associated with bleomycin-induced lung fibrosis.  
 
In this complementary model of PH secondary to pulmonary fibrosis, male and 
female NPR-C KO, and age matched WT littermates, received a single 
oropharyngeal (o.p.) instillation, under light isoflurane anaesthesia, of Bleo-
Kyowa® (Bleomycin Sulphate; Bleo) weight adjusted (1 µl to 1 g of body weight), 
resulting in individual mice receiving 4 mg/kg (4,000 IU or 4 USP) dissolved in 
saline. Control mice received saline (o.p.) only. The mice were then left in 
normal housing conditions for 14 days before haemodynamic measures were 
taken. 
 




Male WT (34.9 ± 0.92 g) mice were slightly heavier than NPR-C KO (32.3 ± 
0.96 g) littermates consistent with previously published work (Matsukawa et al., 
1999; Figure 60). Following administration of Bleo, both WT and KO mice lost 
weight at a steady rate throughout the 14 day period (Figure 60). Immediate 
reductions in BW after lung instillations of Bleo have previously been reported, 
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with the extent of BW loss proportional to dose (Failla et al., 2006; Murakami et 
al., 2004). Although, BW of WT and NPR-C KO animals were significantly 
(P<0.01) different across the 14 day time course (with KO mice always having 
lower BW), the percentage change in BW from day 0 to day 14 was almost 




In the females, WT mice (28.7 ± 0.83 g) were marginally heavier than NPR-C 
KO (27.9 ± 0.94 g) littermates at the start of the study (Figure 61). Both WT and 
NPR-C KO mice steadily lost BW for the first 7 days, after which the loss in BW 
tapered and remained constant until the end of the experiment (Figure 61). BW 
throughout the experiment was not significantly different between WT and KO 
animals, although WTs were consistently heavier than KOs. Percentage change 
in BW between day 0 and 14 was similar between WT and NPR-C KO mice (-
8.6 ± 3.0, -6.8 ± 1.7 %, respectively; Figure 61). 
 




Control (normoxic) male WT mice had an essentially identical RVSP (28.6 ± 
1.22 mm Hg) compared to NPR-C KO animals (26.9 ± 1.88 mm Hg; Figure 62). 
After being treated with bleo, RVSP increased significantly in both WT 
(P<0.001) and KO (P<0.001) mice. Although, the magnitude of this response 
was marginally greater in NPR-C KO mice (43.2 ± 2.79 mm Hg) compared to 
WT (38.7 ± 0.70 mm Hg) there was no significant difference between the two 
genotypes (Figure 62). However, when comparing the change in RVSP 
between normoxia and hypoxia plus SU5416, NPR-C KO (∆16.3 ± 2.79 mm Hg) 
mice developed a significant increase (P<0.05) compared to WT mice (∆10.1 ± 






Female WT and NPR-C KO mice had very similar RVSP under control 
conditions (27.8 ± 1.6 mm Hg and 26.5 ± 1.2 mm Hg, respectively). These 
values increased significantly after treatment with bleomycin (WT: 33.0 ± 1.11 
mm Hg; KO 37.3 ± 0.94 mm Hg; P<0.05 and P<0.001, respectively; Figure 63). 
Of note, bleomycin-treated NPR-C KO mice had significantly (P<0.05) higher 
RVSP than WT animals (Figure 63). This significant difference was reflected 
when change in RVSP was calculated (∆5.3 ± 1.11, ∆10.8 ± 0.94 mm Hg, WT 
and KO respectively; P<0.001; Figure 67). 
 




Male NPR-C KO mice tended to have a lower MABP (77.0 ± 1.53 mm Hg) 
compared to their WT littermates (90.3 ± 3.03 mm Hg) under basal (control) 
conditions, as I showed in the hypoxia model (Figure 62). After administration of 
bleomycin, the MABP in WT (77.4 ± 4.12 mm Hg) mice dropped significantly 
(P<0.01) whereas blood pressure in the NPR-C KO animals underwent little 
change (77.5 ± 2.68 mm Hg) possibly because it is inherently low (Figure 62). 
Nonetheless, MABP is not significantly different between WT and NPR-C KO 




Female NPR-C KO mice had marginally lower MABP (85.2 ± 0.96 mmHg) than 
WT (90.5 ± 1.58 mmHg) under control (normoxic) conditions (Figure 63). This 
remained unchanged in both WT (90.6 ± 1.96 mmHg) and KO (86.4 ± 1.87 mm 








Subsequent to administration of bleomycin, male WT and NPR-C KO mice 
exhibited a trend towards an increase in RVH but this didn’t reach statistical 
significance (Figure 64). RV/(LV+S) ratio was increased in WT mice with 
bleomycin treatment (0.20 ± 0.011 to 0.24 ± 0.017; Figure 64) with an 
analogous change observed in NPR-C KO animals (0.18 ± 0.060 to 0.23 ± 
0.087; Figure 64). This was also the case when calculating change in 





A similar lack of RVH was also observed in female WT animals undergoing 
bleomycin treatment. RV/(LV+S) ratio increased marginally in WT mice (0.20 ± 
0.008 to 0.21 ± 0.004) but not to a statistically significant degree (Figure 65). 
This is in sharp contrast to NPR-C KO mice in which a greater, significant 
(P<0.001) increase was observed (0.19 ± 0.006 to 0.24 ± 0.007), which was 
also significantly (P<0.05) larger than WT (Figure 65). This finding was 
accentuated when change in RV/(LV+S) ratio from normoxia to hypoxia plus 
SU5416 was calculated (∆0.015 ± 0.005, ∆0.049 ± 0.007, WT and KO, 
respectively; P<0.001; Figure 67). 
 




The lung weight in male WT mice (0.176 ± 0.011 g) was similar to NPR-C KO 
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(0.163 ± 0.011 g) under control conditions (Figure 68). Treatment with 
bleomycin caused lung weight to increase significantly in WT (0.328 ± 0.033 g; 
P<0.001) and NPR-C KO (0.176 ± 0.011 g; P<0.01) mice compared to control 
(Figure 68). However, there was no significant differences between genotype in 
this regard (Figure 68). The same pattern was observed when lung weight was 
normalised to BW; both WT and NPR-C KO mice developed significantly (WT: 
0.0044 ± 0.006 to 0.0121 ± 0.002; KO: 0.0048 ± 0. to 0.014 ± 0.002; P<0.01, 




Female NPR-C KO animals had slightly heavier lungs (0.157 ± 0.006 g) 
compared to WT littermates (0.148 ± 0.005 g) under control conditions (Figure 
69). When administered bleomycin, both WT and NPR-C KO mice develop a 
significant (P<0.001 for both) increase in lung weight (Figure 69). Importantly, 
NPR-C KO mice developed a significantly (P<0.05) greater increase (0.377 ± 
0.030 g) than WT (0.268 ± 0.020 g) animals (Figure 69). This was also 
observed when lung weight was normalised to account for changes in BW. 
Control WT lung weight/BW ratio was 0.005 ± 0.003 and increased significantly 
(P<0.01) to 0.010 ± 0.001, whilst KO mice increased from 0.005 ± 0.001 to 
0.016 ± 0.002 (P<0.001); the change in KO is also significantly (P<0.01) larger 
than WT (Figure 69).  
 
4.4.6 Pulmonary vascular remodelling 
 
4.4.6.1 Male and female 
 
Male and female NPR-C WT and KO mice dosed with bleomycin developed 
obvious pulmonary vascular remodelling characterised by areas of fibrosis rich 
in collagen deposits (Table 23). However, time constraints entailed that the 
degree of fibrosis was not quantified.  
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EFFECT OF GLOBAL NPR-C DELETION ON BODY WEIGHT IN MALE MICE 


















































Figure 60. Effect of global NPR-C deletion on body weight in male mice 
with bleomycin-induced pulmonary hypertension. 
Body weight at day 0, 3, 7 and 14 (g; A) and change in body weight between 
day 0 and 14 (%; B) in male natriuretic peptide receptor-C knockout (NPR-C 
KO) mice and wild-type (WT) littermates administered bleomycin (4 mg/kg; o.p.; 
day 0) or saline (at day 0). Data are represented as mean ± SEM. **P<0.01 v 
WT. n=10-14.  
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Figure 61. Effect of global NPR-C deletion on body weight in female mice 
with bleomycin-induced pulmonary hypertension. 
Body weight at day 0, 3, 7 and 14 (g; A) and change in body weight between 
day 0 and 14 (%; B) in female natriuretic peptide receptor-C knockout (NPR-C 
KO) mice and wild-type (WT) littermates administered bleomycin (4 mg/kg; o.p.; 
day 0) or saline (at day 0). Data are represented as mean ± SEM. n=14-16.
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Figure 62. Effect of global NPR-C deletion on haemodynamics in male 
mice with bleomycin-induced pulmonary hypertension. 
Right ventricular systolic pressure (RVSP; A) and mean arterial blood pressure 
(MABP; B) in male natriuretic peptide receptor-C knockout (NPR-C KO) mice 
and wild-type (WT) littermates administered bleomycin (4 mg/kg; o.p.; day 0) or 
saline (at day 0). Data are represented as mean ± SEM. **P<0.01 v WT, 
***P<0.001 v control WT, KO. n=4-11.  
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Figure 63. Effect of global NPR-C deletion on haemodynamics in female 
mice with bleomycin-induced pulmonary hypertension. 
Right ventricular systolic pressure (RVSP; A) and mean arterial blood pressure 
(MABP; B) in female natriuretic peptide receptor-C knockout (NPR-C KO) mice 
and wild-type (WT) littermates administered bleomycin (4 mg/kg; o.p.; day 0) or 
saline (at day 0). Data are represented as mean ± SEM. *P<0.05 v WT, 
***P<0.001 v KO control; #P<0.05 v Bleo WT. n=8-15.  
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Figure 64. Effect of global NPR-C deletion on right ventricular hypertrophy 
in male mice with bleomycin-induced pulmonary hypertension. 
Right ventricle to left ventricle plus septum ratio (RV/[LV+S]) in male natriuretic 
peptide receptor-C knockout (NPR-C KO) mice and wild-type (WT) littermates 
administered bleomycin (4 mg/kg; o.p.; day 0) or saline (at day 0). Data are 
represented as mean ± SEM. n=6-15.
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Figure 65. Effect of global NPR-C deletion on right ventricular hypertrophy 
in female mice with bleomycin-induced pulmonary hypertension. 
Right ventricle to left ventricle plus septum ratio (RV/[LV+S]) in female 
natriuretic peptide receptor-C knockout (NPR-C KO) mice and wild-type (WT) 
littermates administered bleomycin (4 mg/kg; o.p.; day 0) or saline (at day 0). 
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Figure 66. Effect of global NPR-C deletion on change in right ventricular 
systolic pressure and hypertrophy in male mice with bleomycin-induced 
pulmonary hypertension. 
Change in right ventricular systolic pressure (RVSP; A) and right ventricle to left 
ventricle plus septum ratio (RV/[LV+S]; B) in male natriuretic peptide receptor-C 
knockout (NPR-C KO) mice and wild-type (WT) littermates administered 
bleomycin (4 mg/kg; o.p.; day 0) or saline (at day 0). Data are represented as 
mean ± SEM. *P<0.05 v WT. n=10-11.  
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Figure 67. Effect of global NPR-C deletion on change in right ventricular 
systolic pressure and hypertrophy in female mice with bleomycin-induced 
pulmonary hypertension. 
Change in right ventricular systolic pressure (RVSP; A) and right ventricle to left 
ventricle plus septum ratio (RV/[LV+S]; B) in female natriuretic peptide receptor-
C knockout (NPR-C KO) mice and wild-type (WT) littermates administered 
bleomycin (4 mg/kg; o.p.; day 0) or saline (at day 0) . Data are represented as 
mean ± SEM. ***P<0.001 v WT. n=14-15.  
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Figure 68. Effect of global NPR-C deletion on lung weight in male mice 
with bleomycin-induced pulmonary hypertension. 
Lung weight (g; A) and lung weight to body weight ratio (LW/BW; B) in male 
natriuretic peptide receptor-C knockout (NPR-C KO) mice and wild-type (WT) 
littermates administered bleomycin (4 mg/kg; o.p.; day 0) or saline (at day 0). 
Data are represented as mean ± SEM. ***P<0.001 v WT, **P<0.01 v KO (A). 
**P<0.01 v WT, *P<0.05 v KO (B). n=3-10.  
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Figure 69. Effect of global NPR-C deletion on lung weight in female mice 
with bleomycin-induced pulmonary hypertension. 
Lung weight (g; A) and lung weight to body weight ratio (LW/BW; B) in female 
natriuretic peptide receptor-C knockout (NPR-C KO) mice and wild-type (WT) 
littermates administered bleomycin (4 mg/kg; o.p.; day 0) or saline (at day 0). 
Data are represented as mean ± SEM. ***P<0.001 v control WT, KO (A). 
***P<0.001 v KO; **P<0.01 v WT (B). ###P<0.001 v Bleo WT (A & B). n=5-16.  
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REPRESENTATIVE IMAGES SHOWING THE EFFECTS OF GLOBAL NPR-C 
DELETION ON LUNG FIBROSIS IN MALE AND FEMALE MICE WITH 
BLEOMYCIN-INDUCED PULMONARY HYPERTENSION 
 
Table 23. Representative images showing the effects of global NPR-C 
deletion on lung fibrosis in male and female mice with bleomycin-induced 
pulmonary hypertension. 
Representative images of lung fibrosis in male and female natriuretic peptide 
receptor-C knockout (NPR-C KO) mice and wild-type (WT) littermates 14 days 
following administration of bleomycin (4 mg/kg; o.p.; day 0). Picrosirius red 
(PSR) stain (red). Scale bar at x1 magnification = 2 mm. Scale bar at x10 










































CHAPTER 5: DISCUSSION 
 
5.1 Summary of key findings 
 
I have shown that MRPs contribute to cyclic GMP signal termination in the 
vasculature contributing to the regulation of homeostasis. Specifically, I have 
found MRP inhibition alone relaxes mouse aortic rings, and potentiates 
relaxations induced by both sGC and pGC activation, with a preference toward 
pGC. In addition, MRP inhibition significantly attenuates cGMP efflux by 
hCASMCs resulting from pGC activation, which is not seen with sGC 
stimulation or MRP inhibition alone. Despite this, MRP inhibition per se 
concentration-dependently attenuates hCASMC proliferation and enhances the 
anti-proliferative effects of both pGC and sGC -generated cGMP. I have also 
provided evidence for a functional role for MRPs in regulating vascular 
responses in vivo. Whilst MRP inhibition itself does not reduce BP, blockade of 
cGMP efflux does significantly enhance reductions in BP triggered by pGC 
activation (but not sGC). These data demonstrate MRPs contribute to the 
regulation of cGMP-dependent vascular homeostasis, with a preference toward 
membrane produced cGMP rather than cytosolic, in accord with cGMP 
signalling compartmentalisation. 
 
Using male and female endothelial cell-specific CNP KO mice, in a well-
established hypoxia plus SU5416 model of PH, I have found that EC-derived 
CNP does not contribute to the development of PH in either sex. However, I 
found that the CNP receptor, NPR-C, is essential for innate protection against 
the development of significant RVH in both male and female mice using the 
same experimental model of PH (using global NPR-C KO animals), although a 
similar effect against increased RVSP is not seen. My results also demonstrate 
that NPR-C is essential in the protection against the development of bleomycin-
induced PH. Specifically, the absence of NPR-C causes significant increases in 
RVSP in both male and female mice, and greater RVH and lung weights in 
females. In sum, CNP derived from endothelial cells, specifically, is not 
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essential in the protection against PH pathogenesis; however, its receptor, 
NPR-C, appears to be crucial in maintaining normal pulmonary and cardiac 
function in this disease. 
 
5.2 The role of MRPs in vascular 
homeostasis 
 
The intracellular second messenger cGMP is a well characterised, central 
player in the regulation of cardiovascular homeostasis (Francis et al., 2010; Tsai 
and Kass, 2009). Increasing intracellular concentrations of cGMP relaxes 
vessels, inhibits platelet aggregation and prevents VSMC proliferation. 
Maintenance of intracellular cGMP concentrations is thought to consist of a 
finely-tuned balance between cGMP generation by GC enzymes and 
degradation by PDEs. Cellular extrusion of cyclic GMP has been appreciated 
for many years, but with the general opinion that it’s of lesser importance than 
PDEs in terminating cGMP signalling; this has led to this mechanism being 
largely ignored in terms of cGMP dynamics and cardiovascular function 
(Davoren and Sutherland, 1963; Mercapide et al., 1999). Recently, MRPs have 
been identified as the transport mechanism responsible for the cellular efflux of 
cAMP and cGMP. As a consequence, this has led to the hypothesis that MRPs 
contribute to the regulation of cyclic nucleotide dependent vascular 
homeostasis. Indeed, there is mounting evidence that MRP-dependent cAMP 
efflux has a broad array of cardiovascular effects; inhibition of VSMC growth 
and platelet aggregation improved cardiac contractility, reduced cardiac fibrosis, 
and as a therapeutic target in PH (Borgognone and Pulcinelli, 2012; Claude et 
al., 2015; Hara et al., 2011; Sassi et al., 2014, 2008). However, there is a 
paucity of evidence defining cGMP-dependent cardiovascular effects of MRPs. 
Therefore, in this thesis I have investigated functional cGMP-dependent 
biological effects in the vasculature modulated by MRPs. 
 
One key limitation in this field is the lack of potent and selective 
pharmacological MRP inhibitors. Some have circumvented this crucial caveat 
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by utilising siRNA to reduce expression of specific MRPs within different cell-
types, in addition to studies using MRP4 and MRP5 KO mice. However, in the 
absence of these techniques and/or transgenic models, this illustrates a need to 
use structurally-distinct MRP inhibitors to reassure as to target specificity. 
Specifically-designed, selective MRP inhibitors have not yet been developed, 
but compound screening aimed at finding novel competitive inhibitors of this 
transporter protein family have been successful. During such screenings the 
MRP inhibitors MK571 and probenecid were identified. MK571 is an inhibitor of 
MRP4 (Chen et al., 2002; Jedlitschky et al., 2000; Reid et al., 2003) and 
considered by most to be a specific inhibitor of this particular isoform, despite 
other studies showing effective MRP5 inhibition by this compound (Reid et al., 
2003). In contrast, probenecid is a relatively selective inhibitor of MRP5 over 
MRP4 (Jedlitschky et al., 2000; Reid et al., 2003). Although, some evidence 
shows that at the same concentrations probenecid can inhibit MRP4 equally 
well as MRP5 (Chen et al., 2002; van Aubel et al., 2002). In sum, MK571 and 
probenecid are likely to have both MRP4 and MRP5 inhibitory activity and 
therefore the effect of MRP inhibition I observed may have come about from 
either MRP4 or MRP5 or simultaneous MRP4/MRP5 inhibition. 
 
 
Figure 70. Molecular formulae of MK571 and probenecid. 
Molecular formulae demonstrating the structural distinction between multidrug 
resistance protein inhibitors probenecid and MK571.  
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Although, structurally-distinct inhibitors of MRPs (Figure 70), these compounds 
also affect alternate mechanisms such that possible off-target effects should 
therefore be considered. 
 
MK571 was originally developed as a leukotriene D4 (LTD4) receptor (also 
known as a cysteinyl leukotriene receptor-1, CysLT1) antagonist, for the 
treatment of asthma (Jones et al., 1989; Kips et al., 1991; Young, 1991). This 
drug was later dropped for a more potent candidate compound, MK-0476, 
currently prescribed by the name Montelukast. MK571 was originally identified 
as an inhibitor of MRPs because of its structural similarity to the leukotrienes, 
which are well characterised substrates of MRP1 (Gekeler et al., 1995; Leier et 
al., 1996, 1994). MK571 prevents the contraction and proliferation of airway 
smooth muscle and VSMCs caused by leukotriene D4 (Panettieri et al., 1998). 
Moreover, MRP1, another transporter of the ABCC family, can extrude 
leukotrienes contributing to inflammation and oxidative stress -mediated VSMC 
proliferation. However, these actions should not have complicated interpretation 
of my data because leukotrienes were not added to any of my experimental 
setups and the experimental conditions utilised did not involve oxidative stress 
and inflammation. Thus, it is reasonable to assume that antagonism or transport 
of leukotrienes would not have complicated interpretation of my findings (Cole, 
2014; Mueller et al., 2008; Widder et al., 2007). 
 
Probenecid was first synthesised in 1949 and designed to reduce the renal 
clearance of penicillin prescribed to soldiers during World War II with the aim of 
reducing the dose prescribed and thus the cost. Since then, probenecid has 
been found to reduce the clearance, therefore increase the plasma 
concentration and half-life of a multitude of antibiotics making it highly effective 
as an antibiotic adjuvant. The mode of action of probenecid is as a non-specific 
inhibitor of OAT proteins, which also reduce the reabsorption of uric acid, 
explaining the use of probenecid as a treatment for gout (Roch-Ramel and 
Guisan, 1999). During studies investigating the mechanism behind cGMP efflux 
from cells, probenecid was found to inhibit the transport process, leading to the 
hypothesis that cGMP efflux was due to a kind of OAT (Hamet et al., 1989). 
Therefore, probenecid may have affected my results by inhibiting OATs and not 
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MRPs as I assumed. OATs are mainly expressed in excretory organs such as 
the kidney, gastrointestinal tract and liver, which reflect their overall essential 
role in the distribution and excretion of numerous endogenous metabolic 
products and exogenous organic anions. However, they are not found in 
vascular tissue to any extent and therefore the effects I observed in mouse 
aortic rings were most likely due to MRP inhibition (Riedmaier et al., 2012). 
 
Subthreshold concentrations of both MK571 and probenecid were established 
and utilised in vascular reactivity studies such that they inhibited MRPs without 
inducing a vascular effect themselves. Therefore, it should be noted that the 
magnitude of the shifts described within this thesis are concentration-
dependent, with a higher concentration of inhibitor potentially eliciting an 
enhanced response. Practically, however, the use of a higher concentration of 
MRP inhibitor results in an inability to contract the tissue to PE, preventing 
effective study. A larger vascular effect of MRP inhibition has already been 
shown by (Krawutschke et al., 2015), in mouse aortic ring assays where 
relaxations to the NO donor, GS-NO, when pre-incubated with 10 µM MK571; 
this resulted in a larger leftward shift when compared to the relaxations to Sp-
NO in my studies using 3 µM MK571. Thus, whilst the increases in potency 
observed in my functional pharmacological studies are modest, the beneficial 
effects of MRP inhibitors I describe are almost certainly underestimates of the 
maximum attainable outcome.  
 
My data show that both MK571 and probenecid concentration-dependently 
relax mouse aortic rings, suggesting an inherent functional role of MRPs in 
regulating vascular tone. Collectively, MK571 and probenecid significantly 
increased the potency of Sp-NO, ANP and CNP -induced relaxations in pre-
contracted mouse aortic rings, with a preference toward pGC activation. The 
innate ability of MRP inhibitors per se to relax vessels probably resulted from 
intrinsic turn-over of cGMP production by either sGCs or pGCs. The 
endothelium-dependent vasodilator ACh produced significant relaxations 
confirming the presence of an intact, functional endothelium. The presence of 
an intact endothelium in aortic ring segments is known to enhance extracellular 
concentrations of cGMP (33-fold higher) compared to denuded vessels, which 
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results from eNOS activity, release of NO from ECs, which in-turn activates 
sGC present in VSMCs (Schini et al., 1989). Surprisingly, I was unable to see 
potentiation of the dilator response to ACh in my studies. This could be due to 
cGMP signal compartmentalisation within VSMCs; specifically, that ACh-
dependent NO release stimulates VSMC sGC but the cGMP signal generated 
isn’t large enough to be affected by MRPs. Schini et al., (1989), showed that 
treatment of rat aortic rings with ACh causes a peak in tissue cGMP 
concentration (1343 ± 380 fmol pg-1 DNA) after 1 min, but that this 
concentration decreases by approximately 86 % when measured at 5 min. This 
observation suggests that the initial cGMP signal following addition of ACh is 
degraded rapidly by PDEs, perhaps in subcellular locations not under the 
influence of MRPs. Interestingly, the same study reported that significant egress 
of cGMP is observed, but only after 60 min. This gives rise to the possibility that 
the rate of MRP-driven efflux of cGMP is too slow to affect the functional 
response to ACh. However, the vasorelaxant response to pharmacological 
addition of NO (via an NO-donor), rather than through endothelium-dependent 
eNOS activation, is increased in the presence of MK571. One explanation for 
this discrepancy is that ACh relaxes mouse aorta through an alternative, NO-
independent mechanism. However, whilst this is likely to be true in the 
resistance vasculature where EDHF predominates (Villar et al., 2007), 
endothelium-dependent NO release by ACh is the principal vasodilatory 
mechanism in the aorta (Chataigneau et al., 1999; Scotland et al., 2005). An 
alternative argument is that, in contrast to the capacity of ACh to generate NO 
in specific areas of the cytosol, an exogenous NO donor produces considerably 
higher concentrations of NO which leads to maximal activation of the entire sGC 
pool. This idea is alluded to by Schini et al., (1989), since increasing 
concentrations of ACh do not elevate extracellular cGMP whereas the NO 
donor, SNP, results in almost a ten-fold increase in extracellular cGMP 
concentrations. These data imply that more cytosolic cGMP is generated by 
pharmacological concentrations of NO, spilling over into the membrane region 
and resulting in increased extrusion by MRPs (Figure 71). In comparison, some 
studies have reported that cGMP efflux following sGC stimulation (by SNP) is 
more effective than via pGC stimulation (using ANP; Mercapide et al., 1999). 
However, the data from these studies may not best represent what occurs 
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biologically as the concentration of both SNP and ANP used was 
pharmacological rather than physiological (500 µM), entailing that upon 
stimulation with SNP the cGMP generated may have “spilled over” into the 
membrane area increasing its rate of extrusion, in comparison to a normal 
endogenous signal which would result in a contained cytosolic cGMP “cloud” 
(Figure 71). 
 
In functional reactivity studies MRP inhibition demonstrated a preference toward 
potentiating pGC-stimulated vessel relaxations compared with sGC activation. 
Recent innovation has permitted the study of real-time production of cGMP in 
VSMC, visualised and quantified using an intracellular cGMP FRET sensor. In 
these cells, MRP inhibition (using MK571) significantly enhances the magnitude 
of intracellular cGMP generated from both sGC and pGC activation; however, 
cGMP levels stay maximal for longer periods with pGC activation, compared to 
sGC where the signal declines relatively rapidly (Krawutschke et al., 2015). 
These data indicate that MRPs are more important in regulating membrane-
localised cGMP “pools”, rather than cytosolic cGMP, which instead is 
predominantly PDE regulated (Fischmeister et al., 2006; Krawutschke et al., 
2015). This contributes to the understanding of cGMP signalling 
compartmentalisation and the preferential effect of MRP inhibition to membrane, 
compared to cytosolic, -generated cGMP. My data support this notion but also 
go further to show this dichotomy from a functional standpoint, in which MRP 
inhibition had a greater effect on vessel relaxation in response to natriuretic 
peptides than NO donors.   
 
If this difference between sGC and pGC signalling with respect to MRPs can be 
explained by subcellular co-localisation, currently there is little or no data 
defining MRP protein-protein interactions with pGCs. However, MRP4 is 
localised in caveolin-1-enriched membrane fractions in VSMCs, implying that 
proximity is likely (Sassi et al., 2008). Moreover, both NPR-A and NPR-B co-
localise with caveolin-3 in cardiac homogenates (Doyle et al., 1997; Horikawa et 
al., 2011), and NPR-A co-localises with caveolin-1 in lung homogenates (Chen 
et al., 2012). Therefore, one might hypothesise that pGCs and MRPs could be 
co-localised in micro-domains, meaning the effect of cGMP egression would 
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have a greater effect on pGC than sGC -signalling. Furthermore, the cGMP 
downstream effecter molecules PKG and PDEs can also be present either in 
cytosolic or particular subcellular membrane fractions meaning that the co-
localisation of MRPs, pGCs, PKG and PDEs within caveolae/microdomains 
forms a highly regulated cGMP signalling environment through precisely 
controlling concentrations of intracellular cGMP to elicit particular cellular 
functions (Francis et al., 2010). In some situations this phenomenon may also 
be of relevance to sGC because of its ability to translocate to the plasma 
membrane via the chaperone Hsp90 (Agullo et al., 2005; Venema et al., 2003). 
In addition to membrane trafficking by Hsp90, a fraction of endogenous sGC 
within the normal heart is found in caveolin-3 (Tsai et al., 2012) and caveolin-1 
(Linder et al., 2005) -rich micro-domains. When present in the caveolae the 
enzyme is protected against oxidation that can occur from vascular injury, which 
inactivates the catalytic haem domain on the β subunit; therefore, the enzyme 
remains active compared to its cytosolic counterparts (Tsai et al., 2012). 
Overall, this demonstrates that not only can MRP inhibition potentiate pGC 
produced cGMP, but in disease environments characterised by oxidative stress, 
MRP inhibition may also potentiate cGMP generated from membrane located 
sGC, amplifying the signal, thus expanding the therapeutic potential of MRP 
inhibitors (Schnabel and Blankenberg, 2007; Figure 71). Interestingly, in the 
case of probenecid the potency of Sp-NO was significantly inhibited in my 
functional pharmacological studies; this almost certainly results from direct 
inhibition of sGC. This characteristic of probenecid has already been described 
in cultured porcine kidney epithelial and rat fibroblast cells; the mechanism is 
thought to involve blocking of the interaction between two unidentified, heat-
stable, high molecular weight factors that each facilitate the production of cGMP 
by sGC (Patel et al., 1995). This appears to be a sGC specific phenomenon as 
ANP stimulated cGMP is not affected by probenecid (Hamet et al., 1989). 
 
Determining which specific MRP isoform (MRP4 or MRP5) is responsible for the 
effects I observed on vascular reactivity is difficult. The accepted cyclic 
nucleotide transporting specificity of MRP4 and MRP5 is controversial but is 
likely to play a key role in determining the pathways regulated by both cAMP 
and cGMP efflux. MRP4 is universally accepted as a predominantly cAMP 
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transporting protein despite the fact that MRP4 inhibition results in elevated 
intracellular cGMP levels (Hara et al., 2011; Sassi et al., 2008). MRP4 has a 
lower Km value (9.69 ± 2.3 µM) for cGMP compared to cAMP (44.5 ± 5.8 µM) 
suggesting it may actually have a preference for cGMP over cAMP (Chen et al., 
2001). However, the Vmax for cAMP extrusion (4.14 ± 0.40 pmol/mg/min) is 
approximately twice as high as cGMP (2.01 ± 0.34 pmol/mg/min; Chen et al., 
2001). This suggests at low cAMP concentrations MRP4 transports cGMP but 
at high cAMP concentrations, cAMP itself is egressed. This theory appears to 
be supported in practice by studies that show increasing cAMP levels decrease 
cGMP eggression, presumably via competition (Hamet et al., 1989; Patel et al., 
1995). In comparison, MRP5 is commonly accepted as a predominantly cGMP 
transporting protein because of its significantly lower Km and higher Vmax values 
for cGMP (Km = 2.1 ± 0.2 µM; Vmax/Km = 2100 µl x mg-1 protein x min-1) 
compared to cAMP (Km = 379 ± 24 µM; Vmax/Km = 90 µl x mg-1 protein x min-1; 
Jedlitschky et al. 2000). Therefore, in the context of my reactivity studies I 
hypothesise that both MRP4 and MRP5 efflux cGMP simultaneously upon sGC 
and pGC activation, with MRP5 being the more favoured protein because of its 
superior efficiency in exporting cGMP. Whereas, vasodilatation elicited by 
increased cAMP, such as those I observed with Iso, is likely to be more 




Figure 71. An illustration of the multiple interactions multidrug resistance 
proteins have with cGMP and cAMP elevating and degrading enzymes 
within the vasculature. 
Endothelial nitric oxide synthase (eNOS), soluble guanylyl cyclase (sGC), nitric 
oxide (NO), prostacyclin (PGI2), natriuretic peptides (NPs), multidrug resistance 
protein (MRP), phosphodiesterase (PDE), adenylyl cyclase (AC), natriuretic 
peptide receptor (NPR), acetylcholine (ACh).  
 
This notion of simultaneous cAMP and cGMP transport by MRPs is 
complemented by the finding that both MRP4 and MRP5 contain two substrate-
binding sites; MRP4 having a high affinity cAMP substrate-binding site, MRP5 a 
high affinity cGMP binding site, and both proteins a low affinity dual cAMP and 
cGMP binding site (Sager and Ravna, 2009). This entails that, depending on 
local concentration, both cyclic nucleotides can be transported by either one of 
these proteins. This theory is likely to be true because the MRP substrate-
binding pocket is known to bind more than one substrate at one time, based on 
export kinetics of native and conjugated substrates (Deeley and Cole, 2006; 
Schumacher et al., 2004). This facet gives MRPs a broad substrate-transporting 
capability (Sharom, 2008). However, such kinetic variations have not yet been 




Specific cell and tissue expression of MRP4 and MRP5 will also determine their 
role in VSMC relaxation. In the vasculature, MRP4 and MRP5 are both 
expressed on ECs; however, MRP4 is considered by some to be the only MRP 
expressed on VSMCs, and MRP5 mainly an EC located protein (Sassi et al., 
2008). This has led to the assumption that all VSMC effects are elicited by 
MRP4 specifically, although there is plenty of evidence to show MRP5 
expression on VSMC in addition to ECs (Dazert et al., 2003; Meissner et al., 
2007; Mitani et al., 2003; Xu et al., 2004). Evidence supports the thesis that 
both MRP4 and MRP5 are expressed on VSMC and contribute to vessel 
reactivity since reduction of MRP5 expression using siRNA in rat pial arteriolar 
smooth muscle enhances sGC stimulated relaxations and decreases 
extracellular cGMP levels, demonstrating a specific functional effect of MRP5, 
albeit in the cerebral vasculature (Xu et al., 2004). Overall, these findings 
indicate that MRP4 and MRP5 are capable of regulating vascular homeostasis, 
with the inhibition of both proteins likely to elicit an additive, more advantageous 
effect. However, to elucidate the precise role of each in vascular reactivity will 
necessitate the use of MRP4 and MRP5 KO mice (Borst et al., 2007).  
 
A similar pattern of activity with MRP inhibition was observed in parallel 
experiments in cultured hCASMC. I found concentration-dependent reductions 
in proliferation with MK571 alone and, in addition, a subthreshold concentration 
of MK571 potentiated the anti-proliferative effects of ANP and D-NO, with a 
preference toward sGC activation (in contrast to the vascular reactivity data). 
Similar to the vascular reactivity experiments, the ability of MRP inhibition per 
se to attenuate VSMC proliferation is likely due to intrinsic cGMP production, 
supported by MK571 alone generating small increases (~10 % in 15 min) in 
intracellular cGMP in VSMCs as measured by FRET (Krawutschke et al., 2015); 
when sustained over several days this could potentially have inhibited VSMC 
proliferation. In addition, MRP4 expression has been found to be significantly 
increased in proliferating hCASMCs compared to quiescent cells, increasing the 
quantity of cGMP (and cAMP) egressed; thus, an anti-proliferative effect of 
MRP inhibition can be achieved (Sassi et al., 2008). To emphasise the effect of 
MRP inhibition on intracellular cGMP concentrations and VSMC proliferation, 
171 
 
previous studies have shown that in primary hCASMCs rendered deficient in 
MRP4 or MRP5 using siRNA, there is a significant increase in the intra:extra -
cellular cGMP and cAMP ratios under basal conditions, that results in a 
concomitant attenuation of growth (Sassi et al., 2008). However, in these 
studies the authors concluded that this was mainly a cAMP-driven phenomenon 
because the use of the PKG inhibitor, KT5823, did not affect proliferation.  
 
My data demonstrate that MRPs possess the capacity to extrude cGMP in 
terms of functional vasorelaxation and VSMC proliferation, but I didn’t observe 
changes in VSMC intra:extra -cellular cGMP ratios in the presence of MK571 
alone. The anti-proliferative effect of the NO donor, D-NO, was significantly 
enhanced when combined with MK571; however, I observed no difference in 
the VSMC intra:extra -cellular cGMP ratio. In contrast, the extracellular cGMP 
concentrations after pGC activation with ANP showed a substantial, significant 
increase, which was attenuated by MRP inhibition. This reflects my findings in 
vascular reactivity studies where MRPs appear to be preferentially coupled to 
pGC. The apparent lack of difference in VSMC intra:extra -cellular cGMP ratio 
with MRP inhibition alone may have resulted from not allowing sufficient time for 
cGMP to accumulate under basal conditions, since my measurements were 
performed after 24 h compared with those of Sassi et al., (2008) after 72 h. In 
addition, smaller levels of intra:extra -cellular cGMP may have been detectable 
using a more sensitive technique such as FRET. This may also explain the lack 
of difference in the VSMC intra:extra -cellular cGMP ratio with D-NO, where 
significant differences in proliferation were noted over the whole 96 h growth 
period but changes in intra:extra -cellular cGMP after 24 h may have been too 
small to measure by ELISA. In addition, signal compartmentalisation may have 
come into play, where less of the cGMP signal generated from sGC activation 
was under the influence of MRPs compared with that of pGC activation (Figure 
71). 
 
The vasodilatory effect of MRP inhibition alone may only be an isolated vessel 
phenomenon, because MK571 did not significantly affect MABP in 
anaesthetised and conscious mice, despite the compound having a relatively 
long plasma half-life (two to three hours in humans; Margolskee, 1991) and the 
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dose used (25 mg/kg/day) having previously been shown to effectively reverse 
experimental PH (Hara et al., 2011). However, MK571 did exhibit a preference 
to potentiate pGC activation evident by significantly enhanced reductions in 
systemic BP elicited by acute bolus doses of ANP (but not NO). This suggests 
in situations where endogenous circulating levels of NPs are increased (e.g. 
heart failure, MI and PH) that MRP inhibition will potentiate reductions in BP, 
and the lack of an observable effect of MRP inhibition on MABP, in conscious 
mice, may be due to low basal circulating concentrations of circulating NPs. 
This should not be a surprise as the MRP4, MRP5 and MRP4/MRP5 double KO 
mice all lack an obvious phenotype, suggesting under basal conditions MRPs 
aren’t essential to vascular homeostasis (Borst et al., 2007). However, longer-
term MRP4 deficiency results in cardiac hypertrophy, as observed in aging (9 
month old) MRP4 KO mice, which is not apparent in the same strain at 3 
months (Sassi et al., 2012). Thus, in health this mechanism may not be crucial 
to the maintenance of cardiovascular homeostasis in vivo, whereas its role may 
be triggered in cardiovascular disease characterised by enhanced circulating 
levels of NPs (e.g. heart failure, PH and MI; Potter et al., 2006). 
 
Overall, my data describe in detail the role of MRPs in regulating several facets 
of vascular homeostasis, vessel reactivity, VSMC proliferation and BP in vivo, 
by augmenting cGMP signalling. Furthermore, this thesis provides further 
evidence to support the importance of MRPs in contributing to cGMP 
compartmentalisation through the ability of MK571 to favour pGC over sGC 
activation. 
 
5.2.1 Effect of MRPs in cardiovascular disease 
 
A key observation of the potential impact of MRPs in cardiovascular disease 
was made by Hara et al., (2011), who showed that MRP4 expression is 
significantly increased in the pulmonary arteries of PH patients and in the lungs 
of mice exposed to hypoxia. Furthermore, MRP4 expression is increased in 
proliferating VSMCs compared to quiescent cells, suggesting in vascular 
diseases characterised by VSMC hyperplasia, MRPs could be reducing the 
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anti-proliferative effect of cyclic nucleotides (Sassi et al., 2008). Also, MRP5 
expression is increased in blood vessels and cardiomyocytes in the hearts of 
patients with ischaemic cardiomyopathy (Dazert et al., 2003). Overall, this 
demonstrates that in cardiovascular diseases (e.g. PH), MRP expression 
increases substantially, similar to that observed with PDEs, blunting the anti-
proliferative and blood pressure lowering potential of endogenous NO and NP 
signalling (Wharton et al., 2005). Therefore, inhibiting MRPs per se to treat 
cardiovascular disorders could pose an attractive therapeutic target, in addition 
to also being an effective adjuvant to other cGMP elevating agents.  
 
Indeed, the potential power of MRP inhibition alone can be predicted when 
considering the increased levels of circulating ANP, BNP and CNP in patients 
with cardiovascular diseases such as PH, MI and congestive heart failure 
(Kaiser et al., 2015; Potter et al., 2006). Synergy between cGMP elevating 
agents (e.g. PDE and NEP inhibitors) has been well characterised in 
experimental models of PH and fibrosis (Baliga et al., 2014, 2008). Indeed, 
cGMP/cAMP -elevating combination therapies have been shown to be effective 
in patients with PH (e.g. epoprostenol and sildenafil; Simonneau et al., 2008). 
This gives credence to the idea that combination of NP elevating agents (e.g. 
NEP inhibitors and/or PDE inhibitors) with MRP inhibitors is also likely to be of 
therapeutic benefit. Indeed, the link between two such mechanisms, cGMP 
degradation due to PDEs and efflux by MRPs, has been demonstrated through 
greater elevations in VSMC intracellular cGMP concentrations in the presence 
of MRP inhibitors when combined with PDE inhibitors such as sildenafil and 
IBMX (Hara et al., 2011; Krawutschke et al., 2015; Sassi et al., 2008). However, 
the relationship between PDEs and MRPs is not straight-forward. Firstly, 
treatment with the PDE5 inhibitor, sildenafil, in normoxic WT mice and PASMCs 
from patients with PH results in a significant increase in MRP4 expression, 
suggesting a compensatory mechanism to cope with the increased intracellular 
concentrations of cGMP, which may contribute to tachyphylaxis (Hara et al., 
2011). This observation is particularly pertinent as PDE5 inhibitors are already 
prescribed to patients with PH and therefore could result in increased MRP 
expression and reduced therapeutic value. Second, the PDE5 inhibitor sildenafil 
and the PDE3 inhibitor trequinsin have each been identified as inhibitors of 
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MRPs (Chen et al., 2002; Jedlitschky et al., 2000; Reid et al., 2003). This 
observation has muddied the waters somewhat when measuring increases in 
intracellular cGMP; are changes due to a PDE inhibition, MRP inhibition or 
both? This observation leads to the assumption that possible concomitant 
inhibition of PDE5 and MRPs may contribute to the current therapeutic benefit 
of sildenafil, and combining cGMP efflux inhibitors with elevators should be 
explored. Indeed, to support this concept of combination therapy, in the heart 
PDE9 is the predominant isoform that degrades cGMP generated by NPs, 
whereas PDE5 favours NO (Lee et al., 2015). My data show that MRPs also 
favour NP generated cGMP over NO/sGC. Therefore, in diseases characterised 
by elevating responses by NPs appear more advantageous, inhibiting MRPs 
may pose a more attractive therapeutic target (e.g. heart failure, PH and MI; 
Potter et al., 2006)  
 
Other synergistic effects of cyclic nucleotide transport by MRPs have been 
observed in VSMCs (and ECs). Here, increasing intracellular cAMP 
concentrations through adenylyl cyclase activation using forskolin causes an 
increase in intracellular cGMP due to attenuation of cGMP eggression (Hamet 
et al., 1989). Further evidence of this phenomenon is provided by studies from 
(Krawutschke et al., 2015) in which human VSMC intracellular cGMP levels 
were increased by the β-adrenoceptor agonist, isoproterenol (isoprenaline), but 
not by inhibition of PDE3 with cilostamide. This reflects, somewhat, the same 
cyclic nucleotide cross-talk observed with PDEs and would naturally lead to the 
prediction that cAMP based treatments such as the IP receptor agonists 
treprostinil, epoprostenol and iloprost, used in the treatment of PH could be 
exercising further therapeutic effect by additionally elevating intracellular VSMC 





Figure 72. An illustration of the potential cardiovascular benefits of MRP 
inhibition. 
Cyclic adenosine-3',5'-monophosphate (cAMP), cyclic guanosine-3',5'-
monophosphate (cGMP), multidrug resistance protein (MRP). 
 
Multidrug resistance proteins may also exert an effect on the process of 
angiogenesis and repair from vascular injury. Fibroblasts from MRP4 KO mice 
migrate faster and exhibit improved wound healing capability compared to WT 
littermates, which is due to higher intracellular cGMP (and cAMP) 
concentrations (Sinha et al., 2013). Indeed, MRP4 knockdown in EC results in 
enhanced migration and survival because of increased intracellular cyclic 
nucleotide levels (Tagami et al., 2010; Figure 72). The pro-angiogenic factor 
VEGF, present at high levels in PH, is implicated in this process as it leads to 
decreased EC MRP4 expression (Tagami et al., 2010). Overall, this intimates 
that MRPs may play a key role in vascular cell migration, which could be 
particular pertinent in disease states. For example, in fibrotic disorders including 
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PH, pulmonary fibrosis and cardiac fibrosis, MRP inhibition in fibroblasts could 
not only enhance migration and therefore wound repair, but also prevent 
excessive fibrosis by attenuating myofibroblast differentiation which is 
responsible for synthesis and deposition of extracellular matrix, specifically 
collagen (Camelliti et al., 2005; Figure 72). Increasing intracellular cAMP 
(Swaney et al., 2005), and cGMP (Baliga et al., 2014) through PDE5 and NEP 
inhibition, has already been demonstrated to reduce fibrosis. Dual prescription 
of IP receptor agonists with either PDE5 inhibitors or sGC stimulators is already 
in use for the treatment of PH; therefore, targeting both types of cyclic 
nucleotide simultaneously through MRP inhibition poses an obvious advantage 
(Simonneau et al., 2013). 
 
In sum, my thesis contributes to the understanding of the cGMP-dependent 
effects of MRPs in vascular homeostasis by demonstrating their ability to 
modulate vascular reactivity, VSMC proliferation and BP in vivo. This suggests 
that the use of MRP-targeted therapy poses an attractive option for the 
treatment of cardiovascular disease, and quite possibly could already be in play 




5.3 The role of C-type natriuretic peptide and 
its cognate receptor natriuretic peptide 
receptor-C in pulmonary hypertension  
 
Pulmonary hypertension is a devastating and severe pan-vasculopathy with a 
seven year survival rate upon diagnosis. The pathogenesis of PH appears to 
initiate with endothelial dysfunction and develops in to a complex multifaceted 
disease, which particularly benefits from a combination therapy paradigm (Gali 
et al., 2013). CNP is a powerful vasoprotective peptide acting through both 
NPR-C and NPR-B. CNP has been found to be particularly beneficial in the 
protection against vascular diseases (Moyes et al. 2014); however the 
pharmacodynamic effect of CNP in PH is controversial with some studies 
demonstrating beneficial effects (Itoh et al., 2004; Kimura et al., 2016; 
Murakami et al., 2004) and others no effect at all (Casserly et al., 2011). The 
vascular actions of CNP are considered to be through NPR-B stimulation and 
cGMP-dependent mechanisms, the latter of which is exploited in the treatment 
of PH. Additionally, CNP is secreted by endothelial cells in response to shear 
stress and inflammogens, both of which are increased in PH (Wilkins, 2012). 
Thus, experiments were designed to tease out the exact role of endogenously 
generated CNP in PH by using ecCNP KO mice in the hypoxia plus SU5416 
experimental model. Furthermore, to investigate through which receptor CNP 
initiates any potential beneficial effect I utilised global NPR-C KO mice in the 
same preclinical model of PH. Furthermore, since CNP has been demonstrated 
to exert a pronounced anti-fibrotic capability (Kimura et al., 2016; Murakami et 
al., 2004; Soeki et al., 2005), I utilised the bleomycin-induced model of PH and 
investigated the effect of global NPR-C KO on pathogenesis.  
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5.3.1 The role of endothelial cell-derived C-type 
natriuretic peptide in pulmonary hypertension  
 
5.3.1.1 Hypoxia plus SU5416 model of PH 
 
To investigate the role of CNP in PH I utilised an animal model that has recently 
been reported to best recapitulate the characteristic of this disease in mice. The 
hypoxia plus SU5416 model of PH, originally reported by Ciuclan et al., (2011), 
is described as a severe model of PH best mirroring the histopathological 
features and progressive nature of the disease found in humans. In addition, 
this murine model was described to be similar to that published by 
Taraseviciene-Stewart et al., (2001) in rats, which has been thoroughly 
characterised and accurately represents the disease found in patients (Abe et 
al., 2010). Therefore, as I had mice available to me that were either deficient in 
CNP from ECs specifically or NPR-C globally, it logically led me to use this 
murine model to investigate the role of each of these proteins in the 
development of PH. Firstly, as this model hasn’t previously been used in our lab 
I performed experiments to determine whether the PH phenotype reported 
could be reproduced in our lab.  
 
In WT mice exposed to hypoxia plus SU5416, as described by Ciuclan et al., 
(2011) I observed large increases in RVSP and RVH indicative of PH. When 
mice were removed from the chronic hypoxic insult there was a reduction in 
RVSP and RVH indicating reversal of this pathology. These results suggest that 
without the continuous insult of hypoxia the mice recover spontaneously, such 
that the PH phenotype is not irreversible and progressive like the hypoxia plus 
SU5416 model in rats, and more importantly what’s observed in patients. In 
addition, I also investigated whether a longer period of chronic hypoxia (5 
weeks instead of three) resulted in a more severe phenotype. Although, 5 
weeks hypoxia did not cause further increases in RVSP and RVH, the values 
remained essentially the same as at the 3 week time-point, suggesting that the 
hypoxic insult sustains pathology. In addition, to determine whether this model 
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was more akin to the disease characterised by the development of severe 
complex lesions and occluded vessels I qualitatively analysed lungs from mice 
exposed to 5 weeks hypoxia plus SU5416. I assumed this extended model 
would exhibit a more severe pathology than 3 weeks hypoxia, thus increasing 
the chance of detecting signs of advanced vascular lesion. However, I did not 
detect any complex lesions or occluded vessels in the lungs of these mice. In 
conclusion, using this model I was able to recapitulate the findings originally 
published by Ciuclan et al., (2011); this model generates a severe PH 
phenotype whilst the animals are continuously exposed to hypoxia but, in 
contrast to the original findings of Ciuclan et al., (2011), this phenotype reverses 
when animals are removed from hypoxia. In addition, I did not detect the 
presence of complex lesions or occluded vessels derived from hyper-
proliferative ECs suggesting that this model may not completely recapitulate the 
human disease as originally concluded. In fact, my observations are mirrored by 
those of Vitali et al., (2014) who whilst performing an in-depth investigation of 
this model also found that PH like pathologies, RVSP and RVH, regress once 
mice are returned to normoxia. Interestingly, this group found that hypoxia plus 
SU5416 treated mice exhibited significant vascular pruning, which is thought to 
arise from the development of angio-obliterative lesions, also observed in PH 
patients and the rat hypoxia plus SU5416 model (McLaughlin and McGoon, 
2006; Taraseviciene-Stewart et al., 2001). However, vascular pruning or angio-
obliterative lesions are not characteristics of the mouse chronic hypoxia model 
of PH, demonstrating advantages of the current model. In addition, the original 
report demonstrated that when SU5416 is combined with hypoxia in mice, it 
causes a shift from an apoptotic to a hyper-proliferative EC phenotype, a 
hallmark of PH, but not observed in hypoxia alone models. In sum, no one 
animal model recapitulates all the characteristics of PH (Stenmark et al., 2009), 
but I believe the combination of SU5416 with hypoxia better reflects the 
endothelial dysfunction found in the human disease and therefore allowed me to 
more appropriately investigate the vascular protective effects of CNP and NPR-
C.  
 
To ensure the continual use of this model was economically viable, I 
investigated possible differences in potency of SU5416 sourced commercially 
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compared to that synthesised in-house, the latter being significantly cheaper. I 
did not find any differences in the degree of PH developed when using either 
source of SU5416. Therefore the less expensive SU5416 (synthesised in-
house) was selected and used for all subsequent experiments involving 
transgenic animals. 
 
The pathophysiological effect of endothelial cell-derived CNP (ecCNP KO 
mouse) deletion in mice has been well characterised (Moyes et al., 2014). Both 
male and female ecCNP KO mice exhibit increased leukocyte adhesion and 
platelet aggregation, which contribute to an enhanced development of aortic 
atherosclerotic plaques and aneurysms (males only, 50 %) when compared to 
WT littermates. However, only female ecCNP KO mice are inherently 
hypertensive. These data along with those demonstrating the ability of CNP to 
modulate EC and VSMC growth (Khambata et al., 2011), suggest that 
endothelial cell-derived CNP is an essential regulator of vascular homeostasis. 
These striking findings led to the hypothesis that ecCNP plays an essential role 
in a disease characterised by inflammation, thrombosis, endothelial dysfunction 
and VSMC proliferation; an excellent example being PH. 
 
Male and female ecCNP WT and KO mice when exposed to hypoxia plus 
SU5416 developed PH evidenced by significantly increased RVSP, RVH and 
muscularisation of the pulmonary small arteries. However, no significant 
differences in RVSP, RVH and extent of muscularisation were observed 
between genotypes. Overall, these data show that CNP derived from ECs 
specifically is not essential in the development of PH using this model. This 
finding is surprising as endothelium-derived CNP has previously been shown to 
protect against the pathogenesis of vascular disease (atherosclerosis; Moyes et 
al., 2014). In addition, the importance of endothelium-derived CNP in vascular 
function is more evident in female ecCNP KO mice than males; for this reason I 
studied both sexes in the experimental model of PH but no overt changes were 
apparent in either sex. If anything, one would predict that female ecCNP KO 
mice would have exhibited a pulmonary hypertensive phenotype, assuming the 
higher blood pressure in the systemic vasculature would be mirrored in the 
pulmonary circulation. However, I did not observe a high RVSP in female 
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ecCNP KO mice, under normoxic conditions suggesting ecCNP in females has 
a disparate function between the pulmonary and systemic circulation. 
Furthermore, a hallmark of PH is the development of thrombi in the pulmonary 
circulation exacerbated by vascular lesions, this is due to enhanced platelet 
aggregation and inflammation that precedes vascular remodelling and predicts 
survival (Rabinovitch et al., 2014). Therefore, the significant anti-thrombotic and 
leukocyte adhesive properties of ecCNP should be vital to disease 
pathogenesis. Again, this should lead to a worsening of the PH phenotype in 
ecCNP KO mice. However, whilst this may potentially be the case in PH 
patients, this characteristic of the disease may not be best recapitulated in the 
mouse hypoxia plus SU5416 model. Chronic hypoxia in both rodents and 
humans is characterised by inflammation consisting of increased infiltration of 
macrophages and neutrophils, with enhanced secretion of pro-inflammatory 
cytokines such as TNF-α, IL-1β , IL-6, and IL-8 that increase the risk of aberrant 
platelet aggregation (Stenmark et al., 2006b). Rats and mice exposed to 
hypoxia plus SU5416 also have increased secretion of pro-inflammatory 
cytokines and leukocyte recruitment (Ciuclan et al., 2011; Taraseviciene-
Stewart et al., 2001). Although differences in the inflammatory cell profile have 
been noted; the rat hypoxia plus SU5416 model has only a small number of 
macrophages in the alveolar space whereas the mouse hypoxia plus SU5416 
model demonstrates a significant expression of the macrophage recruitment 
marker CD68, which is also found in plexiform lesions of PH patients 
(Rabinovitch et al., 2014). Regardless, using the mouse hypoxia plus SU5416 
model with its pro-inflammatory phenotype should have illustrated the vital anti-
inflammatory properties of EC-derived CNP present in WT mice but absent in 
KOs, which should have resulted in a more severe phenotype in KOs; it remains 
unclear why this was not observed.  
 
Anti -thrombotic and -inflammatory characteristics of CNP have been 
demonstrated with CNP infusion (0.75 μg/h) in the rat monocrotaline model of 
PH resulting in both reversal of established disease and prevention of its 
progression (Itoh et al., 2004). Specifically, CNP decreases 
monocyte/macrophage infiltration and reduces expression of pro-thrombotic 
markers. In addition, CNP infused (2.5 mg/kg/min) prophylactically significantly 
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attenuates the number of macrophage, neutrophil and lymphocyte lung 
infiltrates caused by LPS (Kimura et al., 2015). In contrast, but mirroring my 
own findings, Casserly et al., (2011) reported that CNP infusion (0.75 and 2.25 
µg/h) had no beneficial effect in rats exposed to either chronic hypoxia alone or 
hypoxia plus SU5416. When CNP was used in the monocrotaline model of PH it 
was shown to suppress pulmonary EC apoptosis and increase proliferation, in 
addition to reducing VSMC proliferation. This suggests CNP aided the 
maintenance of the endothelial barrier, the initial site of monocrotaline insult, 
inhibiting VSMC proliferation (Itoh et al., 2004; Rosenberg and Rabinovitch, 
1988). Moreover, when VEGF is added to ECs this same pro-proliferative EC 
phenotype also occurs (Alon et al., 1995; Gerber et al., 1998). Furthermore, this 
forms the foundation for the rat and mouse hypoxia plus SU5416 model where 
VEGFR inhibition prevents VEGF mediated EC survival and instead 
encourages EC apoptosis, leading to the selection of a hyper-proliferative 
apoptotic-resistant EC phenotype (Taraseviciene-Stewart et al., 2001). Akin to 
VEGF, CNP has the ability to promote endothelial cell proliferation, which has 
been demonstrated extensively to aid neovascularisation, enhancing wound 
repair after vascular injury (Furuya et al., 1995, 1991; Khambata et al., 2011; 
Kühnl et al., 2005; Morishige et al., 2000; Ohno et al., 2002; Pelisek et al., 
2006); thus, it is perplexing that I didn’t observe a more severe PH-like 
phenotype in mice absent of EC derived CNP. 
 
A speculative explanation for the disparity in effectiveness of exogenously 
administered CNP (monocrotaline v hypoxia or hypoxia plus SU5416) may 
depend on the type and degree of pathogenic insult that initiates these different 
in vivo models. Different vascular insults may result in different mechanisms 
that modulate EC and VSMC growth, which also determine the effectiveness of 
CNP in attenuating a phenotype in one model over another. Chronic exposure 
to hypoxia in general, and hypoxia plus SU5416 models of PH, results in an 
increased secretion of VEGF (Ciuclan et al., 2011; Stenmark et al., 2006b; 
Taraseviciene-Stewart et al., 2001). VEGF administered to ECs under routine 
culture significantly reduces CNP secretion and expression (Doi et al., 1996). 
Moreover, exposing VSMC to hypoxia increases expression of VEGF but not 
bFGF, which contrastingly increases CNP secretion by ECs (Brogi et al., 2008; 
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Suga et al., 1992b). Although there are many different mitogens and pro-
inflammatory cytokines secreted during hypoxia that can simultaneously 
increase and decrease CNP secretion, these specifics illustrate that the precise 
mix of mitogens and pro-inflammatory cytokines generated by hypoxia 
determine the balance between enhanced or suppressed CNP secretion. 
Furthermore, it may not just be whether CNP itself is secreted but also the 
simultaneous secretion of vasoconstrictive, pro-vascular remodelling agents. 
Suga et al., (1992b) demonstrated a number of different mediators that 
significantly increase CNP secretion from EC cells such as TGF-β, bFGF, 
thrombin and arginine-vasopressin (AVP); however, the same factors also 
simultaneously increase ET-1 production suggesting that the secretion of 
vasodilator/anti-proliferative factors are balanced with vasoconstrictive/pro-
proliferative ones. Furthermore, 8-bromo-cAMP and 8-bromo-cGMP, membrane 
permeable PKA and PKG activators, respectively, increase CNP secretion from 
ECs in the absence of increased ET-1 secretions. This suggests a potential 
beneficial positive feedback mechanism where by increased cAMP and cGMP 
production by either GC or adenylyl cyclase in response to NO, NPs or PGI2 
elevates CNP secretion. Therefore, in PH characterised by reduced cGMP and 
cAMP signalling, and enhanced ET-1 signalling, it is conceivable that the 
disease is by nature one of deficient CNP secretion and that its absence in the 
ecCNP KO I studied does not affect pathogenesis because CNP secretion is 
also reduced in WT mice. 
 
Another point to consider is whether endothelial cell-derived CNP is the 
predominant source of CNP. If endothelial cell-derived CNP isn’t a major player 
in the protection against PH pathogenesis, as suggested by my results, could 
CNP produced from another cell-type be more important? Elegant studies 
performed by Chauhan et al., (2003), clearly demonstrate that ACh-induced 
CNP secretion from resistance arteries (mesenteric) is dependent completely 
on the presence of an intact endothelium. However, there are alternative lines 
of evidence demonstrating CNP is secreted by other cell-types, which could 
potentially play a role in PH; these include VSMC (Casco et al., 2002; Kelsall et 
al., 2006; Mendonca et al., 2006; Naruko et al., 2005, 1996; Suga et al., 1998; 
Woodard et al., 2002), macrophages (Casco et al., 2002), fibroblasts (Chrisman 
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and Garbers, 1999; Horio et al., 2003) and cardiomyocytes (Del Ry et al., 2011; 
Kelsall et al., 2006). 
 
Vascular SMCs could be considered ideally located to elicit beneficial autocrine 
and paracrine effects on CNP secretion. ECs co-cultured with VSMCs 
significantly increase EC secreted CNP but only when the cells are in direct 
contact demonstrating a reciprocal relationship between VSMCs and ECs. This 
effect is dependent on the release of TGF-β from VSMCs when in direct contact 
with ECs, and lends support to the overall importance of an intact endothelium. 
However, ecCNP KO mice are absent of endothelial cell-derived CNP 
suggesting if this mechanism was significant, a worse phenotype would have 
been observed in KO mice using this model (Komatsu et al., 1996). In addition, 
mitogens such as PDGF, the expression of which is increased in hypoxic 
mammals and PH patients, enhances CNP expression in VSMCs and ECs from 
humans, but does the opposite in rodents (Mendonca et al., 2006). This 
suggests that the release of mitogens such as PDGF with chronic hypoxia in 
rats may decrease the secretion of CNP from VSMC possibly contributing to 
pathogenesis, whereas in humans it appears hypoxia may increase the 
secretion of VSMC-derived CNP reducing disease progression. Therefore, 
endogenous CNP secretion from both ECs and VSMCs in mice exposed to 
hypoxia plus SU5416 may play an inherently menial role in preventing disease 
progression because secretion of this peptide is inhibited in both WT and 
ecCNP KO mice due to mitogen-triggered downregulation. However, similar to 
that observed in ECs, the combination of specific mitogens and cytokines may 
determine the extent to which CNP is secreted by VSMCs. Thus, it is difficult to 
conclude whether in the mouse hypoxia plus SU5416 model there is a 
compensatory effect of elevated CNP secretion from VSMCs in the absence of 
ecCNP, or that inherently CNP secretion is attenuated in both cell-types; 
regardless, this would account for no observable difference between ecCNP KO 
and WT mice.  
 
Macrophage lung infiltration is a common component in the mouse hypoxia plus 
SU5416 model of PH, but absent in the rat model (Ciuclan et al., 2011; 
Taraseviciene-Stewart et al., 2001). In addition, macrophage pulmonary 
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infiltrates are also a common feature in PH patients (Rabinovitch et al., 2014). 
Macrophages can secrete CNP, specifically when monocytes are exposed to 
pro-inflammatory stimuli (e.g. TGF-β) causing them to differentiate into 
macrophages (Kubo et al., 2001). Further, Suga et al., (1992b) showed that co-
culturing macrophages with ECs increases EC-derived CNP secretion by ~10-
fold. Therefore, macrophages secrete CNP themselves and also increase EC-
derived CNP secretion. The importance of one mechanism over the other as a 
vasoprotective effect has already been shown. Macrophages are a predominant 
feature in atherosclerosis (Casco et al., 2002) but the absence of ecCNP in 
mice results in enhanced atherosclerotic lesions with increased macrophage 
infiltration meaning that the CNP secreted by macrophages is not significant 
enough to compensate for the lack of EC-derived CNP (Moyes et al., 2014). 
Therefore, in my studies it would be reasonable to assume that CNP derived 
from macrophages did not compensate for the lack of ecCNP.  
 
Fibroblasts are known to accumulate in the pulmonary vascular adventitia of PH 
patients and also during chronic hypoxia, this is followed by fibroblast migration 
into the intimal and medial layers, forming part of the vascular lesion through 
proliferation and production of extracellular matrix (Stenmark et al., 2006a). In 
fact, rat cardiac fibroblasts secrete CNP which is significantly enhanced through 
stimulation with TGF-β, bFGF, and ET-1 (Horio et al., 2003). C-type natriuretic 
peptide released by fibroblasts can act as an autocrine signal by inhibiting 
fibroblast differentiation, migration and collagen deposition (Li et al., 2015). 
Therefore, fibroblast-derived CNP is a potential source of CNP that could have 
blunted any detrimental effects of ecCNP deletion. 
 
CNP is expressed and secreted by the heart, particularly in cardiac disorders 
such as heart failure (Kalra et al., 2003), suggesting that CNP acts in an 
autocrine fashion to attenuate cardiac remodelling. Although this could account 
for a lack of significant difference in RVH between WT and ecCNP KO mice in 
the PH model it is unlikely to account for a similar phenotype with respect to 
vascular remodelling. In particular, CNP does not have endocrine capabilities 
akin to ANP and BNP as it has a very short half-life in the circulation. 
Nonetheless, it would be of interest to evaluate the phenotype of 
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cardiomyocyte-specific CNP null mice which have recently been developed by 
our lab (Moyes et al., 2015).  
 
The study by Casserly et al., (2011) demonstrating little or no effect of CNP 
infusion in rats exposed to hypoxia or hypoxia plus SU5416 noted significantly 
elevated plasma levels of CNP, implying adequate activation of NPR-B (or 
possibly NPR-C). This led to the assumption that the observed lack of effect 
was likely due to decreased receptor expression. The authors showed that 
NPR-B protein expression was undetectable in the lungs of rats exposed to 
hypoxia plus SU5416 and treated with CNP. However, Li et al., (1995) showed 
a 2-fold increase in NPR-B expression in lungs from rats exposed to 4 weeks 
hypoxia, suggesting either the hypoxia plus SU5416 combination or continuous 
CNP infusion decreases NPR-B expression. Continuous CNP infusion has been 
commonly used and demonstrated to be of therapeutic value in a wide range of 
experimental models, for example reducing intimal thickening from vascular 
injury (1 µg/kg/h; 5 or 14 day infusion; Furuya et al., 1995), decreasing Ang-II 
induced cardiac hypertrophy and fibrosis (0.05 µg/kg/min; 2 week infusion; 
Izumiya et al., 2012), attenuating the magnitude of cardiac infarct area and 
fibrosis due to experimental MI (0.1µg/kg/min; 2 week infusion; Soeki et al., 
2005) and preventing monocrotaline induced PH (0.75 µg/hour; 4 and 8 week 
infusion; Itoh et al., 2004). Consequently, CNP infusion does not appear to 
attenuate either NPR-B or NPR-C signalling otherwise CNP would not have 
exhibited a therapeutic effect. In addition, desensitisation does not appear to 
occur in disease models since infusion of both ANP and BNP significantly 
reduce severity of PH developed from chronic hypoxia in rats (Jin et al., 1990; J 
R Klinger et al., 1998). In fact, exposure of rats to chronic hypoxia (4 weeks) 
causes a ~2-fold increase in NPR-B lung expression (Li et al., 1995). In sum, 
these data suggest that the hypoxia and SU5416 combination itself, and not 
CNP infusion per se, decreases lung NPR-B protein expression preventing any 
beneficial effect of CNP. Thus, in my studies, the reason underlying a lack of 
effect of ecCNP KO may well reside with a decrease in NPR-B expression 
which abrogated any beneficial effect of an increased CNP secretion in WT 
mice. In addition to activating NPR-B, CNP also activates NPR-C (Chauhan et 
al., 2003; Moyes et al., 2014; Villar et al., 2007). NPR-C expression has been 
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shown previously to be highly sensitive to hypoxia, being significantly reduced 
in the lungs of mice (~20 %) after just 48 h hypoxia, with a further decrease 
after 4 weeks (Li et al., 1995). Indeed, a reduction in NPR-C expression was 
originally alluded to by Klinger et al., (1994), reporting that ANP clearance was 
reduced in the lungs of rats exposed to 3 weeks hypoxia. This has also been 
shown in mice exposed to chronic hypoxia where lung NPR-C mRNA 
expression is significantly reduced in both WT and ANP KO mice, suggesting a 
reduction in NPR-C expression is independent of circulating NP concentrations 
and most probably due to the hypoxic insult itself (Sun et al., 2000). In fact it is 
not hypoxia per se that decreases NPR-C expression but rather the 
combination of hypoxia-responsive growth factors, FGF and PDGF, that 
activate tyrosine kinase receptors, decreasing NPR-C expression in rat 
pulmonary VSMCs (Sun et al., 2001). Thus, NPR-C is most highly expressed in 
the lung under basal conditions suggesting a prominent role in the pulmonary 
circulation. However, if NPR-C played a critical role in the pulmonary circulation 
I would have expected NPR-C KO mice to develop spontaneous PH, similar to 
that observed with eNOS KO mice (Steudel et al., 1997), but this was not the 
case (see 5.3.2). 
 
In sum, the lack of an overt effect between WT and ecCNP KO mice using the 
murine hypoxia plus SU5416 model of PH may have been due to a 
compensatory increase in cardiac-derived CNP attenuating an effect on RVH 
and/or fibroblast-derived CNP ameliorating an effect on vascular remodelling. 
Moreover, decreased expression of CNP, NPR-B and NPR-C in the setting of 
PH entails that, in both WT and ecCNP KO mice the capacity of the peptide to 
elicit any beneficial effects would have been absent.   
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5.3.2 The role of natriuretic peptide receptor-C in 
pulmonary hypertension 
 
5.4.2.1 Hypoxia plus SU5416 model of PH  
 
Initially, I hypothesised that CNP can elicit a cGMP-dependent beneficial effect 
in PH via activation of NPR-B and production of cGMP. To study this possibility 
I planned to exploit the NPR-B KO mouse colony maintained by our lab, but the 
availability of such animals was markedly reduced as a result of poor fecundity 
and innately poor survival. However, since recent evidence points to an 
important signalling function for NPR-C in the heart and vasculature (Anand-
Srivastava, 2005; Moyes et al., 2014; Rose and Giles, 2008), I decided to 
explore the phenotype of global NPR-C null animals. Although the signalling 
pathways triggered by NPR-C activation are not mediated by cGMP, rather Gi/o 
G-proteins, NPR-C does possess a NP clearance function, suggesting that 
depletion of this receptor could increase cGMP signalling indirectly (Matsukawa 
et al., 1999). 
 
Male NPR-C KO mice exhibit a hypotensive phenotype, which has been 
attributed to a reduction in NP clearance (Matsukawa et al., 1999; Moyes et al., 
2014). In contrast, female NPR-C KO mice exhibit a hypertensive phenotype 
resulting from the role of this receptor in orchestrating the EDHF-like activity of 
CNP. Furthermore, male and female NPR-C KO mice demonstrate enhanced 
vascular wall leukocyte adhesion properties, similar to male and female ecCNP 
KOs (Moyes et al., 2014). In addition to NPR-B, NPR-C mediates the anti-
proliferative effects of CNP on VSMC and pro-proliferative effects on ECs 
(Khambata et al., 2011). In sum, deletion of NPR-C increases inflammation and 
disables the ability of CNP to prevent aberrant VSMC mitogenesis and sustain 
the endothelial barrier; collectively these facets of CNP biology led to the 
hypothesis that the absence of NPR-C signalling would be severely detrimental 
to the development of PH, a disease characterised by inflammation, VSMC 
proliferation and endothelial cell dysfunction. Therefore, using the same mouse 
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hypoxia plus SU5416 model of PH described above, I investigated the effect of 
global deletion of NPR-C on disease severity.  
 
Hypoxia plus SU5416 caused PH in both male and female WT and NPR-C KO 
mice evident by significant increases in RVSP when compared to mice under 
control (normoxic) conditions. These increases in RVSP were accompanied by 
significantly enhanced RVH in all mice except male WT. Both genotypes of 
either sex had a predominance of partially and fully muscularised pulmonary 
arterioles (<100 µm diameter) suggesting that this model was able to induce 
severe vascular remodelling characterised by VSMC proliferation. However, this 
was not affected by genotype in either sex. Despite global deletion of NPR-C 
not causing significant differences in RVSP and pulmonary vascular remodelling 
between genotypes, NPR-C KO mice did develop significantly increased RVH 
compared to WT. Overall, these data show that NPR-C is not essential to the 
development of higher RVSP and pulmonary vascular remodelling but instead 
this receptor contributes to the protection against RVH associated with the 
disease. This is surprising as both male and female NPR-C KO mice exhibit 
increased leukocyte adhesion to the vascular wall under basal conditions and 
when stimulated by the addition of IL-1β (Moyes et al., 2014). Therefore, as this 
PH model exhibits a significant inflammatory component one would expect 
pathogenesis to be exacerbated in NPR-C KO mice, and in both sexes. 
 
Arguably the most important feature of NPR-C signalling in the context of PH, is 
its ability to inhibit VSMC proliferation but enhance EC growth (Khambata et al., 
2011; Figure 73). Aberrant VSMC proliferation and EC apoptosis are key 
components of PH in humans and both the rat and mouse hypoxia plus SU5416 
models (Ciuclan et al., 2011; Taraseviciene-Stewart et al., 2001; R. M. Tuder et 
al., 2007). Therefore, the ability of CNP/NPR-C signalling to oppose these 
pathological vasculature features would be expected to offer protection against 
PH pathogenesis. However, no differences in RVSP or pulmonary vascular 
remodelling were observed between NPR-C KO and WT mice. This could be 
explained by the dual functionality of NPR-C, signalling through G-proteins and 
NP clearance (Maack et al., 1987; Matsukawa et al., 1999); in this way, the 
absence of this receptor could have also led to an enhanced presence of NPs 
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within the vasculature, increasing the beneficial effects of pGC activation on 
ECs and VSMCs, balancing out the negative effects of disabled CNP/NPR-C 
signalling. Indeed, the plasma half-life of ANP is extended in the NPR-C KO 
mice (Matsukawa et al., 1999), both BNP and CNP also bind to this receptor 
(Bennett et al., 1991), and therefore one could envisage a substantial net 
beneficial effect of reduced NP clearance. However, my results offer evidence 
to the contrary in that both male and female NPR-C KO developed significantly 
higher RVH compared to their WT counterparts. There is evidence 
demonstrating the benefit of NPR-A and/or NPR-B activation in attenuating 
cardiac hypertrophy (Knowles et al., 2001; Langenickel et al., 2006) but if 
clearance was the predominant functional role of this receptor then RVH would 
have been attenuated, when in fact the opposite was true. A direct link between 
NPR-C signalling and cardiac hypertrophy has yet to be shown. However, there 
are several possible mechanisms that might explain a protective role. For 
example, Gi/o-driven activation of PI3K/Akt might result in eNOS 
phosphorylation to produce cardioprotective NO (Watts et al., 2013), akin to the 
beneficial effect of β3-adrenoceptors (Xiao et al., 1999) and shown to occur in 
response to NPR-C activation in the vasculature (El Andalousi et al., 2013; 
Murthy et al., 2000, 1998). Also, inhibition of the cardiac sarcolemmal Na+/H+ 
exchanger (NHE) prevents the development of hypertrophy via downregulation 
of calcineurin/NFAT activation (Avkiran and Haworth, 2003); Gi/o-linked 
receptors downregulate NHE. Third, Gi/o-coupled receptors would inhibit 
adenylyl cyclase to reduce cAMP-driven hypertrophic responses (Kudej et al., 
1997). 
 
In addition to cardiomyocytes, NPR-C expressed on fibroblasts might also have 
contributed to the RVH associated with PH. NPR-C KO mice, under basal 
conditions, have substantial fibrosis in the right and left atria but not in the 
ventricles (Egom et al., 2015). Therefore, with an innate cardiac fibrotic 
phenotype it would be reasonable to assume that under high pressure, such as 
in those induced by the hypoxia plus SU5416 model, that NPR-C KO mice 





In sum, global deletion of NPR-C is detrimental to the pathogenesis of PH with 
respect to RVH, but not pulmonary vascular pressure or remodelling. Thus, I 
have established a novel cardioprotective action of NPR-C that offsets the 
development of pressure-induced cardiac hypertrophy, although exactly how 
this occurs will require further investigation. The lack of effect of NPR-C deletion 
on vascular morphology and reactivity may be due to the dual functionality of 
NPR-C (clearance and signalling). 
 
5.4.2.2 Bleomycin-induced model of PH  
 
Since CNP has been reported to exert substantial anti-fibrotic effects in many 
organs, including the kidney (Hu et al., 2015) and liver (Tao et al., 1999), 
coupled to the anti-hypertrophic activity of NPR-C I identified in the previous set 
of experiments, I investigated the hypothesis that NPR-C might also prevent the 
development of PH secondary to lung fibrosis.  
 
The administration of bleomycin to male and female WT and NPR-C KO mice 
resulted in PH evident by significant increases in RVSP in all groups. However, 
only female NPR-C KO mice developed significantly elevated RVH upon 
bleomycin administration compared to controls, which was not seen with any 
other sex or genotype, hinting that the pathology developed in these mice was 
more severe. Indeed, female NPR-C KO mice administered bleomycin had 
significantly higher RVSP and RVH when compared to WT. A similar 
exacerbation in RVSP was not observed in male NPR-C KO, compared to WT, 
suggesting a sex-difference with females being more prone to pulmonary 
fibrosis than males. This was reflected in differences in lung weight, which 
showed that female NPR-C KO mice had significantly elevated lung weight 
compared to WT in response to bleomycin, whereas no difference was 
observed in male mice. This was reflected in differences in lung weight; after 
initial bleomycin instillation lung weight correlates with collagen content (Scotton 
et al., 2013), and female NPR-C KO mice had significantly elevated lung weight 
compared to WT, whereas no difference was observed in male mice. However, 
lung weight is also determined by vascular permeability leading to pulmonary 
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oedema (Scotton et al., 2009). NPR-C contributes to the regulation of 
pulmonary vascular permeability (Klinger et al., 2013), suggesting the changes 
in female NPR-C KO lung weight might be due to a combination of elevated 
pulmonary fibrosis and/or oedema. 
 
Although Moyes et al., (2014) found that both male and female NPR-C KO mice 
develop equally augmented inflammatory responses (e.g. increased leukocyte 
recruitment and atherosclerosis) I observed a profound sex-difference with 
respect to disease severity in experimental pulmonary fibrosis. In humans with 
pulmonary fibrosis males have a higher incidence and poorer survival than 
females, which would fit with my findings hinting at a more effective utilisation of 
NPR-C in females (Han et al., 2008). Pathological severity in the bleomycin 
model is known to be influenced by the female sex hormone, oestrogen, which 
exacerbates the detrimental phenotype (Gharaee-kermani et al., 2005); this is 
thought to be due to fibroblasts exhibiting differences in collagen and TGF-β 
production. Therefore, the absence of NPR-C on fibroblasts specifically might 
contribute to the sex-difference observed in my studies. The production of CNP 
is significantly enhanced in fibroblasts stimulated with TGF-β as well as other 
growth factors (e.g. bFGF and ET-1; Horio et al., 2003), and as TGF-β plays a 
key role in the deposition of extracellular matrix in both experimental and human 
pulmonary fibrosis, this likely results in a negative feedback mechanism, 
whereby CNP acts as a autocrine and paracrine messenger, activating NPR-C 
present on fibroblasts to regulate proliferation and collagen deposition, 
alongside BNP and possibly ANP (Huntley et al., 2006; Figure 73).  
 
Although the precise mechanism through which NPR-C activation inhibits 
fibrosis is not known, it is unlikely to occur through modulating intracellular 
cAMP, unlike the beneficial effects observed in RVH. In fact, powerful fibroblast 
mitogens such as lysophosphatidate are known to function through Gi/o -protein 
activation (van Corven et al., 1989) and fibroblast proliferation and extracellular 
matrix production is attenuated by increasing intracellular cAMP concentrations 
(D’armiento et al., 1973; Dubey et al., 2001; He & Grinnell, 1994; Liu et al., 
2004). Interestingly however, whilst the α-subunit of Gi/o-proteins inhibits cAMP 
production, the βγ-subunit simulates phospholipase-C (PLC). C-type natriuretic 
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peptide, acting through NPR-C with subsequent PLC stimulation, triggers an 
increase in outwardly rectifying non-selective cation currents due to transient 
receptor potential (TRP) channels in rat fibroblasts (Rose et al., 2007). 
Furthermore, a number of different TRP channels are expressed on fibroblasts 
which regulate TGF-β mediated fibroblast proliferation and collagen deposition 
(Du et al., 2010; Nilius & Szallasi, 2014; Yue et al., 2013). Therefore, the anti-
fibrotic effects of NPR-C signalling could have been mediated through 
modulation of the same TRP channels used to elicit pro-fibrotic effects of TGF-β 
(Figure 73). 
 
Figure 73. An illustration of the potential cardiovascular benefits of CNP. 
C-type natriuretic peptide (CNP), natriuretic peptide receptor-C (NPR-C), Gi/o  
-protein-coupled receptor (Gi/o -protein).  
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Overall, this demonstrates an initial proof of concept study that NPR-C is 
protective against the development of pulmonary fibrosis. This is an important 
observation because of the dual functionality of NPR-C (clearance and 
signalling) and fits well with the protective role of NPR-C in the RV I 
demonstrated in the hypoxia plus SU5416 model of PH. Again, in this setting of 
lung fibrosis, deletion of NPR-C worsens disease progression, implying that 
extending the half-life of NPs in the circulation is not the predominate effect; 
rather the signalling capacity of the receptor is more important. Pulmonary 
vascular remodelling was not analysed specifically, nor quantification of lung 
collagen content to determine differences in fibrosis between genotypes; 
however, NPR-C is known to maintain the EC barrier, prevent VSMC 
proliferation, attenuate leukocyte recruitment and reduce fibroblast proliferation, 
which would indicate that the absence of this capacity in the NPR-C KO would 
lead to an increase susceptibility to the development of pulmonary fibrosis.  
 
5.4 Conclusions & future studies 
 
I have demonstrated that MRPs can be targeted to regulate cGMP-dependent 
vascular homeostasis. Multidrug resistance proteins contribute to the tight 
control of intracellular cGMP concentrations mediated through active efflux of 
membrane located cGMP “clouds” in VSMCs; facilitating cGMP 
compartmentalisation by acting as an adjuvant to PDEs. These transporter 
proteins facilitate the termination of the cardioprotective cGMP signal generated 
by sGC and pGC; therefore, MRP inhibition represents a novel therapeutic 
paradigm for the treatment of cardiovascular diseases by enhancing NO and 
NP signalling.  
 
I have also shown that endothelial cell-derived CNP is not essential to host 
protection against PH, although alternate cellular sources of this peptide may 
offset pathogenesis using the hypoxia plus SU5416 model. In contrast, NPR-C 
has a cardioprotective capacity in PH identifying a new avenue of enquiry 
toward sustaining RV function in this disease (which is the best predictor of 
prognosis). This receptor also exhibits both a cardio- and vaso- protective 
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capacity in the bleomycin-induced model of pulmonary fibrosis with secondary 
PH, especially in females. Therefore, the development of NPR-C agonists may 
provide an effective, novel treatment for PH patients.  
 
To build on my research into the role(s) of MRPs in regulating cGMP signalling 
one would ideally acquire the MRP4 and MRP5 KO mice, and repeat vascular 
reactivity, VSMC proliferation and in vivo BP studies to accurately delineate the 
roles of these transporter proteins in vascular homeostasis. Further still, it 
would be worthwhile to, investigate the role(s) of MRP4 and MRP5, using 
pharmacological interventions and transgenic lines, in disease models 
associated with altered NO and/or NP signalling (e.g. stroke, MI, and heart 
failure). Since probenecid is already a licensed medicine, repurposing of this 
MRP inhibitor might prove a quick and inexpensive approach to improve the 
treatment of cardiovascular disease. 
 
Further elucidation of the role(s) of NPR-C in lung fibrosis and RV remodeling is 
also warranted by my thesis research. In particular, one might explore the 
cause of the increased lung weight observed in the female NPR-C KO mice by 
comparing wet to dry lung weight, the extent of pulmonary oedema, and lung 
collagen content using high performance liquid chromatography (HPLC). To 
more fully investigate a role for CNP in PH it will be necessary to generate 
VSMC, fibroblast or cardiomyocyte cell-specific CNP KO mice to better 
understand how this peptide contributes to PH pathogenesis in each cell-type, 
thereby contributing to the overall understanding of this devastating condition. 
Additionally, studies using specific agonists/antagonists of NPR-B and NPR-C, 
and/or cell-specific NPR-B and NPR-C KO mice, would allow delineation of 






















Aaronson, P.I., Robertson, T.P., Knock, G.A., Becker, S., Lewis, T.H., Snetkov, 
V., Ward, J.P.T., 2006. Hypoxic pulmonary vasoconstriction: mechanisms 
and controversies. The Journal of Physiology 570, 53–8. 
Abbey, S.E., Potter, L.R., 2002. Vasopressin-dependent inhibition of the C-type 
natriuretic peptide receptor, NPR-B/GC-B, requires elevated intracellular 
calcium concentrations. The Journal of Biological Chemistry 277, 42423–
30. 
Abe, K., Toba, M., Alzoubi, A., Ito, M., Fagan, K.A., Cool, D., Voelkel, N.F., 
Mcmurtry, I.F., Oka, M., 2010. Formation of plexiform lesions in 
experimental severe pulmonary arterial hypertension. Circulation 121, 
2747–2754. 
Abu-Soud, H.M., Stuehr, D.J., 1993. Nitric oxide synthases reveal a role for 
calmodulin in controlling electron transfer. Proceedings of the National 
Academy of Sciences of the United States of America 90, 10769–10772. 
Achcar, R.O.D., Yung, G.L., Saffer, H., Cool, C.D., Voelkel, N.F., Yi, E.S., 2006. 
Morphologic changes in explanted lungs after prostacyclin therapy for 
pulmonary hypertension. European Journal of Medical Research 11, 203–
7. 
Adamson, I.Y., 1976. Pulmonary toxicity of bleomycin. Environmental Health 
Perspectives 16, 119–26. 
Agullo, L., Garciadorado, D., Escalona, N., Ruizmeana, M., Mirabet, M., Inserte, 
J., Solersoler, J., 2005. Membrane association of nitric oxide-sensitive 
guanylyl cyclase in cardiomyocytes. Cardiovascular Research 68, 65–74. 
Aizawa, N., Ishizuka, O., Ogawa, T., Mizusawa, H., Igawa, Y., Nishizawa, O., 
Andersson, K.-E., 2008. Effects of natriuretic peptides on intracavernous 
pressure and blood pressure in conscious rats. The Journal of Sexual 
Medicine 5, 2312–7. 
Akagi, S., Nakamura, K., Matsubara, H., Ohta-Ogo, K., Yutani, C., Miyaji, K., 
Ogawa, A., Kusano, K., Oto, T., Ishibashi-Ueda, H., Ito, H., 2014. Reverse 
remodeling of pulmonary arteries by high-dose prostaglandin I2 therapy: A 
case report, Journal of Cardiology Cases. 
Alderton, W.K., Cooper, C.E., Knowles, R.G., 2001. Nitric oxide synthases: 
structure, function and inhibition. The Biochemical Journal 357, 593–615. 
Alheid, U., Frölich, J.C., Förstermann, U., 1987. Endothelium-derived relaxing 
factor from cultured human endothelial cells inhibits aggregation of human 
platelets. Thrombosis Research 47, 561–571. 
Alon, T., Hemo, I., Itin, A., Pe’er, J., Stone, J., Keshet, E., 1995. Vascular 
endothelial growth factor acts as a survival factor for newly formed retinal 
vessels and has implications for retinopathy of prematurity. Nature 
Medicine 1, 1024–1028. 
Alonzo, G.E.D., Barst, R.J., Ayres, S.M., Bergofsky, E.H., Brundage, B.H., 
Detre, K.M., Fishman, A.P., Goldring, R.M., Groves, B.M., Kernis, J.T., 
Levy, P.S., Pietra, G.G., Reid, L.M., Reeves, J.T., Rich, S., Vreim, C.E., 
Williams, G.W., Wu, M., 1991. Survival in Patients with Primary Pulmonary 
Hypertension Results from a National Prospective Registry. Annals of 
Internal Medicine 115, 343–349. 
Anand, I., Heath, D., Williams, D., Deen, M., Ferrari, R., Bergel, D., Harris, P., 
198 
 
1988. The pulmonary circulation of some domestic animals at high altitude, 
in: International Journal of Biometeorology. pp. 56–64. 
Anand-Srivastava, B.M., 2005. Natriuretic peptide receptor-C signaling and 
regulation. Peptides 26, 1044–59. 
Anand-Srivastava, M.B., Cantin, M., 1986. Atrial natriuretic factor receptors are 
negatively coupled to adenylate cyclase in cultured atrial and ventricular 
cardiocytes. Biochemical and Biophysical Research Communications 138, 
427–36. 
Anand-Srivastava, M.B., Sairam, M.R., Cantin, M., 1990. Ring-deleted analogs 
of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible 
coupling of clearance atrial natriuretic factor receptors to adenylate 
cyclase/cAMP signal transduction system. The Journal of Biological 
Chemistry 265, 8566–72. 
Anand-Srivastava, M.B., Sehl, P.D., Lowe, D.G., 1996. Cytoplasmic domain of 
natriuretic peptide receptor-C inhibits adenylyl cyclase. Involvement of a 
pertussis toxin-sensitive G protein. The Journal of Biological Chemistry 
271, 19324–9. 
Archer, S.L., Weir, E.K., Wilkins, M.R., 2010. Basic Science for Clinicians New 
Concepts and Experimental Therapies. Circulation 121, 2045–2066. 
Arias-Stella, J., Saldana, M., 1963. The Terminal Portion of the Pulmonary 
Arterial Tree in People Native to High Altitudes. Circulation 28, 915–925. 
Arndt, H., Smith, C.W., Granger, D.N., 1993. Leukocyte-endothelial cell 
adhesion in spontaneously hypertensive and normotensive rats. 
Hypertension 21, 667–673. 
Arnold, W.P., Mittal, C.K., Katsuki, S., Murad, F., 1977. Nitric oxide activates 
guanylate cyclase and increases guanosine 3’:5'-cyclic monophosphate 
levels in various tissue preparations. Proceedings of the National Academy 
of Sciences of the United States of America 74, 3203–7. 
Arora, K., Sinha, C., Zhang, W., 2013. Compartmentalization of cyclic 
nucleotide signaling : a question of when , where , and why ? European 
Journal of Physiology 465, 1397–1407. 
Arora, P., Wu, C., Khan, A.M., Bloch, D.B., Davis-dusenbery, B.N., Ghorbani, 
A., Spagnolli, E., Martinez, A., Ryan, A., Tainsh, L.T., Kim, S., Rong, J., 
Huan, T., Freedman, J.E., Levy, D., Miller, K.K., Hata, A., Monte, F., 
Vandenwijngaert, S., Swinnen, M., Janssens, S., Holmes, T.M., Buys, E.S., 
Bloch, K.D., Newton-cheh, C., Wang, T.J., 2013. Brief report Atrial 
natriuretic peptide is negatively regulated by microRNA-425. Journal of 
Clinical Investigation 123, 4–8. 
Ashman, D.F., Lipton, R., Melicow, M.M., Price, T.D., 1963. Isolation of 
adenosine 3′, 5′-monophosphate and guanosine 3′, 5′-monophosphate from 
rat urine. Biochemical and Biophysical Research Communications 11, 330–
334. 
Avkiran, M., Haworth, R.S., 2003. Regulatory effects of G protein-coupled 
receptors on cardiac sarcolemmal Na+/H+ exchanger activity: Signalling 
and significance. Cardiovascular Research 57, 942–952. 
Baliga, R.S., Scotton, C.J., Trinder, S.L., Chambers, R.C., Macallister, R.J., 
Hobbs, A.J., 2014. Intrinsic defence capacity and therapeutic potential of 
natriuretic peptides in pulmonary hypertension associated with lung 
fibrosis. British Journal of Pharmacology 171, 3463–3475. 
Baliga, R.S., Zhao, L., Madhani, M., Lopez-torondel, B., Visintin, C., Selwood, 
D., Wilkins, M.R., MacAllister, R.J., Hobbs, A.J., 2008. Synergy between 
199 
 
natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates 
pulmonary arterial hypertension. American Journal of Respiratory and 
Critical Care Medicine 178, 861–9. 
Barst, R., Rubin, L.J., Crow, J., Rich, S., Long, M., 1996. A comparison of 
continous intravenous epoprostenol (prostacyclin) with conventional 
therapy for primary pulmonary hypertension. The New England Journal of 
Medicine 334, 296–301. 
Bartels, C.F., Bükülmez, H., Padayatti, P., Rhee, D.K., van Ravenswaaij-Arts, 
C., Pauli, R.M., Mundlos, S., Chitayat, D., Shih, L.-Y., Al-Gazali, L.I., Kant, 
S., Cole, T., Morton, J., Cormier-Daire, V., Faivre, L., Lees, M., Kirk, J., 
Mortier, G.R., Leroy, J., Zabel, B., Kim, C.A., Crow, Y., Braverman, N.E., 
van den Akker, F., Warman, M.L., 2004. Mutations in the transmembrane 
natriuretic peptide receptor NPR-B impair skeletal growth and cause 
acromesomelic dysplasia, type Maroteaux. American Journal of Human 
Genetics 75, 27–34. 
Bauer, M., Wilkens, H., Langer, F., Schneider, S.O., Lausberg, H., Schäfers, H.-
J., 2002. Selective Upregulation of Endothelin B Receptor Gene 
Expression in Severe Pulmonary Hypertension. Circulation 105, 1034–
1036. 
Behr, J., Ryu, J.H., 2008. Pulmonary hypertension in interstitial lung disease. 
The European respiratory journal 31, 1357–67. 
Belik, J., 2009. Riociguat, an oral soluble guanylate cyclase stimulator for the 
treatment of pulmonary hypertension. Current Opinion in Investigational 
Drugs 10, 971–9. 
Bender, A.T., Beavo, J. a, 2006. Cyclic Nucleotide Phosphodiesterases : 
Molecular Regulation to Clinical Use. The American Society for 
Pharmacology and Experimental Therapeutics 58, 488–520. 
Benisty, J.I., McLaughlin, V. V, Landzberg, M.J., Rich, J.D., Newburger, J.W., 
Rich, S., Folkman, J., 2004. Elevated basic fibroblast growth factor levels in 
patients with pulmonary arterial hypertension. Chest 126, 1255–61. 
Bennett, B.D., Bennett, G.L., Vitangcol, R. V, Jewett, J.R., Burnier, J., Henzel, 
W., Lowe, D.G., 1991. Extracellular domain-IgG fusion proteins for three 
human natriuretic peptide receptors. Hormone pharmacology and 
application to solid phase screening of synthetic peptide antisera. The 
Journal of biological chemistry 266, 23060–7. 
Benza, R.L., Miller, D.P., Barst, R.J., Badesch, D.B., Frost, A.E., McGoon, M.D., 
2012. An evaluation of long-term survival from time of diagnosis in 
pulmonary arterial hypertension from the REVEAL Registry. Chest 142, 
448–56. 
Bera, T.K., Lee, S., Salvatore, G., Lee, B., Pastan, I., 2001. MRP8, a new 
member of ABC transporter superfamily, identified by EST database mining 
and gene prediction program, is highly expressed in breast cancer. 
Molecular medicine (Cambridge, Mass.) 7, 509–16. 
Bergmann, L., Kröncke, K.-D., Suschek, C., Kolb, H., Kolb-Bachofern, V., 1992. 
Cytotoxic action of IL-1β against pancreatic islets is mediated via nitric 
oxide formation and is inhibited by NG-monomethyl-l-arginine. FEBS 
Letters 299, 103–106. 
Bevan, E.G., Connell, J.M., Doyle, J., Carmichael, H.A., Davies, D.L., Lorimer, 
A.R., McInnes, G.T., 1992. Candoxatril, a neutral endopeptidase inhibitor: 




Bianchi, C., Gutkowska, J., Thibault, G., Garcia, R., Genest, J., Cantin, M., 
1986. Distinct localization of atrial natriuretic factor and angiotensin II 
binding sites in the glomerulus. The American journal of physiology 251, 
F594–602. 
Boo, Y.C., Sorescu, G., Boyd, N., Shiojima, I., Walsh, K., Du, J., Jo, H., 2002. 
Shear Stress Stimulates Phosphorylation of Endothelial Nitric-oxide 
Synthase at Ser1179 by Akt-independent Mechanisms: role of protein 
kinase A. Journal of Biological Chemistry 277, 3388–3396. 
Bordicchia, M., Liu, D., Amri, E., Ailhaud, G., Dessì-fulgheri, P., Zhang, C., 
Takahashi, N., Sarzani, R., Collins, S., 2012. Cardiac natriuretic peptides 
act via p38 MAPK to induce the brown fat thermogenic program in mouse 
and human adipocytes. Journal of Clinical Investigation 122, 1022–1036. 
Borgognone, A., Pulcinelli, F.M., 2012. Reduction of cAMP and cGMP inhibitory 
effects in human platelets by MRP4-mediated transport. Thrombosis and 
haemostasis 108, 955–62. 
Borst, P., de Wolf, C., Van De Wetering, K., 2007. Multidrug resistance-
associated proteins 3, 4, and 5. Pflügers Archiv : European journal of 
physiology 453, 661–673. 
Brandt, I., 2006. Dipeptidyl-Peptidase IV Converts Intact B-Type Natriuretic 
Peptide into Its des-SerPro Form. Clinical Chemistry 52, 82–87. 
Brogi, E., Wu, T., Namiki, A., Isner, J., 2008. Indirect Angiogenic Cytokines 
Upregulate VEGF and bFGF Gene Expression in Vascular Smooth Muscle 
Cells, Whereas Hypoxia Upregulates VEGF Expression Only. Circulation 
90, 649–652. 
Brunton, L.L., Hayes, J.S., Mayer, S.E., 1979. Hormonally specific 
phosphorylation of cardiac troponin I and activation of glycogen 
phosphorylase. Nature 280, 78–80. 
Bryan, P.M., Smirnov, D., Smolenski, A., Feil, S., Feil, R., Hofmann, F., 
Lohmann, S., Potter, L.R., 2006. A sensitive method for determining the 
phosphorylation status of natriuretic peptide receptors: cGK-Ialpha does 
not regulate NPR-A. Biochemistry 45, 1295–303. 
Bubb, K.J., Trinder, S.L., Baliga, R.S., Patel, J., Clapp, L.H., MacAllister, R.J., 
Hobbs, A.J., 2014. Inhibition of Phosphodiesterase 2 Augments cGMP and 
cAMP Signaling to Ameliorate Pulmonary Hypertension. Circulation 130, 
496–507. 
Budworth, J., Meillerais, S., Charles, I., Powell, K., 1999. Tissue distribution of 
the human soluble guanylate cyclases. Biochemical and biophysical 
research communications 263, 696–701. 
Bull, T.M., Coldren, C.D., Geraci, M.W., Voelkel, N.F., 2007. Gene expression 
profiling in pulmonary hypertension. Proceedings of the American Thoracic 
Society 4, 117–20. 
Burg, E.D., Remillard, C. V, Yuan, J.X.-J., 2008. Potassium channels in the 
regulation of pulmonary artery smooth muscle cell proliferation and 
apoptosis: pharmacotherapeutic implications. British journal of 
pharmacology 153 Suppl , S99–S111. 
Burnett, J.C., Granger, J.P., Opgenorth, T.J., 1984. Effects of synthetic atrial 
natriuretic factor on renal function and renin release. The American journal 
of physiology 247, F863–6. 
Burnett, J.C., Kao, P.C., Hu, D.C., Heser, D.W., Heublein, D., Granger, J.P., 
Opgenorth, T.J., Reeder, G.S., 1986. Atrial natriuretic peptide elevation in 
congestive heart failure in the human. Science 231, 1145–7. 
201 
 
Busse, R., Lückhoff, A., Bassenge, E., 1987. Endothelium-derived relaxant 
factor inhibits platelet activation. Naunyn-Schmiedeberg’s Archives of 
Pharmacology 336, 566–71. 
Butcher, R.W., Sutherland, E.W., 1962. Adenosine 3’,5'-phosphate in biological 
materials. I. Purification and properties of cyclic 3',5'-nucleotide 
phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-
phosphate in human urine. The Journal of biological chemistry 237, 1244–
50. 
C. S. Houston, Sutton, J.R., Cymerman, A., Reeves, J.T., 1987. Operation 
Everest II: man at extreme altitude. Journal of Applied Physiology 62, 877–
882. 
Camelliti, P., Borg, T.K., Kohl, P., 2005. Structural and functional 
characterisation of cardiac fibroblasts. Cardiovascular Research 65, 40–51. 
Campbell, I.L., Taylor, K.W., 1981. The effect of metabolites, papaverine, and 
probenecid on cyclic AMP efflux from isolated rat islets of Langerhans. 
Biochimica et Biophysica Acta (BBA) - General Subjects 676, 357–364. 
Casco, V.H., Veinot, J.P., Kuroski de Bold, M.L., Masters, R.G., Stevenson, 
M.M., de Bold, A.J., 2002. Natriuretic peptide system gene expression in 
human coronary arteries. The journal of histochemistry and cytochemistry : 
official journal of the Histochemistry Society 50, 799–809. 
Casserly, B., Mazer, J.M., Vang, A., Harrington, E.O., Klinger, J.R., Rounds, S., 
Choudhary, G., 2011. C-type natriuretic peptide does not attenuate the 
development of pulmonary hypertension caused by hypoxia and VEGF 
receptor blockade. Life Sciences 89, 460–466. 
Castro, L.R. V, Verde, I., Cooper, D.M.F., Fischmeister, R., 2006. Cyclic 
guanosine monophosphate compartmentation in rat cardiac myocytes. 
Circulation 113, 2221–8. 
Chan, J.C.Y., Knudson, O., Wu, F., Morser, J., Dole, W.P., Wu, Q., 2005. 
Hypertension in mice lacking the proatrial natriuretic peptide convertase 
corin. Proceedings of the National Academy of Sciences of the United 
States of America 102, 785–90. 
Chataigneau, T., Félétou, M., Huang, P.L., Fishman, M.C., Duhault, J., 
Vanhoutte, P.M., 1999. Acetylcholine-induced relaxation in blood vessels 
from endothelial nitric oxide synthase knockout mice. British journal of 
pharmacology 126, 219–26. 
Chaudhary, N.I., Schnapp, A., Park, J.E., 2006. Pharmacologic differentiation of 
inflammation and fibrosis in the rat bleomycin model. American journal of 
respiratory and critical care medicine 173, 769–76. 
Chauhan, S.D., Nilsson, H., Ahluwalia, A., Hobbs, A.J., 2003. Release of C-type 
natriuretic peptide accounts for the biological activity of endothelium-
derived hyperpolarizing factor. Proceedings of the National Academy of 
Sciences of the United States of America 100, 1426–31. 
Cheepala, S., Hulot, J., Morgan, J.A., Sassi, Y., Zhang, W., Naren, A.P., 
Schuetz, J.D., 2011. Cyclic Nucleotide Compartmentalization: Contributions 
of Phosphodiesterases and ATP-Binding Cassette Transporters. Annu Rev 
Pharmacol Toxicol 72, 181–204. 
Chen, G., Suzuki, H., Weston, A.H., 1988. Acetylcholine releases endothelium-
derived hyperpolarizing factor and EDRF from rat blood vessels. British 
Journal of Pharmacology 95, 1165–1174. 
Chen, W., Gassner, B., Börner, S., Nikolaev, V.O., Schlegel, N., Waschke, J., 
Steinbronn, N., Strasser, R., Kuhn, M., 2012. Atrial natriuretic peptide 
202 
 
enhances microvascular albumin permeability by the caveolae-mediated 
transcellular pathway. Cardiovascular research 93, 141–51. 
Chen, Z.S., Lee, K., Walther, S., Raftogianis, R.B., Kuwano, M., Zeng, H., Kruh, 
G.D., 2002. Analysis of methotrexate and folate transport by multidrug 
resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate 
efflux system. Cancer Research 62, 3144–3150. 
Chen, Z.-S.S., Lee, K., Kruh, G.D., 2001. Transport of Cyclic Nucleotides and 
Estradiol 17- -D-Glucuronide by Multidrug Resistance Protein 4: Resistance 
to 6-mercaptopurine and 6-thioguanine. Journal of Biological Chemistry 
276, 33747–33754. 
Chinkers, M., Garbers, D., 1989. The protein kinase domain of the ANP 
receptor is required for signaling. Science 245, 1392–1394. 
Chinkers, M., Garbers, D.L., Chang, M.S., Lowe, D.G., Chin, H.M., Goeddel, D. 
V, Schulz, S., 1989. A membrane form of guanylate cyclase is an atrial 
natriuretic peptide receptor. Nature 338, 78–83. 
Cho, H.J., Xie, Q.W., Calaycay, J., Mumford, R.A., Swiderek, K.M., Lee, T.D., 
Nathan, C., 1992. Calmodulin is a subunit of nitric oxide synthase from 
macrophages. The Journal of experimental medicine 176, 599–604. 
Chrisman, T.D., Garbers, D.L., 1999. Reciprocal antagonism coordinates C-
type natriuretic peptide and mitogen-signaling pathways in fibroblasts. 
Journal of Biological Chemistry 274, 4293–4299. 
Chrisman, T.D., Schulz, S., Potter, L.R., Garbers, D.L., 1993. Seminal plasma 
factors that cause large elevations in cellular cyclic GMP are C-type 
natriuretic peptides. The Journal of biological chemistry 268, 3698–703. 
Christman, B., 1992. An imbalance between the excretion of thromboxane and 
prostacyclin metabolites in pulmonary hypertension. … England Journal of 
… 327, 70–75. 
Chua, F., Gauldie, J., Laurent, G.J., 2005. Pulmonary fibrosis: searching for 
model answers. American journal of respiratory cell and molecular biology 
33, 9–13. 
Chun, T.H., Itoh, H., Ogawa, Y., Tamura, N., Takaya, K., Igaki, T., Yamashita, 
J., Doi, K., Inoue, M., Masatsugu, K., Korenaga, R., Ando, J., Nakao, K., 
1997. Shear stress augments expression of C-type natriuretic peptide and 
adrenomedullin. Hypertension 29, 1296–302. 
Chusho, H., Tamura, N., Ogawa, Y., Yasoda,  a, Suda, M., Miyazawa, T., 
Nakamura, K., Nakao, K., Kurihara, T., Komatsu, Y., Itoh, H., Tanaka, K., 
Saito, Y., Katsuki, M., Nakao, K., 2001. Dwarfism and early death in mice 
lacking C-type natriuretic peptide. Proceedings of the National Academy of 
Sciences of the United States of America 98, 4016–4021. 
Ciuclan, L., Bonneau, O., Hussey, M., Duggan, N., Holmes, A.M., Good, R., 
Stringer, R., Jones, P., Morrell, N.W., Jarai, G., Walker, C., Westwick, J., 
Thomas, M., 2011. A novel murine model of severe pulmonary arterial 
hypertension. American journal of respiratory and critical care medicine 
184, 1171–82. 
Clapp, L.H., Finney, P., Turcato, S., Tran, S., Rubin, L.J., Tinker, A., 2002. 
Differential effects of stable prostacyclin analogs on smooth muscle 
proliferation and cyclic AMP generation in human pulmonary artery. 
American journal of respiratory cell and molecular biology 26, 194–201. 
Claude, C., Mougenot, N., Bechaux, J., Hadri, L., Brockschnieder, D., Clergue, 
M., Atassi, F., 2015. Inhalable delivery of AAV-based MRP4 / ABCC4 
silencing RNA prevents monocrotaline-induced pulmonary hypertension. 
203 
 
Molecular Therapy — Methods & Clinical Development 2, 1–6. 
Claussen, C.A., Long, E.C., 1999. Nucleic Acid recognition by metal complexes 
of bleomycin. Chemical reviews 99, 2797–816. 
Clavell, A.L., Stingo, A.J., Wei, C.M., Heublein, D.M., Burnett, J.C., 1993. C-
type natriuretic peptide: a selective cardiovascular peptide. The American 
journal of physiology 264, R290–5. 
Cogan, M.G., Huang, C.L., Liu, F.Y., Madden, D., Wong, K.R., 1986. Effect of 
atrial natriuretic factor on acid-base homeostasis. Journal of hypertension. 
Supplement : official journal of the International Society of Hypertension 4, 
S31–4. 
Cohen, D., Koh, G.Y., Nikonoval, L.N., Porter, J.G., Maack, T., 1996. Molecular 
Determinants of the Clearance Function of Type C Receptors of Natriuretic 
Peptides. Journal of Biological Chemistry 271, 9863–9869. 
Cole, S.P., Bhardwaj, G., Gerlach, J.H., Mackie, J.E., Grant, C.E., Almquist, 
K.C., Stewart,  a J., Kurz, E.U., Duncan,  a M., Deeley, R.G., 1992. 
Overexpression of a transporter gene in a multidrug-resistant human lung 
cancer cell line. Science 258, 1650–4. 
Cole, S.P., Deeley, R.G., 1998. Multidrug resistance mediated by the ATP-
binding cassette transporter protein MRP. BioEssays : news and reviews in 
molecular, cellular and developmental biology 20, 931–40. 
Cole, S.P.C., 2014. Targeting multidrug resistance protein 1 (MRP1, ABCC1): 
past, present, and future. Annual review of pharmacology and toxicology 
54, 95–117. 
Colucci, W.S., Elkayam, U., Horton, D.P., Abraham, W.T., Bourge, R.C., 
Johnson, A.D., Wagoner, L.E., Givertz, M.M., Liang, C.S., Neibaur, M., 
Haught, W.H., LeJemtel, T.H., 2000. Intravenous nesiritide, a natriuretic 
peptide, in the treatment of deompensated congestive heart failure. The 
New England Journal of Medicine 343, 246–253. 
Conti, M., Beavo, J., 2007. Biochemistry and physiology of cyclic nucleotide 
phosphodiesterases: essential components in cyclic nucleotide signaling. 
Annual review of biochemistry 76, 481–511. 
Copple, B., 2003. Liver inflammation during monocrotaline hepatotoxicity. 
Toxicology 190, 155–169. 
Corbin, J.D., Sugden, P.H., Lincoln, T.M., Keely, S.L., 1977. 
Compartmentalization of adenosine 3’:5'-monophosphate and adenosine 
3':5'-monophosphate-dependent protein kinase in heart tissue. The Journal 
of biological chemistry 252, 3854–61. 
Coward, W.R., Saini, G., Jenkins, G., 2010. The pathogenesis of idiopathic 
pulmonary fibrosis. Therapeutic advances in respiratory disease 4, 367–88. 
Crane, B.R., Arvai, A.S., Ghosh, D.K., Wu, C., Getzoff, E.D., Stuehr, D.J., 
Tainer, J.A., 1998. Structure of nitric oxide synthase oxygenase dimer with 
pterin and substrate. Science 279, 2121–6. 
Cras, T.D.L.E., Kim, D., Markham, N.E., Abman, S.H., Cras, L., Timothy, D., 
2000. Early abnormalities of pulmonary vascular development in the Fawn-
Hooded rat raised at Denver ’ s altitude. American Journal of Physiology - 
Lung Cellular and Molecular Physiology 279, 283–291. 
Creagh-Brown, B.C., Griffiths, M.J.D., Evans, T.W., 2009. Bench-to-bedside 
review: Inhaled nitric oxide therapy in adults. Critical Care (London, 
England) 13, 221. 
Currie, M.G., Geller, D.M., Cole, B.R., Boylan, J.G., YuSheng, W., Holmberg, 
S.W., Needleman, P., 1983. Bioactive cardiac substances: potent 
204 
 
vasorelaxant activity in mammalian atria. Science (New York, N.Y.) 221, 
71–3. 
D’armiento, M., Johnson, G.S., Pastan, I., 1973. Cyclic AMP and Growth of 
Fibroblasts: Effect of Environmental pH. Nature 242, 78. 
D’Souza, S.P., Davis, M., Baxter, G.F., 2004. Autocrine and paracrine actions of 
natriuretic peptides in the heart. Pharmacology & therapeutics 101, 113–
29. 
Davie, N., Haleen, S.J., Upton, P.D., Polak, J.M., Yacoub, M.H., Morrell, N.W., 
Wharton, J., 2002. ET(A) and ET(B) receptors modulate the proliferation of 
human pulmonary artery smooth muscle cells. American journal of 
respiratory and critical care medicine 165, 398–405. 
Davoren, P.R., Sutherland, E.W., 1963. The effect of L-epinephrine and other 
agents on the synthesis and release of adenosine 3’,5'- phosphate by 
whole pigeon erythrocytes. The Journal of biological chemistry 238, 3009–
15. 
Dazert, P., Meissner, K., Vogelgesang, S., Eckel, L., Bo, M., Warzok, R., Kerb, 
R., Brinkmann, U., Schaeffeler, E., Schwab, M., Cascorbi, I., Jedlitschky, 
G., Kroemer, H.K., 2003. Expression and Localization of the Multidrug 
Resistance Protein 5 ( MRP5 / ABCC5 ), a Cellular Export Pump for Cyclic 
Nucleotides, in Human Heart. American Journal of Pathology 163, 1567–
1577. 
de Bold, A.J., Borenstein, H.B., Veress, A.T., Sonnenberg, H., 1981. A rapid 
and potent natriuretic response to intravenous injection of atrial myocardial 
extract in rats. Life Sciences 28, 89–94. 
de Wolf, C.J.F., Yamaguchi, H., van der Heijden, I., Wielinga, P.R., Hundscheid, 
S.L., Ono, N., Scheffer, G.L., de Haas, M., Schuetz, J.D., Wijnholds, J., 
Borst, P., 2007. cGMP transport by vesicles from human and mouse 
erythrocytes. The FEBS journal 274, 439–50. 
Dean, M., Allikmets, R., 2001. Complete characterization of the human ABC 
gene family., in: Journal of Bioenergetics and Biomembranes. pp. 475–9. 
Dean, M., Rzhetsky, A., Allikmets, R., 2001. The human ATP-binding cassette 
(ABC) transporter superfamily. Genome research 11, 1156–66. 
Decouture, B., Dreano, E., Belleville-rolland, T., Kuci, O., Dizier, B., Bazaa, A., 
Coqueran, B., Lompre,  a.-M., Denis, C. V., Hulot, J.-S., Bachelot-Loza, C., 
Gaussem, P., Denis, V., 2015. Impaired platelet activation and cAMP 
homeostasis in MRP4-deficient mice. Blood 1, 1689–1699. 
Deeley, R.G., Cole, S.P.C., 2006. Substrate recognition and transport by 
multidrug resistance protein 1 (ABCC1). FEBS Letters 580, 1103–1111. 
Deeley, R.G., Westlake, C., Cole, S.P.C., 2006. Transmembrane Transport of 
Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug 
Resistance Proteins. Physiological Reviews 86, 849–899. 
Del Ry, S., Cabiati, M., Vozzi, F., Battolla, B., Caselli, C., Forini, F., Segnani, C., 
Prescimone, T., Giannessi, D., Mattii, L., 2011. Expression of C-type 
natriuretic peptide and its receptor NPR-B in cardiomyocytes. Peptides 32, 
1713–1718. 
Dempsey, E.C., Das, M., Frid, M.G., Stenmark, K.R., 1996. Unique growth 
properties of neonatal pulmonary vascular cells: importance of time- and 
site-specific responses, cell-cell interaction, and synergy. Journal of 
Perinatology 2, 2–11. 
Derbyshire, E.R., Marletta, M. a, 2012. Structure and regulation of soluble 
guanylate cyclase. Annual review of biochemistry 81, 533–59. 
205 
 
Dhainaut, J.-F., Charpentier, J., Chiche, J.-D., 2003. Transforming growth 
factor-beta: a mediator of cell regulation in acute respiratory distress 
syndrome. Critical care medicine 31, S258–64. 
Dickey, D.M., Flora, D.R., Bryan, P.M., Xu, X., Chen, Y., Potter, L.R., 2007. 
Differential regulation of membrane guanylyl cyclases in congestive heart 
failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the 
predominant natriuretic peptide receptor in the failing heart. Endocrinology 
148, 3518–22. 
Doi, K., Ikeda, T., Itoh, H., Ueyama, K., Hosoda, K., Ogawa, Y., Yamashita, J., 
Chun, T.H., Inoue, M., Masatsugu, K., Sawada, N., Fukunaga, Y., Saito, T., 
Sone, M., Yamahara, K., Kook, H., Komeda, M., Ueda, M., Nakao, K., 
2001. C-type natriuretic peptide induces redifferentiation of vascular 
smooth muscle cells with accelerated reendothelialization. Arteriosclerosis, 
thrombosis, and vascular biology 21, 930–6. 
Doi, K., Itoh, H., Komatsu, Y., Igaki, T., Chun, T.-H., Takaya, K., Yamashita, J., 
Inoue, M., Yoshimasa, T., Nakao, K., 1996. Vascular Endothelial Growth 
Factor Suppresses C-Type Natriuretic Peptide Secretion. Hypertension 27, 
811–815. 
Doore, B.J., Bashor, M.M., Spitzer, N., Mawe, R.C., Saier, M.H., 1975. 
Regulation of adenosine 3’ :5'-monophosphate efflux from rat glioma cells 
in culture*. The Journal of biological chemistry 250, 4371–2. 
Doyle, D.D., Ambler, S.K., Upshaw-Earley, J., Bastawrous, A., Goings, G.E., 
Page, E., 1997. Type B atrial natriuretic peptide receptor in cardiac 
myocyte caveolae. Circulation research 81, 86–91. 
Drewett, J.G., Fendly, B.M., Garbers, D.L., Lowe, D.G., 1995. Natriuretic 
peptide receptor-B (guanylyl cyclase-B) mediates C-type natriuretic peptide 
relaxation of precontracted rat aorta. The journal of biological chemistry 
270, 4668–4674. 
Drexler, E.S., Bischoff, J.E., Slifka, A.J., Mccowan, C.N., Quinn, T.P., Shandas, 
R., Ivy, D.D., Stenmark, K.R., 2008. Stiffening of the Extrapulmonary 
Arteries From Rats in Chronic Hypoxic Pulmonary Hypertension. Journal of 
Research of the National Insitute of Standards and Technology 113, 239–
249. 
Du, J., Xie, J., Zhang, Z., Tsujikawa, H., Fusco, D., Silverman, D., Liang, B., 
Yue, L., 2010. TRPM7-mediated Ca2+ signals confer fibrogenesis in 
human atrial fibrillation. Circulation research 106, 992–1003. 
Dubey, R.K., Gillespie, D.G., Mi, Z., Jackson, E.K., 2001. Endogenous cyclic 
AMP-adenosine pathway regulates cardiac fibroblast growth. Hypertension 
37, 1095–100. 
Dumitrascu, R., Koebrich, S., Dony, E., Weissmann, N., Savai, R., Pullamsetti, 
S.S., Ghofrani, H. a, Samidurai, A., Traupe, H., Seeger, W., Grimminger, 
F., Schermuly, R.T., 2008. Characterization of a murine model of 
monocrotaline pyrrole-induced acute lung injury. BMC pulmonary medicine 
8, 25. 
Durmowicz, A.G., Hofmeister, S., Kadyraliev, T.K., Aldashev, A.A., 1993. 
Functional and structural adaptation of the yak pulmonary circulation to 
residence at high altitude Functional pulmonary and structural adaptation of 
the yak circulation to residence at high altitude. Journal of Applied 
Physiology 74, 2276–2285. 
Dussaule, J.C., Stefanski, A., Béa, M.L., Ronco, P., Ardaillou, R., 1993. 
Characterization of neutral endopeptidase in vascular smooth muscle cells 
206 
 
of rabbit renal cortex. The American journal of physiology 264, F45–52. 
Ebihara, T., Venkatesan, N., Tanaka, R., Ludwig, M.S., 2000. Changes in 
extracellular matrix and tissue viscoelasticity in bleomycin-induced lung 
fibrosis. Temporal aspects. American journal of respiratory and critical care 
medicine 162, 1569–76. 
Eddahibi, S., Guignabert, C., Barlier-Mur, A.-M., Dewachter, L., Fadel, E., 
Dartevelle, P., Humbert, M., Simonneau, G., Hanoun, N., Saurini, F., 
Hamon, M., Adnot, S., 2006. Cross talk between endothelial and smooth 
muscle cells in pulmonary hypertension: critical role for serotonin-induced 
smooth muscle hyperplasia. Circulation 113, 1857–64. 
Eddahibi, S., Hanoun, N., Lanfumey, L., Lesch, K.P., Raffestin, B., Hamon, M., 
Adnot, S., 2000. Attenuated hypoxic pulmonary hypertension in mice 
lacking the 5-hydroxytryptamine transporter gene. The Journal of clinical 
investigation 105, 1555–62. 
Egom, E.E., Vella, K., Hua, R., Jansen, H.J., Moghtadaei, M., Polina, I., 
Bogachev, O., Hurnik, R., Mackasey, M., Rafferty, S., Ray, G., Rose, R. a., 
2015. Impaired sinoatrial node function and increased susceptibility to atrial 
fibrillation in mice lacking natriuretic peptide receptor C. The Journal of 
Physiology 593, 1127–1146. 
Ehret, G.B., Munroe, P.B., Rice, K.M., Bochud, M., Johnson, A.D., Chasman, 
D.I., Smith, A. V, Tobin, M.D., Verwoert, G.C., Hwang, S.-J., Pihur, V., 
Vollenweider, P., O’Reilly, P.F., Amin, N., Bragg-Gresham, J.L., Teumer, 
A., Glazer, N.L., Launer, L., Zhao, J.H., Aulchenko, Y., Heath, S., Sõber, 
S., Parsa, A., Luan, J., Arora, P., Dehghan, A., Zhang, F., Lucas, G., Hicks, 
A.A., Jackson, A.U., Peden, J.F., Tanaka, T., Wild, S.H., Rudan, I., Igl, W., 
Milaneschi, Y., Parker, A.N., Fava, C., Chambers, J.C., Fox, E.R., Kumari, 
M., Go, M.J., van der Harst, P., Kao, W.H.L., Sjögren, M., Vinay, D.G., 
Alexander, M., Tabara, Y., Shaw-Hawkins, S., Whincup, P.H., Liu, Y., Shi, 
G., Kuusisto, J., Tayo, B., Seielstad, M., Sim, X., Nguyen, K.-D.H., 
Lehtimäki, T., Matullo, G., Wu, Y., Gaunt, T.R., Onland-Moret, N.C., 
Cooper, M.N., Platou, C.G.P., Org, E., Hardy, R., Dahgam, S., Palmen, J., 
Vitart, V., Braund, P.S., Kuznetsova, T., Uiterwaal, C.S.P.M., Adeyemo, A., 
Palmas, W., Campbell, H., Ludwig, B., Tomaszewski, M., Tzoulaki, I., 
Palmer, N.D., Consortium, Cardi., CKDGen Consortium, KidneyGen 
Consortium, EchoGen consortium, CHARGE-HF consortium, Aspelund, T., 
Garcia, M., Chang, Y.-P.C., O’Connell, J.R., Steinle, N.I., Grobbee, D.E., 
Arking, D.E., Kardia, S.L., Morrison, A.C., Hernandez, D., Najjar, S., 
McArdle, W.L., Hadley, D., Brown, M.J., Connell, J.M., Hingorani, A.D., 
Day, I.N.M., Lawlor, D.A., Beilby, J.P., Lawrence, R.W., Clarke, R., 
Hopewell, J.C., Ongen, H., Dreisbach, A.W., Li, Y., Young, J.H., Bis, J.C., 
Kähönen, M., Viikari, J., Adair, L.S., Lee, N.R., Chen, M.-H., Olden, M., 
Pattaro, C., Bolton, J.A.H., Köttgen, A., Bergmann, S., Mooser, V., 
Chaturvedi, N., Frayling, T.M., Islam, M., Jafar, T.H., Erdmann, J., Kulkarni, 
S.R., Bornstein, S.R., Grässler, J., Groop, L., Voight, B.F., Kettunen, J., 
Howard, P., Taylor, A., Guarrera, S., Ricceri, F., Emilsson, V., Plump, A., 
Barroso, I., Khaw, K.-T., Weder, A.B., Hunt, S.C., Sun, Y. V, Bergman, 
R.N., Collins, F.S., Bonnycastle, L.L., Scott, L.J., Stringham, H.M., 
Peltonen, L., Perola, M., Vartiainen, E., Brand, S.-M., Staessen, J.A., 
Wang, T.J., Burton, P.R., Soler Artigas, M., Dong, Y., Snieder, H., Wang, 
X., Zhu, H., Lohman, K.K., Rudock, M.E., Heckbert, S.R., Smith, N.L., 
Wiggins, K.L., Doumatey, A., Shriner, D., Veldre, G., Viigimaa, M., Kinra, 
207 
 
S., Prabhakaran, D., Tripathy, V., Langefeld, C.D., Rosengren, A., Thelle, 
D.S., Corsi, A.M., Singleton, A., Forrester, T., Hilton, G., McKenzie, C.A., 
Salako, T., Iwai, N., Kita, Y., Ogihara, T., Ohkubo, T., Okamura, T., 
Ueshima, H., Umemura, S., Eyheramendy, S., Meitinger, T., Wichmann, 
H.-E., Cho, Y.S., Kim, H.-L., Lee, J.-Y., Scott, J., Sehmi, J.S., Zhang, W., 
Hedblad, B., Nilsson, P., Smith, G.D., Wong, A., Narisu, N., Stančáková, 
A., Raffel, L.J., Yao, J., Kathiresan, S., O’Donnell, C.J., Schwartz, S.M., 
Ikram, M.A., Longstreth, W.T., Mosley, T.H., Seshadri, S., Shrine, N.R.G., 
Wain, L. V, Morken, M.A., Swift, A.J., Laitinen, J., Prokopenko, I., Zitting, 
P., Cooper, J.A., Humphries, S.E., Danesh, J., Rasheed, A., Goel, A., 
Hamsten, A., Watkins, H., Bakker, S.J.L., van Gilst, W.H., Janipalli, C.S., 
Mani, K.R., Yajnik, C.S., Hofman, A., Mattace-Raso, F.U.S., Oostra, B.A., 
Demirkan, A., Isaacs, A., Rivadeneira, F., Lakatta, E.G., Orru, M., Scuteri, 
A., Ala-Korpela, M., Kangas, A.J., Lyytikäinen, L.-P., Soininen, P., 
Tukiainen, T., Würtz, P., Ong, R.T.-H., Dörr, M., Kroemer, H.K., Völker, U., 
Völzke, H., Galan, P., Hercberg, S., Lathrop, M., Zelenika, D., Deloukas, 
P., Mangino, M., Spector, T.D., Zhai, G., Meschia, J.F., Nalls, M.A., 
Sharma, P., Terzic, J., Kumar, M.V.K., Denniff, M., Zukowska-
Szczechowska, E., Wagenknecht, L.E., Fowkes, F.G.R., Charchar, F.J., 
Schwarz, P.E.H., Hayward, C., Guo, X., Rotimi, C., Bots, M.L., Brand, E., 
Samani, N.J., Polasek, O., Talmud, P.J., Nyberg, F., Kuh, D., Laan, M., 
Hveem, K., Palmer, L.J., van der Schouw, Y.T., Casas, J.P., Mohlke, K.L., 
Vineis, P., Raitakari, O., Ganesh, S.K., Wong, T.Y., Tai, E.S., Cooper, R.S., 
Laakso, M., Rao, D.C., Harris, T.B., Morris, R.W., Dominiczak, A.F., 
Kivimaki, M., Marmot, M.G., Miki, T., Saleheen, D., Chandak, G.R., Coresh, 
J., Navis, G., Salomaa, V., Han, B.-G., Zhu, X., Kooner, J.S., Melander, O., 
Ridker, P.M., Bandinelli, S., Gyllensten, U.B., Wright, A.F., Wilson, J.F., 
Ferrucci, L., Farrall, M., Tuomilehto, J., Pramstaller, P.P., Elosua, R., 
Soranzo, N., Sijbrands, E.J.G., Altshuler, D., Loos, R.J.F., Shuldiner, A.R., 
Gieger, C., Meneton, P., Uitterlinden, A.G., Wareham, N.J., Gudnason, V., 
Rotter, J.I., Rettig, R., Uda, M., Strachan, D.P., Witteman, J.C.M., 
Hartikainen, A.-L., Beckmann, J.S., Boerwinkle, E., Vasan, R.S., Boehnke, 
M., Larson, M.G., Järvelin, M.-R., Psaty, B.M., Abecasis, G.R., Chakravarti, 
A., Elliott, P., van Duijn, C.M., Newton-Cheh, C., Levy, D., Caulfield, M.J., 
Johnson, T., 2011. Genetic variants in novel pathways influence blood 
pressure and cardiovascular disease risk. Nature 478, 103–9. 
El Andalousi, J., Li, Y., Anand-Srivastava, M.B., Signaling, P., Andalousi, J. El, 
Li, Y., Anand-Srivastava, M.B., 2013. Natriuretic peptide receptor-C agonist 
attenuates the expression of cell cycle proteins and proliferation of vascular 
smooth muscle cells from spontaneously hypertensive rats: role of Gi 
proteins and MAPkinase/PI3kinase signaling. PloS one 8, e76183. 
Emoto, N., Yanagisawa, M., 1995. Endothelin-converting enzyme-2 is a 
membrane-bound, phosphoramidon-sensitive metalloprotease with acidic 
pH optimum. The Journal of biological chemistry 270, 15262–8. 
Epperly, M.W., Goff, J.P., Zhang, X., Niu, Y., Shields, D.S., Wang, H., Shen, H., 
Franicola, D., Bahnson, A.B., Nie, S., Greenberger, E.E., Greenberger, 
J.S., 2006. Increased radioresistance, g(2)/m checkpoint inhibition, and 
impaired migration of bone marrow stromal cell lines derived from Smad3(-
/-) mice. Radiation research 165, 671–7. 
Erdös, E.G., Skidgel, R.A., 1989. Neutral endopeptidase 24.11 (enkephalinase) 
and related regulators of peptide hormones. FASEB Journal 3, 145–51. 
208 
 
Estrada, K.D., Chesler, N.C., 2009. Collagen-related gene and protein 
expression changes in the lung in response to chronic hypoxia 8, 263–272. 
Evans, J.M., Day, J.P., Cabrero, P., Dow, J.A.T., Davies, S.-A., 2008. A new 
role for a classical gene: white transports cyclic GMP. The Journal of 
experimental biology 211, 890–9. 
Failla, M., Genovese, T., Mazzon, E., Gili, E., Muià, C., Sortino, M., Crimi, N., 
Caputi, A.P., Cuzzocrea, S., Vancheri, C., 2006. Pharmacological inhibition 
of leukotrienes in an animal model of bleomycin-induced acute lung injury. 
Respiratory research 7, 137. 
Fan, D., 2005. Down-Regulation Does Not Mediate Natriuretic Peptide-
Dependent Desensitization of Natriuretic Peptide Receptor (NPR)-A or 
NPR-B: Guanylyl Cyclase-Linked Natriuretic Peptide Receptors Do Not 
Internalize. Molecular Pharmacology 67, 174–183. 
Fike, C.D., Pfister, S.L., Kaplowitz, M.R., Madden, J.A., 2002. Cyclooxygenase 
contracting factors and altered pulmonary vascular responses in chronically 
hypoxic newborn pigs. Journal of Applied Physiology 92, 67–74. 
Finnegan, S., Clarke, S., Gibson, D., McAllister, C., Rooney, M., 2011. Synovial 
membrane immunohistology in early untreated juvenile idiopathic arthritis: 
differences between clinical subgroups. Annals of the rheumatic diseases 
70, 1842–1850. 
Fischmeister, R., Castro, L.R. V, Abi-Gerges, A., Rochais, F., Jurevicius, J., 
Leroy, J., Vandecasteele, G., 2006. Compartmentation of cyclic nucleotide 
signaling in the heart: the role of cyclic nucleotide phosphodiesterases. 
Circulation research 99, 816–28. 
Flynn, T.G., de Bold, M.L., de Bold, A., 1983. The amino acid sequence of an 
atrial peptide with potent diuretic and natriuretic properties. Biochemical 
and biophysical research communications 117, 859–65. 
Forssmann, W., 2001. The renal urodilatin system: clinical implications. 
Cardiovascular Research 51, 450–462. 
Francis, S.H., Busch, J.L., Corbin, J.D., Sibley, D., 2010. cGMP-Dependent 
Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP 
Action. Pharmacological reviews 62, 525–563. 
Frank, D.B., Lowery, J., Anderson, L., Brink, M., Reese, J., de Caestecker, M., 
Caestecker, M. De, Db, F., Lowery, J., Anderson, L., Brink, M., Reese, J., 
2008. Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 
mutant mice is associated with endothelial dysfunction in the pulmonary 
vasculature. American Journal of Physiology - Lung Cellular and Molecular 
Physiology 294, 98–109. 
Frid, M.G., Brunetti, J.A., Burke, D.L., Carpenter, T.C., Davie, N.J., Reeves, 
J.T., Roedersheimer, M.T., Rooijen, N. Van, Stenmark, K.R., 2006. 
Hypoxia-induced pulmonary vascular remodeling requires recruitment of 
circulating mesenchymal precursors of a monocyte/macrophage lineage. 
The American journal of pathology 168, 659–69. 
Friebe, A., Mergia, E., Dangel, O., Lange, A., Koesling, D., 2007. Fatal 
gastrointestinal obstruction and hypertension in mice lacking nitric oxide-
sensitive guanylyl cyclase. Proceedings of the National Academy of 
Sciences of the United States of America 104, 7699–704. 
Fried, T.A., McCoy, R.N., Osgood, R.W., Stein, J.H., 1986. Effect of atriopeptin 
II on determinants of glomerular filtration rate in the in vitro perfused dog 
glomerulus. The American journal of physiology 250, F1119–22. 
Fujishige, K., Yanaka, N., Akatsuka, H., Omori, K., 1998. Localization of 
209 
 
clearance receptor in rat lung and trachea: association with chondrogenic 
differentiation. The American journal of physiology 274, L425–31. 
Fuller, F., Porter, J.G., Arfsten, A.E., Miller, J., Schilling, J.W., Scarborough, 
R.M., Lewicki, J.A., Schenk, D.B., 1988. Atrial natriuretic peptide clearance 
receptor. Complete sequence and functional expression of cDNA clones. 
The Journal of biological chemistry 263, 9395–401. 
Fulton, D., Gratton, J.P., McCabe, T.J., Fontana, J., Fujio, Y., Walsh, K., 
Franke, T.F., Papapetropoulos, A., Sessa, W.C., 1999. Regulation of 
endothelium-derived nitric oxide production by the protein kinase Akt. 
Nature 399, 597–601. 
Furchgott, R.F., Zawadzki, J. V, 1980. The obligatory role of endothelial cells in 
the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373–
376. 
Furuya, M., Aisaka, K., Miyazaki, T., Honbou, N., Kawashima, K., Ohno, T., 
Tanaka, S., Minamino, N., Kangawa, K., Matsuo, H., 1995. C-type 
natriuretic peptide inhibits intimal thickening after vascular injury. Annals of 
the New York Academy of Sciences 748, 517–23. 
Furuya, M., Yoshida, M., Hayashi, Y., Ohnuma, N., Minamino, N., Kangawa, K., 
Matsuo, H., 1991. C-type natriuretic peptide is a growth inhibitor of rat 
vascular smooth muscle cells. Biochemical and biophysical research 
communications 177, 927–31. 
Fuster, V., Steele, P.M., Edwards, W.D., Gersh, B.J., McGoon, M.D., Frye, R.L., 
1984. Primary pulmonary hypertension: natural history and the importance 
of thrombosis. Circulation 70, 580–587. 
Gali, N., Corris, P.A., Frost, A., Girgis, R.E., Granton, J., Jing, Z.C., Klepetko, 
W., McGoon, M.D., McLaughlin, V. V., Preston, I.R., Rubin, L.J., Sandoval, 
J., Seeger, W., Keogh, A., 2013. Updated treatment algorithm of pulmonary 
arterial hypertension. Journal of the American College of Cardiology 62, 
D60–D72. 
Galiè, N., Brundage, B.H., Ghofrani, H.A., Oudiz, R.J., Simonneau, G., Safdar, 
Z., Shapiro, S., White, R.J., Chan, M., Beardsworth, A., Frumkin, L., Barst, 
R.J., Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) 
Study Group, 2009. Tadalafil therapy for pulmonary arterial hypertension. 
Circulation 119, 2894–903. 
Galiè, N., Ghofrani, H.A., Torbicki, A., Barst, R.J., Rubin, L.J., Badesch, D., 
Fleming, T., Parpia, T., Burgess, G., Branzi, A., Grimminger, F., Kurzyna, 
M., Simonneau, G., 2005. Sildenafil Citrate Therapy for Pulmonary Arterial 
Hypertension. New England Journal of Medicine 353, 2148–2157. 
Garbers, D.L., Lowe, D.G., 1994. Guanylyl cyclase receptors. The Journal of 
biological chemistry 269, 30741–4. 
Garg, U.C., Hassid, A., 1989. Nitric oxide-generating vasodilators and 8-bromo-
cyclic guanosine monophosphate inhibit mitogenesis and proliferation of 
cultured rat vascular smooth muscle cells. Jounal of Clinical Investigation 
83, 1774–1777. 
Geiger, R., Berger, R.M., Hess, J., Bogers, A.J., Sharma, H.S., Mooi, W.J., 
2000. Enhanced expression of vascular endothelial growth factor in 
pulmonary plexogenic arteriopathy due to congenital heart disease. The 
Journal of pathology 191, 202–7. 
Gekeler, V., Ise, W., Sanders, K.H., Ulrich, W.-R.R., Beck, J., 1995. The 
Leukotriene LTD4 receptor antangonist MK571 specifically modulates MRP 
associated multidrug resistance. Biochemical and biophysical research 
210 
 
communications 208, 345–352. 
Gerber, H.P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B.A., Dixit, V., Ferrara, 
N., 1998. Vascular endothelial growth factor regulates endothelial cell 
survival through the phosphatidylinositol 3’-kinase/Akt signal transduction 
pathway. Requirement for Flk-1/KDR activation. The Journal of biological 
chemistry 273, 30336–43. 
Gharaee-kermani, M., Hatano, K., Nozaki, Y., Phan, S.H., 2005. Gender-based 
differences in bleomycin-induced pulmonary fibrosis. The American journal 
of pathology 166, 1593–1606. 
Giaid, A., Saleh, D., 1995. Reduced Expression of Endothelial Nitric Oxide 
Synthase in the Lungs of Patients with Pulmonary Hypertension. The New 
England journal of medicine 333, 214–221. 
Giles, F.J., Stopeck, A.T., Silverman, L.R., Lancet, J.E., Cooper, M.A., Hannah, 
A.L., Cherrington, J.M., Farrell, A.O., Yuen, H.A., Louie, S.G., Hong, W., 
Cortes, J.E., 2003. SU5416, a small molecule tyrosine kinase receptor 
inhibitor, has biologic activity in patients with refractory acute myeloid 
leukemia or myelodysplastic syndromes. Blood 102, 801–801. 
Giordano, D., De Stefano, M.E., Citro, G., Modica, A., Giorgi, M., 2001. 
Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in 
mouse tissues and cell lines using an antibody against the enzyme amino-
terminal domain. Biochimica et biophysica acta 1539, 16–27. 
Giuili, G., Scholl, U., Bulle, F., Guellaën, G., 1992. Molecular cloning of the 
cDNAs coding for the two subunits of soluble guanylyl cyclase from human 
brain. FEBS letters 304, 83–8. 
Gomez-Arroyo, J., Saleem, S.J., Mizuno, S., Syed, A. a, Bogaard, H.J., Abbate, 
A., Taraseviciene-Stewart, L., Sung, Y., Kraskauskas, D., Farkas, D., 
Conrad, D.H., Nicolls, M.R., Voelkel, N.F., 2012. A brief overview of mouse 
models of pulmonary arterial hypertension: problems and prospects. 
American Journal of Physiology - Lung Cellular and Molecular Physiology 
302, 977–991. 
Gomez-Arroyo, J.G., Farkas, L., Alhussaini, A.A., Farkas, D., Kraskauskas, D., 
Voelkel, N.F., Bogaard, H.J., 2012. The monocrotaline model of pulmonary 
hypertension in perspective. American Journal of Physiology, Lung Cellular 
and Molecular Physiology 302, L363–9. 
Goy, M.F., Oliver, P.M., Purdy, K.E., Knowles, J.W., Fox, J.E., Mohler, P.J., 
Qian, X., Smithies, O., Maeda, N., 2001. Evidence for a novel natriuretic 
peptide receptor that prefers brain natriuretic peptide over atrial natriuretic 
peptide. The Biochemical journal 358, 379–87. 
Graf, K., Koehne, P., Gräfe, M., Zhang, M., Auch-Schwelk, W., Fleck, E., 1995. 
Regulation and differential expression of neutral endopeptidase 24.11 in 
human endothelial cells. Hypertension 26, 230–5. 
Grande, N.R., Salazar, L.A., Peão, M.N.D., De Sá, C.M., Águas, A.P., 1998. 
Lung fibrosis induced by bleomycin: Structural changes and overview of 
recent advances. Scanning Microscopy 12, 487–494. 
Green, S.J., Mellouk, S., Hoffman, S.L., Meltzer, M.S., Nacy, C.A., 1990. 
Cellular mechanisms of nonspecific immunity to intracellular infection: 
cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by 
macrophages and hepatocytes. Immunology letters 25, 15–9. 
Grépin, C., Dagnino, L., Robitaille, L., Haberstroh, L., Antakly, T., Nemer, M., 
1994. A hormone-encoding gene identifies a pathway for cardiac but not 




Guo, F.H., De Raeve, H.R., Rice, T.W., Stuehr, D.J., Thunnissen, F.B., 
Erzurum, S.C., 1995. Continuous nitric oxide synthesis by inducible nitric 
oxide synthase in normal human airway epithelium in vivo. Proceedings of 
the National Academy of Sciences of the United States of America 92, 
7809–7813. 
Hagiwara, H., Sakaguchi, H., Itakura, M., Yoshimoto, T., Furuya, M., Tanaka, 
S., Hirose, S., 1994. Autocrine regulation of rat chondrocyte proliferation by 
natriuretic peptide C and its receptor, natriuretic peptide receptor-B. The 
Journal of biological chemistry 269, 10729–33. 
Hamet, P., Pang, S.C., Tremblay, J., 1989. Atrial Natriuretic Factor-induced 
Egression of Cyclic Guanosine 3 ’: 5 ’ -Monophosphate in Cultured 
Vascular Smooth Muscle and Endothelial Cells. The Journal of Biological 
Chemistry 264, 12364–12369. 
Han, M.K., Murray, S., Fell, C.D., Flaherty, K.R., Toews, G.B., Myers, J., Colby, 
T. V., Travis, W.D., Kazerooni, E. a., Gross, B.H., Martinez, F.J., Arbor, A., 
2008. Sex differences in physiological progression of idiopathic pulmonary 
fibrosis. European Respiratory Journal 31, 1183–1188. 
Hara, Y., Sassi, Y., Guibert, C., Gambaryan, N., Dorfmüller, P., Eddahibi, S., 
Lompré, A.M., Humbert, M., Hulot, J.S., 2011. Inhibition of MRP4 prevents 
and reverses pulmonary hypertension in mice. Journal of Clinical 
Investigation 121, 2888–2897. 
Harari, S., Caminati, A., 2010. IPF: new insight on pathogenesis and treatment. 
Allergy 65, 537–53. 
Hardie, W.D., Glasser, S.W., Hagood, J.S., 2009. Emerging concepts in the 
pathogenesis of lung fibrosis. The American journal of pathology 175, 3–
16. 
Harvey, W., 1628. Exercitatio Anatomica de Motu Cordis et Sanguinis in 
Animalibus. 
Haworth, S.G., Hislop, A. a., 2003. Lung development—the effects of chronic 
hypoxia. Seminars in Neonatology 8, 1–8. 
He, Y., Grinnell, F., 1994. Stress relaxation of fibroblasts activates a cyclic AMP 
signaling pathway. The Journal of cell biology 126, 457–64. 
Heath, D., Edwards, J.E., 1958. The pathology of hypertensive pulmonary 
vascular disease; a description of six grades of structural changes in the 
pulmonary arteries with special reference to congenital cardiac septal 
defects. Circulation 18, 533–47. 
Henry, J.P., Gauer, O.H., Reeves, J.L., 1956. Evidence of the Atrial Location of 
Receptors Influencing Urine Flow. Circulation Research 4, 85–90. 
Herman, J.P., Dolgas, C.M., Rucker, D., Langub, M.J., 1996. Localization of 
natriuretic peptide-activated guanylate cyclase mRNAs in the rat brain. The 
Journal of Comparative Neurology 369, 165–87. 
Hervé, P., Launay, J.M., Scrobohaci, M.L., Brenot, F., Simonneau, G., 
Petitpretz, P., Poubeau, P., Cerrina, J., Duroux, P., Drouet, L., 1995. 
Increased plasma serotonin in primary pulmonary hypertension. The 
American journal of medicine 99, 249–54. 
Hobbs, A., Foster, P., Prescott, C., Scotland, R., Ahluwalia, A., 2004. Natriuretic 
peptide receptor-C regulates coronary blood flow and prevents myocardial 
ischemia/reperfusion injury: Novel cardioprotective role for endothelium-
derived C-type natriuretic peptide. Circulation 110, 1231–1235. 
Hoeper, M.M., Bogaard, H.J., Condliffe, R., Frantz, R., Khanna, D., Kurzyna, 
212 
 
M., Langleben, D., Manes, A., Satoh, T., Torres, F., Wilkins, M.R., 
Badesch, D.B., 2013. Definitions and diagnosis of pulmonary hypertension. 
Journal of the American College of Cardiology 62, D42–D50. 
Honda, A., Adams, S.R., Sawyer, C.L., Lev-Ram, V., Tsien, R.Y., Dostmann, 
W.R., 2001. Spatiotemporal dynamics of guanosine 3’,5'-cyclic 
monophosphate revealed by a genetically encoded, fluorescent indicator. 
Proceedings of the National Academy of Sciences of the United States of 
America 98, 2437–42. 
Horikawa, Y.T., Panneerselvam, M., Kawaraguchi, Y., Tsutsumi, Y.M., Ali, S.S., 
Balijepalli, R.C., Murray, F., Head, B.P., Niesman, I.R., Rieg, T., Vallon, V., 
Insel, P.A., Patel, H.H., Roth, D.M., 2011. Cardiac-specific overexpression 
of caveolin-3 attenuates cardiac hypertrophy and increases natriuretic 
peptide expression and signaling. Journal of the American College of 
Cardiology 57, 2273–83. 
Horio, T., Tokudome, T., Maki, T., Yoshihara, F., Suga, S.-I., Nishikimi, T., 
Kojima, M., Kawano, Y., Kangawa, K., 2003. Gene expression, secretion, 
and autocrine action of C-type natriuretic peptide in cultured adult rat 
cardiac fibroblasts. Endocrinology 144, 2279–84. 
Hoshikawa, Y., Nana-Sinkam, P., Moore, M.D., Sotto-Santiago, S., Phang, T., 
Keith, R.L., Morris, K.G., Kondo, T., Tuder, R.M., Voelkel, N.F., Geraci, 
M.W., 2003. Hypoxia induces different genes in the lungs of rats compared 
with mice. Physiological genomics 12, 209–19. 
Hosoda, K., Nakao, K., Mukoyama, M., Saito, Y., Jougasaki, M., Shirakami, G., 
Suga, S., Ogawa, Y., Yasue, H., Imura, H., 1991. Expression of brain 
natriuretic peptide gene in human heart. Production in the ventricle. 
Hypertension 17, 1152–5. 
Hu, P., Zhang, X.C., Kong, H.B., Xia, X., Hu, B., Qin, Y.H., 2015. Exogenous C-
type natriuretic peptide infusion ameliorates unilateral ureteral obstruction-
induced tubulointerstitial fibrosis in rats. Laboratory Investigation 95, 263–
272. 
Huang, J., Wolk, J.H., Gewitz, M.H., Mathew, R., 2010. Progressive endothelial 
cell damage in an inflammatory model of pulmonary hypertension. 
Experimental Lung Research 36, 57–66. 
Huang, P.L., Huang, Z., Mashimo, H., Bloch, K.D., Moskowitz, M.A., Bevan, 
J.A., Fishman, M.C., 1995. Hypertension in mice lacking the gene for 
endothelial nitric oxide synthase. Nature 377, 239–42. 
Huang, Z., Huang, P.L., Ma, J., Meng, W., Ayata, C., Fishman, M.C., 
Moskowitz, M.A., 1996. Enlarged infarcts in endothelial nitric oxide 
synthase knockout mice are attenuated by nitro-L-arginine. Journal of 
cerebral blood flow and metabolism : official journal of the International 
Society of Cerebral Blood Flow and Metabolism 16, 981–7. 
Huang, Z., Huang, P.L., Panahian, N., Dalkara, T., Fishman, M.C., Moskowitz, 
M.A., 1994. Effects of cerebral ischemia in mice deficient in neuronal nitric 
oxide synthase. Science 265, 1883–5. 
Huntley, B.K., Sandberg, S.M., Noser, J.A., Cataliotti, A., Redfield, M.M., 
Matsuda, Y., Burnett, J.C., 2006. BNP-induced activation of cGMP in 
human cardiac fibroblasts: interactions with fibronectin and natriuretic 
peptide receptors. Journal of cellular physiology 209, 943–9. 
Hutchinson, H.G., Trindade, P.T., Cunanan, D.B., Wu, C.F., Pratt, R.E., 1997. 
Mechanisms of natriuretic-peptide-induced growth inhibition of vascular 
smooth muscle cells. Cardiovascular research 35, 158–167. 
213 
 
Ichiki, T., Huntley, B.K., Heublein, D.M., Sandberg, S.M., McKie, P.M., Martin, 
F.L., Jougasaki, M., Burnett, J.C., 2011. Corin is present in the normal 
human heart, kidney, and blood, with pro-B-type natriuretic peptide 
processing in the circulation. Clinical chemistry 57, 40–7. 
Ichinose, F., Roberts, J.D., Zapol, W.M., 2004. Inhaled Nitric Oxide: A Selective 
Pulmonary Vasodilator: Current Uses and Therapeutic Potential. 
Circulation 109, 3106–3111. 
Igaki, T., Itoh, H., Suga, S., Hama, N., Ogawa, Y., Komatsu, Y., Yamashita, J., 
Doi, K., Chun, T., Nakao, K., 1998. Effects of Intravenously Administered 
C-type Nat riure Peptide in Humans : Comparison with Atrial Natriuretic 
Peptide. Hypertension Research 21, 7–13. 
Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., Chaudhurit, G., Sawyer, 
C.H., 1987. Endothelium-derived relaxing factor produced and released 
from artery and vein is nitric oxide (endothelium-dependent 
relaxation/vascular smooth muscle/cyclic GMP). Medical Sciences 84, 
9265–9269. 
Ignarro, L.J., Wood, K.S., Wolin, M.S., 1982. Activation of purified soluble 
guanylate cyclase by protoporphyrin IX. Proceedings of the National 
Academy of Sciences 79, 2870–2873. 
Intengan, H.D., Schiffrin, E.L., 2000. Structure and mechanical properties of 
resistance arteries in hypertension: role of adhesion molecules and 
extracellular matrix determinants. Hypertension 36, 312–318. 
Itoh, T., Nagaya, N., Murakami, S., Fujii, T., Iwase, T., Ishibashi-ueda, H., 
Yutani, C., Yamagishi, M., Kimura, H., Kangawa, K., 2004. C-type 
natriuretic peptide ameliorates monocrotaline-induced pulmonary 
hypertension in rats. American journal of respiratory and critical care 
medicine 170, 1204–11. 
Izbicki, G., Segel, M.J., Christensen, T.G., Conner, M.W., Breuer, R., 2002. 
Time course of bleomycin-induced lung fibrosis. International journal of 
experimental pathology 83, 111–9. 
Izikki, M., Guignabert, C., Fadel, E., Humbert, M., Tu, L., Zadigue, P., 
Dartevelle, P., Simonneau, G., Adnot, S., Maitre, B., Raffestin, B., 
Eddahibi, S., 2009. Endothelial-derived FGF2 contributes to the 
progression of pulmonary hypertension in humans and rodents. The 
Journal of clinical investigation 119, 512–23. 
Izumiya, Y., Araki, S., Usuku, H., Rokutanda, T., Hanatani, S., Ogawa, H., 
2012. Chronic C-Type Natriuretic Peptide Infusion Attenuates Angiotensin 
II-Induced Myocardial Superoxide Production and Cardiac Remodeling. 
International Journal of Vascular Medicine 2012, 246058–67. 
Janick-Buckner, D., Ranges, G.E., Hacker, M.P., 1989. Alteration of 
bronchoalveolar lavage cell populations following bleomycin treatment in 
mice. Toxicology and applied pharmacology 100, 465–73. 
Jedlitschky, G., Burchell, B., Keppler, D., 2000. The multidrug resistance protein 
5 functions as an ATP-dependent export pump for cyclic nucleotides. The 
Journal of biological chemistry 275, 30069–74. 
Jeffery, T.K., Upton, P.D., Trembath, R.C., Morrell, N.W., Costello, C.M., Cahill, 
E., Martin, F., Gaine, S., Mcloughlin, P., Long, L., Crosby, A., Yang, X., 
Southwood, M., Kim, D., Rai, P.R., Cool, C.D., King, J.A.C., Stevens, T., 
Burns, N., Winn, R.A., Kasper, M., Voelkel, N.F., Hong, K., Lee, Y.J., Lee, 
E., Park, S.O., Han, C., Beppu, H., Li, E., Trina, K., 2005. BMP4 inhibits 
proliferation and promotes myocyte differentiation of lung fibroblasts via 
214 
 
Smad1 and JNK pathways. American Journal of Physiology. Lung Cellular 
and Molecular Physiology 288, L370–8. 
Jin, H., Yang, R.H., Chen, Y.F., Jackson, R.M., Oparil, S., 1990. Atrial 
natriuretic peptide attenuates the development of pulmonary hypertension 
in rats adapted to chronic hypoxia. The Journal of clinical investigation 85, 
115–20. 
Jin, S.L., Swinnen, J. V, Conti, M., 1992. Characterization of the structure of a 
low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the 
catalytic domain. The Journal of biological chemistry 267, 18929–39. 
Jing, Z.-C., Yu, Z.-X., Shen, J.-Y., Wu, B.-X., Xu, K.-F., Zhu, X.-Y., Pan, L., 
Zhang, Z.-L., Liu, X.-Q., Zhang, Y.-S., Jiang, X., Galiè, N., Efficacy and 
Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension 
(EVALUATION) Study Group, 2011. Vardenafil in pulmonary arterial 
hypertension: a randomized, double-blind, placebo-controlled study. 
American journal of respiratory and critical care medicine 183, 1723–9. 
Johnson, T., Gaunt, T.R., Newhouse, S.J., Padmanabhan, S., Tomaszewski, 
M., Kumari, M., Morris, R.W., Tzoulaki, I., O’Brien, E.T., Poulter, N.R., 
Sever, P., Shields, D.C., Thom, S., Wannamethee, S.G., Whincup, P.H., 
Brown, M.J., Connell, J.M., Dobson, R.J., Howard, P.J., Mein, C.A., 
Onipinla, A., Shaw-Hawkins, S., Zhang, Y., Davey Smith, G., Day, I.N.M., 
Lawlor, D.A., Goodall, A.H., Cardiogenics Consortium, Fowkes, F.G., 
Abecasis, G.R., Elliott, P., Gateva, V., Global BPgen Consortium, Braund, 
P.S., Burton, P.R., Nelson, C.P., Tobin, M.D., van der Harst, P., Glorioso, 
N., Neuvrith, H., Salvi, E., Staessen, J.A., Stucchi, A., Devos, N., 
Jeunemaitre, X., Plouin, P.-F., Tichet, J., Juhanson, P., Org, E., Putku, M., 
Sõber, S., Veldre, G., Viigimaa, M., Levinsson, A., Rosengren, A., Thelle, 
D.S., Hastie, C.E., Hedner, T., Lee, W.K., Melander, O., Wahlstrand, B., 
Hardy, R., Wong, A., Cooper, J.A., Palmen, J., Chen, L., Stewart, A.F.R., 
Wells, G.A., Westra, H.-J., Wolfs, M.G.M., Clarke, R., Franzosi, M.G., Goel, 
A., Hamsten, A., Lathrop, M., Peden, J.F., Seedorf, U., Watkins, H., 
Ouwehand, W.H., Sambrook, J., Stephens, J., Casas, J.-P., Drenos, F., 
Holmes, M. V, Kivimaki, M., Shah, S., Shah, T., Talmud, P.J., Whittaker, J., 
Wallace, C., Delles, C., Laan, M., Kuh, D., Humphries, S.E., Nyberg, F., 
Cusi, D., Roberts, R., Newton-Cheh, C., Franke, L., Stanton, A. V, 
Dominiczak, A.F., Farrall, M., Hingorani, A.D., Samani, N.J., Caulfield, M.J., 
Munroe, P.B., 2011. Blood pressure loci identified with a gene-centric 
array. American journal of human genetics 89, 688–700. 
Jones, T.R., Zamboni, R., Belley, M., Champion, E., Charette, L., Ford-
Hutchinson, A.W., Frenette, R., Gauthier, J.Y., Leger, S., Masson, P., 
1989. Pharmacology of L-660,711 (MK-571): a novel potent and selective 
leukotriene D4 receptor antagonist. Canadian journal of physiology and 
pharmacology 67, 17–28. 
Kaiser, R., Grotemeyer, K., Lepper, P., Stokes, C., Bals, R., Wilkens, H., 2015. 
Associations of circulating natriuretic peptides with haemodynamics in 
precapillary pulmonary hypertension. Respiratory Medicine 109, 1213–
1223. 
Kalra, P.R., Clague, J.R., Bolger, A.P., Anker, S.D., Poole-Wilson, P.A., 
Struthers, A.D., Coats, A.J., 2003. Myocardial production of C-type 
natriuretic peptide in chronic heart failure. Circulation 107, 571–573. 
Kapoun, A.M., Liang, F., O’Young, G., Damm, D.L., Quon, D., White, R.T., 
Munson, K., Lam, A., Schreiner, G.F., Protter, A.A., 2004. B-type natriuretic 
215 
 
peptide exerts broad functional opposition to transforming growth factor-
beta in primary human cardiac fibroblasts: fibrosis, myofibroblast 
conversion, proliferation, and inflammation. Circulation research 94, 453–
61. 
Kasahara, Y., Kiyatake, K., Tatsumi, K., Sugito, K., Kakusaka, I., Yamagata, S., 
Ohmori, S., Kitada, M., Kuriyama, T., 1997. Bioactivation of monocrotaline 
by P-450 3A in rat liver. Journal of Cardiovascular Pharmacology 30, 124–
129. 
Kathiresan, S., Larson, M.G., Vasan, R.S., Guo, C.-Y., Vita, J.A., Mitchell, G.F., 
Keyes, M.J., Newton-Cheh, C., Musone, S.L., Lochner, A.L., Drake, J.A., 
Levy, D., O’Donnell, C.J., Hirschhorn, J.N., Benjamin, E.J., 2005. Common 
genetic variation at the endothelial nitric oxide synthase locus and relations 
to brachial artery vasodilator function in the community. Circulation 112, 
1419–27. 
Katsuki, S., Arnold, W., Mittal, C., Murad, F., 1977. Stimulation of guanylate 
cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various 
tissue preparations and comparison to the effects of sodium azide and 
hydroxylamine. Journal of cyclic nucleotide research 3, 23–35. 
Kay, J.M., Harris, P., Heath, D., 1967. Pulmonary hypertension produced in rats 
by ingestion of Crotalaria spectabilis seeds. Thorax 22, 176–9. 
Keefer, L.K., 2005. Nitric oxide (NO)- and nitroxyl (HNO)-generating 
diazeniumdiolates (NONOates): emerging commercial opportunities. 
Current topics in medicinal chemistry 5, 625–36. 
Kelsall, C.J., Chester, A.H., Sarathchandra, P., Singer, D.R.J., 2006. 
Expression and localization of C-type natriuretic peptide in human vascular 
smooth muscle cells. Vascular pharmacology 45, 368–373. 
Kenny, A.J., Bourne, A., Ingram, J., 1993. Hydrolysis of human and pig brain 
natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-
receptor ligands by endopeptidase-24.11. Biochem. J 291, 83–88. 
Kentera, D., Susić, D., Veljković, V., Tucaković, G., Koko, V., 1988. Pulmonary 
artery pressure in rats with hereditary platelet function defect. Respiration; 
international review of thoracic diseases 54, 110–4. 
Kerr, M.A., Kenny, A.J., 1974a. The Purification and Specificity of a Neutral 
Endopeptidase from Rabbit Kidney Brush Border. Biochem. J 137. 
Kerr, M.A., Kenny, A.J., 1974b. The molecular weight and properties of a 
neutral metallo-endopeptidase from rabbit kidney brush border. The 
Biochemical journal 137, 489–95. 
Khambata, R.S., Panayiotou, C.M., Hobbs, A.J., 2011. Natriuretic peptide 
receptor-3 underpins the disparate regulation of endothelial and vascular 
smooth muscle cell proliferation by C-type natriuretic peptide. British journal 
of pharmacology 164, 584–97. 
Kimura, T., Nojiri, T., Hino, J., Hosoda, H., Miura, K., Shintani, Y., Inoue, M., 
Zenitani, M., Takabatake, H., Miyazato, M., Okumura, M., Kangawa, K., 
2016. C-type natriuretic peptide ameliorates pulmonary fibrosis by acting 
on lung fibroblasts in mice. Respiratory Research 1–17. 
Kimura, T., Nojiri, T., Hosoda, H., Ishikane, S., Shintani, Y., Inoue, M., 
Miyazato, M., Okumura, M., Kangawa, K., 2015. C-type natriuretic peptide 
attenuates lipopolysaccharide-induced acute lung injury in mice. Journal of 
Surgical Research 194, 631–637. 
Kips, J.C., Joos, G.F., De Lepeleire, I., Margolskee, D.J., Buntinx, A., Pauwels, 
R. a, Van der Straeten, M.E., 1991. MK-571, a potent antagonist of 
216 
 
leukotriene D4-induced bronchoconstriction in the human. The American 
review of respiratory disease 144, 617–21. 
Klatt, P., Pfeiffer, S., List, B.M., Lehner, D., Glatter, O., Bächinger, H.P., 
Werner, E.R., Schmidt, K., Mayer, B., 1996. Characterization of heme-
deficient neuronal nitric-oxide synthase reveals a role for heme in subunit 
dimerization and binding of the amino acid substrate and 
tetrahydrobiopterin. The Journal of biological chemistry 271, 7336–42. 
Klinger, J.R., Arnal, F., Warburton, R.R., Ou, L.C., Hill, N.S., 1994. 
Downregulation of pulmonary atrial natriuretic peptide receptors in rats 
exposed to chronic hypoxia. Journal of Applied Physiology 77, 1309–16. 
Klinger, J.R., Siddiq, F.M., Swift, R.A., Jackson, C., Pietras, L., Warburton, 
R.O.D.R., Alia, C., Hill, N.S., James, R., Siddiq, F.M., Richard, A., Jackson, 
C., Pietras, L., Warburton, R.R., Alia, C., Hill, N.S., 1998. C-type natriuretic 
peptide expression and pulmonary vasodilation in hypoxia-adapted rats. 
American Physiological Society 645–652. 
Klinger, J.R., Thaker, S., Houtchens, J., Preston, I.R., Hill, N.S., Farber, H.W., 
2006. Pulmonary hemodynamic responses to brain natriuretic peptide and 
sildenafil in patients with pulmonary arterial hypertension. Chest 129, 417–
25. 
Klinger, J.R., Tsai, S.-W., Green, S., Grinnell, K.L., Machan, J.T., Harrington, 
E.O., 2013. Atrial natriuretic peptide attenuates agonist-induced pulmonary 
edema in mice with targeted disruption of the gene for natriuretic peptide 
receptor-A. Journal of Applied Physiology 114, 307–15. 
Klinger, J.R., Warburton, R.R., Pietras, L., Hill, N.S., 1998. Brain natriuretic 
peptide inhibits hypoxic pulmonary hypertension in rats. Journal of applied 
physiology (Bethesda, Md. : 1985) 84, 1646–52. 
Knowles, J.W., Esposito, G., Mao, L., Hagaman, J.R., Fox, J.E., Smithies, O., 
Rockman, H.A., Maeda, N., 2001. Pressure-independent enhancement of 
cardiac hypertrophy in natriuretic peptide receptor A–deficient mice. 
Journal of Clinical Investigation 107, 975–984. 
Koh, G.Y., Nussenzveig, D.R., Okolicany, J., Price, D.A., Maack, T., 1992. 
Dynamics of atrial natriuretic factor-guanylate cyclase receptors and 
receptor-ligand complexes in cultured glomerular mesangial and 
renomedullary interstitial cells. The Journal of biological chemistry 267, 
11987–94. 
Kolb, M., Margetts, P.J., Galt, T., Sime, P.J., Xing, Z., Schmidt, M., Gauldie, J., 
2001. Transient transgene expression of decorin in the lung reduces the 
fibrotic response to bleomycin. American journal of respiratory and critical 
care medicine 163, 770–7. 
Koller, K.J., Lowe, D.G., Bennett, G.L., Minamino, N., Kangawa, K., Matsuo, H., 
Goeddel, D. V, 1991. Selective activation of the B natriuretic peptide 
receptor by C-type natriuretic peptide (CNP). Science 252, 120–3. 
Komatsu, Y., Chusho, H., Tamura, N., Yasoda, A., Miyazawa, T., Suda, M., 
Miura, M., Ogawa, Y., Nakao, K., 2002. Significance of C-type natriuretic 
peptide (CNP) in endochondral ossification: Analysis of CNP knockout 
mice. Journal of Bone and Mineral Metabolism 20, 331–336. 
Komatsu, Y., Itoh, H., Suga, S. -i., Ogawa, Y., Hama, N., Kishimoto, I., 
Nakagawa, O., Igaki, T., Doi, K., Yoshimasa, T., Nakao, K., 1996. 
Regulation of Endothelial Production of C-Type Natriuretic Peptide in 
Coculture With Vascular Smooth Muscle Cells : Role of the Vascular 
Natriuretic Peptide System in Vascular Growth Inhibition. Circulation 
217 
 
Research 78, 606–614. 
Komatsu, Y., Nakao, K., Suga, S., Ogawa, Y., Mukoyama, M., Arai, H., 
Shirakami, G., Hosoda, K., Nakagawa, O., Hama, N., 1991. C-type 
natriuretic peptide (CNP) in rats and humans. Endocrinology 129, 1104–6. 
Kotera, J., Fujishige, K., Omori, K., 2000. Immunohistochemical localization of 
cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. 
The Journal of Histochemistry and Cytochemistry 48, 685–93. 
Kranenburg, A.R., de Boer, W.I., T Alagappan, V.K., Sterk, P.J., Sharma, H.S., 
2005. Enhanced bronchial expression of vascular endothelial growth factor 
and receptors (Flk-1 and Flt-1) in patients with chronic obstructive 
pulmonary disease. Thorax 60, 106–113. 
Krawutschke, C., Koesling, D., Russwurm, M., 2015. Cyclic GMP in Vascular 
Relaxation Export Is of Similar Importance as Degradation. Arterioscler 
Thromb Vasc Biol 35, 1–9. 
Kröncke, K.D., Fehsel, K., Kolb-Bachofen, V., 1998. Inducible nitric oxide 
synthase in human diseases. Clinical and Experimental Immunology 113, 
147–156. 
Kröncke, K.D., Kolb-Bachofen, V., Berschick, B., Burkart, V., Kolb, H., 1991. 
Activated macrophages kill pancreatic syngeneic islet cells via arginine-
dependent nitric oxide generation. Biochemical and biophysical research 
communications 175, 752–8. 
Kubes, P., Suzuki, M., Granger, D.N., 1991. Nitric oxide: an endogenous 
modulator of leukocyte adhesion. Proceedings of the National Academy of 
Sciences of the United States of America 88, 4651–5. 
Kubo, A., Isumi, Y., Ishizaka, Y., Tomoda, Y., Kangawa, K., Dohi, K., Matsuo, 
H., Minamino, N., 2001. C-type natriuretic peptide is synthesized and 
secreted from leukemia cell lines, peripheral blood cells, and peritoneal 
macrophages. Experimental hematology 29, 609–15. 
Kudej, R.K., Iwase, M., Uechi, M., Vatner, D.E., Oka, N., Ishikawa, Y., Shannon, 
R.P., Bishop, S.P., Vatner, S.F., 1997. Effects of chronic beta-adrenergic 
receptor stimulation in mice. Journal of molecular and cellular cardiology 
29, 2735–46. 
Kuhn, K.P., Byrne, D.W., Arbogast, P.G., Doyle, T.P., Loyd, J.E., Robbins, I.M., 
2003. Outcome in 91 consecutive patients with pulmonary arterial 
hypertension receiving epoprostenol. American journal of respiratory and 
critical care medicine 167, 580–6. 
Kühnl, A., Pelisek, J., Tian, W., Kuhlmann, M., Rolland, P.H., Mekkaoui, C., 
Fuchs, A., Nikol, S., 2005. C-type natriuretic peptide inhibits constrictive 
remodeling without compromising re-endothelialization in balloon-dilated 
renal arteries. Journal of Endovascular Therapy 12, 171–82. 
Kuriyama, Y., Koyama, J., Egami, F., 1964. Digestion of chemically synthesised 
polyguanylic acids by ribonuclease T1 and spleen phophodiesterase. 
Seikagaku 36, 135–139. 
Kurtz, A., Della Bruna, R., Pfeilschifter, J., Taugner, R., Bauer, C., 1986. Atrial 
natriuretic peptide inhibits renin release from juxtaglomerular cells by a 
cGMP-mediated process. Proceedings of the National Academy of 
Sciences of the United States of America 83, 4769–73. 
Lalich, J.L., Johnson, W.D., Raczniak, T.J., Shumaker, R.C., 1977. Fibrin 
thrombosis in monocrotaline pyrrole-induced cor pulmonale in rats. 
Archives of pathology & laboratory medicine 101, 69–73. 
Langenickel, T.H., Buttgereit, J., Pagel-Langenickel, I., Lindner, M., Monti, J., 
218 
 
Beuerlein, K., Al-Saadi, N., Plehm, R., Popova, E., Tank, J., Dietz, R., 
Willenbrock, R., Bader, M., 2006. Cardiac hypertrophy in transgenic rats 
expressing a dominant-negative mutant of the natriuretic peptide receptor 
B. Proceedings of the National Academy of Sciences of the United States 
of America 103, 4735–40. 
Langub, M.C.J., Dolgas, C.M., Watson, R.E.J., Herman, J.P., 1995. The C-type 
natriuretic peptide receptor is the predominant natriuretic peptide receptor 
mRNA expressed in rat hypothalamus. The Journal of Neuroendocrinology 
7, 305–9. 
Lawrie,  a, 2014. A report on the use of animal models and phenotyping 
methods in pulmonary hypertension research. Pulmonary circulation 4, 2–
9. 
Lee, D.I., Zhu, G., Sasaki, T., Cho, G.-S., Hamdani, N., Holewinski, R., Jo, S.-
H., Danner, T., Zhang, M., Rainer, P.P., Bedja, D., Kirk, J. a., Ranek, M.J., 
Dostmann, W.R., Kwon, C., Margulies, K.B., Van Eyk, J.E., Paulus, W.J., 
Takimoto, E., Kass, D. a., 2015. Phosphodiesterase 9A controls nitric-
oxide-independent cGMP and hypertrophic heart disease. Nature 519, 
472–6. 
Lee, J., Reich, R., Xu, F., Sehgal, P.B., 2009. Golgi, trafficking, and mitosis 
dysfunctions in pulmonary arterial endothelial cells exposed to 
monocrotaline pyrrole and NO scavenging. American Journal of 
Physiology. Lung Cell Molecular Physiology 297, 715–28. 
Lefebvre, R.A., 2002. Pharmacological characterization of the nitrergic 
innervation of the stomach. Verhandelingen - Koninklijke Academie voor 
Geneeskunde van België 64, 151–66. 
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